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Abstract
The limited availability of autologous bone for grafting post-surgical defects in 
patients with craniosynostosis, necessitates the use of alloplastic materials which are 
prone to rejection or infection. The use of bio-composite materials consisting of alloplastic 
bioabsorbable scaffolds and autologous osteoprogenitor cells to avoid rejection, could 
provide a valuable approach to the repair of critical bone defects in the skull. However, in 
patients with syndromic craniosynostosis, autologous osteoprogenitors carry the mutations 
which cause premature ossification and consequent malformations requiring cranioplasty. 
The aim of this study was to develop strategies for growing effectively mutated 
osteoprogenitors with the view to developing autologous therapies for patients with 
craniosynostosis.
To this purpose, the behaviour of mouse osteoprogenitor cell lines carrying either a 
common human mutation (FGFR2-C278F) for syndromic craniosynostosis or the human 
wild type FGFR2 (WT-FGFR2) was investigated. In particular the focus was on i) how the 
mutation affected proliferation and osteogenisis; ii) the effect of exogenous fibroblast 
growth factor (FGF) 18 on cell growth and morphology; iii) analysis of osteoprogenitor 
attachment and growth on bioabsorbable scaffolds uncoated or coated with extracellular 
matrix molecules (fibronectin, laminin).
RT-PCR analysis of cells carrying the FGFR2-C278F mutation and wild type FGFR2 
cells, revealed differential expression of FGF18 and molecules important in the terminal 
differentiation of mineralising osteoblasts: Osteocalcin was expressed at greater levels in 
cells carrying the mutation compared to wild type cells at 1.8 fold (p < 0.01) and 1.4 fold (p 
= 0.02) in pre-confluent and day 5 confluent cells respectively. Wild type cells expressed 
alkaline phosphatase from day 5 compared to mutated cells which did not express until 
day 30. Most striking was the greater expression of FGF18 in the mutated cells; 1.8 fold 
(p < 0.01) at pre confluence, 1.3 fold (p = 0.01) at day 5 and 1.5 fold (p < 0.01) at day 30.
In the early phase of cell cultures, cells carrying the mutation demonstrated higher 
mitotic activity than wild type cells as determined by p-H3 staining (18.6% +ve and 11.2% 
+ve respectively; p < 0.01, day 2 post plating). However, mutated cells demonstrated 
altered attachment behaviour, clustering forming early nodules and did not reach full 
confluence. Subsequent treatment of mutated cells with FGF 18 [10‘9M] appeared to allow 
cells to reach confluence and “rescue” the phenotype. A concentration dependent increase
in cellular mitosis for all cell lines was observed. This was significantly greater at day 1 in 
mutated cells compared to wild type cells (51% and 29% respectively; p <0.01 at FGF18 
[10r9M], and 60% and 43% respectively; p < 0.01 at FGF18[10^M]).
Attachment and growth of osteoblasts to a commercially available, clinically licensed 
scaffold could be enhanced by modification of the surface with the extracellular matrix 
(ECM) molecules, fibronectin and laminin. Both substrates significantly enhanced 
attachment at all time points up to 48 hours post plating (e.g. C278F cells at 1 hour post 
plating: 10,020 cells [-ve]; 37,600 [fibronectin]; 41,670 [laminin]; p < 0.01).
These findings indicated that the use of osteoprogenitor cells carrying mutations 
could present a feasible strategy in bone tissue engineering, which warrants further 
development towards the overall multidisciplinary approach in the management of these 
complex clinical challenges.
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Chapter 1: Introduction
This thesis presents a study of osteoprogenitor ceils carrying a mutation in the 
human fibroblast growth factor receptor 2, coding for a syndromic form of 
craniosynostosis. It further explores the potential use of cells carrying a mutation for bone 
tissue engineering. The introduction will discuss the major themes of the study by giving 
an overview of:
•  Craniofacial development and craniosynostosis
• The surgical difficulties in managing craniosynostosis
•  Fibroblast growth factor receptors (FGFRs) and fibroblast growth factors (FGFs)
• Biomaterials in bone tissue engineering
These themes will then be consolidated to form the hypothesis for this study.
1.1: Cranial Development and Ossification
1.1.1: Origin of the Craniofacial Skeleton
The mammalian craniofacial skeleton accommodates the expanding brain and 
supports the structures and functions of existence such as feeding, breathing, seeing and 
social interaction. It is a composite of neurocranium (calvaria/vault) which forms principally 
in membranous bone and viscerocranium (skull base and facial skeleton) which forms by 
endochondral ossification via a cartilaginous precursor (Fig. 1.1). The membranous bones 
of the cranial vault are formed by ossification of mesenchymal condensations (Hall & 
Miyake 1992), derived from early populations of cephalic neural crest which have migrated 
from the closing neural folds (Noden 1975, 1983; Couly & LeDourian 1985; Tan & Morriss- 
Kay 1985) and mesoderm (Morriss-Kay 2001; Jiang et al., 2002; Jeong et al., 2004). The 
cranial bones lie between the dura mater which surrounds the brain and is derived from 
neural crest (Yu et al., 1997) and by aponeurosis and skin originating in the ectoderm. The 
sutures, which lie between the numerous bone plates of the skull vault and base, are 
formed by neural crest-mesoderm boundaries (Jiang et al., 2002).
A B
■ Neurocranium (skull vault)□ Neurocranium (skull base)
□ Viscerocranium
Figure 1.1: Development of the foetal cranium
A: Lateral view defining nomenclature boundaries.
B: Lateral view of foetal skull showing the principal bones and their mode of osteogenisis 
(adapted from: www.hopkinsmedicine.org/craniofacial)
1.1.2: Skull Morphology Sutures and Fontanelles
Sutures form the interface zones between two bones of the cranial base or calvaria, 
whilst fontanelles form where three or more bones meet. The principal sutures being the 
coronal sutures (paired) between the frontal and parietal bones, the metopic suture 
between the two hemi-frontal bones, the lambdoidal suture (paired) between the parietal 
and occipital bone and the sagittal suture between the two parietal bones. The anterior 
fontanelle exists at the confluence of the two parietal and frontal bones and the posterior 
fontanelle, at the confluence of the two parietal bones and the occipital bone (Fig. 1.2).
Frontal 
Sphenoid
Ethmoid
Zygoma------
Maxilla 
Mandible
□ Intramembranous
□ Endochondral
Parietal
 Occipital
—— Temporal
^-M iddle ear bones 
Styloid
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A B
Metopic suture
Parietal bone Anterior
fontanelleFrontal bone
Coronal suture
Lambdoidal /  
suture.
Sagittal
suture
t Posterior
fontanelle
Occipital bone irietal
bone Lambdoidal
sutureMastoid fontanelle Temporoparietal Occipital bone
suture
Figure1.2: Illustration of principal sutures and fontanelles of the foetal cranium
A: Lateral view of the skull representing approximately 25 weeks gestation and showing 
coronal, temporoparietal and lambdoidal sutures.
B: Antero-posterior view of the skull showing the occipital bone, paired parietal and frontal 
bones with intervening lambdoidal, sagittal and parietal sutures, expanded by the 
fontanelles. (Redrawn after Morriss-Kay & Wilkie 2005)
Sutures and fontanelles allow for a degree of compression of the skull during birth 
and subsequent growth and remodelling, driven principally by the expanding brain. 
Sutures are fundamental in allowing changes in form, size and orientation of the 
craniofacial skeleton in response to normal or pathological growth of adjacent structures. 
This occurs by a coordinated balance of bone deposition and resorption at the 
bone/mesenchyme/periosteal/dural interface. (Fig. 1.3)
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Unmineralised osteoid
differentiated osteoblasts Periosteum
Mineralised bone
Undifferentiated 
mesenchymal cells and
Dura Mater
preosteoblasts of suture
Figure 1.3: Schematic illustration of cranial suture
Diagrammatic section through a patent cranial suture. In the adult human these are 
normally obliterated in a temporal sequence (Table 1.1). In craniosynostosis, suture 
obliteration occurs prematurely and often in-utero. (Redrawn after Marie 2003)
Patency of the sutures is maintained during growth of the brain, which initially keeps 
the sutures widely separated (Cohen & McLean, 2000) and subsequently by signalling 
mechanisms within the premineralised mesenchymal zone. Cells within the suture area 
differentiate into osteogenic cells, and contribute towards the formation of new calvarial 
bone, whilst others persist in an undifferentiated, proliferative state (Cohen, 1993). 
Following birth, human sutures fuse in a site and time dependent manner which can be 
highly variable (Sahni, 2004), although generally earlier in males than females and 
commencing on the endocranial surface (Vu, 2001), consistent with findings in mice 
(Opperman et al., 1997; Roth et al., 1997). Table 1.1 shows the normal sequence of 
suture fusion. Whilst most of the calvarial sutures remain patent through adulthood, the 
metopic suture closes within the first two years of life. This may be related to the finding 
that the metopic is the only suture which forms solely within neural crest domain, the 
others being formed at neural crest-mesodermal boundaries (Jieng et al., 2002).
- 2 0 -
Fontanelle Timing of Closure
Posterior 0-4 months
Mastoid 6-12 months
Anterior 12-24 months
Suture Timing of Fusion
Metopic
Sagittal
3-48 months 
20-45 years
Lambdoidal 25-45 years
Coronal 25-50 years
Spheno-temporo-parietal 30-60 years
Table 1.1: Normal timing of human suture and fontanelle closure post-partum
(Created from data in: Perizonius, 1984; Vu et al., 2001; Sahni et al., 2004)
1.1.3: Dura mater
Sutures also require the proximity of the dura mater for sustained patency. 
Oppenman et al., (1993, 1995), demonstrated that the dura initially plays an inductive role, 
then a permissive role in maintaining sutural patency through various signalling factors. 
Embryonic mouse dura has been shown to regulate sutural patency (Kim et al., 1998) and 
Levine et al., (1998), determined that the dura generates signals and that these signals 
could be blocked by a silastic sheet interposed between the dura and the overlying suture. 
Dura transplanted from under normally patent sutures to sites of sutural fusion in a 
naturally occurring craniosynostotic rabbit model, successfully kept these sites from re- 
obliterating following surgery (Mooney et al., 2001).
1.1.4: Mechanical forces
Mechanical forces may also play a role in maintaining sutural patency or premature 
fusion. It is a striking observation that skull size and form, matches brain size, in both 
children with normal brains and in those with hydrocephalus or microcephaly, a condition 
in which there has been an “appropriate” premature suture fusion. In this situation, a 
primary failure of the brain to grow is interpreted by poorly understood biofeedback 
mechanisms within the sutures, which then go on to fuse.
Fusion of the right coronal suture is twice as common as on the left, possibly 
reflecting the 3:1 right laterality bias of cephalic presentation births (Ververs et al., 1994). 
The application of tensile forces across rat sutures has been shown to cause an increase 
in the production of Insulin like growth factor receptors in osteoblast-like cells, resulting in 
cellular proliferation at the suture (Hirukawa et al., 2004).
Sutures thus allow the growth of the craniofacial skeleton, usually symmetrically and 
principally in response to the growing brain. However, if individual or multiple sutures fuse 
prematurely, the remaining patent sutures can respond by compensatory growth, often 
leading to asymmetry (Jane & Persing, 1986). Where sutures have fused prematurely, this 
is known as craniosynostosis and shall be discussed in further detail.
1.2: Craniosynostosis
1.2.1: Description of Craniosynostosis
Craniosynostosis is a defect which effects the normal temporo-spatial development 
of the sutures of the cranial vault and/or skull base. It follows failure of the signalling 
mechanisms that govern the processes of growth and differentiation at the suture margins. 
This results in the premature fusion of one or more of the cranial sutures. Fused sutures 
may be found in isolation (non-syndromic craniosynostosis), as part of a syndrome 
(syndromic or complex craniosynostosis), or as a secondary consequence of a primary 
disease process such as one of the metabolic disorders. The combined incidence of these 
disorders is approximately 1 in 2500 live births (Cohen & McLean, 2000).
Premature fusion of sutures prevents further bone apposition and hence growth of 
the bone perpendicular to the line of the suture. Continued and compensatory bone growth 
in those sutures which have remained patent, results in the development of an abnormal
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skull shape (Fig. 1.4), the form of which depends upon the sequence and site of 
premature fusion. Traditionally, craniosynostosis is classified according to the 
sutures involved, the resulting dysmorphology of the head, the presence or 
absence of an identified craniofacial syndrome, and the degree of progression of 
the anomaly. Whilst the multi-suture and syndromic craniosynostosis do not lend 
themselves so readily to descriptive classification, specific head shapes are 
recognised most obviously in single suture craniosynostosis and a descriptive 
classification based on head shape exists (Table 1.2).
Affected
Suture Lambdoid Sagittal
Clinical
Classification
Posterior
plagiocephaty Scaphocephaly
Uni­
coronal
Plagiocephaly
Bicoronal Metopic
Brachycephaly Trigonocephaly
Clinical
Features
Flattened
occiput,
Asymmetric
ear
position,
Tilted head 
position
Antero­
posterior 
elongation of 
the head
Narrowing
across
temples
Asymmetric 
flattening of 
forehead
Raised 
supraorbital 
rim on 
affected side
Symmetric 
loss of 
forehead 
contour 
Commonly 
associated 
with a 
syndromic 
form 
(Seathre- 
Chotzen)
Pointed
forehead
Diagramatic
Form
Table 1.2: Clinical classification of single suture craniosynostosis
Adapted from Posnick (1999)
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Figure 1.4: 3-Dimensional 
computer tomograms(CT) of 
craniosynostosis
A: Lateral view of a six month old 
child with bicoronal synstosis 
associated with Muenke 
syndrome. Arrow “a” denotes the 
location of the fused (absent) 
coronal suture.
B: Axial view of a 1 year old child 
with metopic synostosis. Arrow “b” 
denotes the location of the fused 
metopic suture.
C: Lateral view of a two year old 
child with sagittal synostosis. The 
fused suture is not visible in this 
view which demonstrates the 
typical antero-posterior elongation 
of the skull
(Great Ormond Street Hospital)
1.2.2: Aetiology of Craniosynostosis
The causes of craniosynostosis are numerous and involve a wide spectrum of 
conditions. The majority are not syndromic, but sporadic, isolated, single suture 
synostoses, where no molecular abnormality can be identified, and where it is likely that 
their aetiology is not of genetic origin (Cohen & McLean, 2000). Craniosynostosis can 
occur secondary to pathogenesis such as metabolic diseases e.g. hyperthyroidism, 
haematological disease, such as thalassaemia, glycogen storage disorders such as 
Hurler syndrome, and foetal teratogenesis induced by drugs such as retinoic acid and 
phenytoin (Gorlin et al., 2001; Thompson et al., 1994). Over 100 forms of causally related 
craniosynostosis have been described (Cohen & McLean, 2000). However, in up to 15% of 
cases of craniosynostosis there is evidence of Mendelian inheritance (Reardon & Winter, 
1995). For historical reasons, these have been named eponymously by those first given 
credit for describing the clinical features of the syndrome. The most common 
craniosynostoses or syndromes with a defined molecular basis are, Seathre-Chotzen 
syndrome (1 in 20,000 live births) Crouzon syndrome (1 in 25,000), Jackson-Weiss 
syndrome (1 in 26,000), Apert syndrome (1 in 100,000), Pfeiffer syndrome (1 in 200,000) 
(Gorlin et al., 2001). In addition, the recently described Muenke syndrome which presents 
as a highly variable, atypical syndrome which is not easily categorised on clinical grounds 
(Muenke et al., 1997), accounts for between 17% and 31% of apparently non-syndromic 
coronal or bicoronal synostosis (Moloney et al., 1997; Lajeunie et al., 1999). The molecular 
mechanisms underlying these genetically based syndromes will be explored more fully 
later in this chapter.
1.2.3: Clinical Manifestations of syndromic craniosynosis
A number of presenting features are shared between the syndromes, these are 
summarised for the commonest syndromes in Table 1.3. These features are used to 
distinguish one syndromic case from another in clinical terms.
An abnormal skull shape [turricephally (tall flattened forehead), acrocephally (cone 
shaped) or “klebblatschader (dover-Leaf), widely spaced orbits (hypertelorism)], proptosis 
and an underdeveloped midface with apparent prognathism are characteristic features of 
these disorders. Hand and foot anomalies are observed in some, but not all 
craniosynostosis syndromes. The severest digital anomalies are found in Aperts syndrome 
and involve variable but significant degrees of syndactely (fusion of the digits) which 
usually require surgery to improve function (Upton, 1991), Children with Saethre-Chotzen
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syndrome have variable and often subtle degrees of sydactely of the 2nd 3rd or 4th web 
spaces, whilst children with Pfeiffer syndrome have broad thumbs and broad big toes 
which are deviated towards the midline. They may also demonstrate mild levels of 
webbing between the digits of the hands and feet. Jackson-Weiss syndrome demonstrates 
foot abnormalities very similar to Pfeiffer syndrome, but interestingly the digits of the hand 
are unaffected. (Cohen & McLean, 2000)
Phenotype
Craniosynostosis + + + + +
Midface hyposplasia + + + - +
Hand anomalies + + - + -
Foot anomalies + + - + +
Table 1.3: Phenotypes in craniosynostosis syndromes.
AS: Apert syndrome, PS: Pfeiffer syndrome CS: Crouzon syndrome, SCS. Saethre- 
Chotzen syndrome, JW: Jackson-Weiss syndrome,(Muenke syndrome has been omitted 
as the clinical phenotype is less severe). Adapted from Muenke and Schell, (1995)
The clinical phenotype is not limited to premature fusion of the cranial sutures and 
defective limb development. Individuals may present with additional cutaneous (Orlow, 
1992; Hall 1992), dental (Berkowitz 1971; Sidhu 1989), ophthalmic (Matthews, 1979), 
aural (Bergstrom et al., 1972), cardiac (Hunter & Rudd, 1977), respiratory (Gonzalez et al., 
1997) and CNS abnormalities (Davidson & Young, 1981; Thompson et al., 1997). As a 
result of this spectrum of potential clinical manifestations, children with craniosynostosis 
suffer from a variety of often serious functional complications. These include airway 
obstruction, due to midface hypoplasia (Lauritzen et al., 1986; Gonzalez et al., 1996), 
hydrocephalus (Murtagh & Baird, 1961; Noetzal et al., 1985), intracranial venous 
hypertension (Sainte-Rose, 1984; Thompson et al., 1995), raised intracranial pressure 
(Lundar and Homes, 1991; Gault et al., 1992; Hayward et al., 1992; Gosain et al., 1995, 
Murovic et al., 1993; Thompson et al., 1995), palatal clefting (Cohen et al., 1971) and 
occlusal anomalies (Kreiborg & Cohen, 1992), visual problems such as proptosis, 
keratopathy and papilloedema (Miller 1984; Newman 1991), speech and language delay 
(Shipster et al., 2003) and developmental delay (Patton et al., 1988; Renier & Marchac 
1988). In addition, psychosocial problems are increasingly recognised (Pertzchuk & 
Whitaker, 1987; Endriga & Kapp-Simon, 1999).
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Raised intracranial pressure (ICP) represents one of the most serious consequences 
of syndromic craniosynostosis. Raised ICP can cause impaired cerebral perfusion and 
retinal damage, leading to blindness (Stavrou et al., 1997), impairment of intellectual 
development (Renier et al., 1982; Bellew et al., 2005), seizures, and can occasionally lead 
to premature sudden death in this group of individuals (Gosain et al., 1995). The incidence 
of raised ICP in individuals with syndromic craniosynostosis is at least twice as high as in 
non-syndromic cases. In addition to raised intracranial pressure, high-pressure 
hydrocephalus is prevalent amongst individuals with syndromic craniosynostosis. Hayward 
and Gonzales, (2005), have concluded that cerebral perfusion, raised intracranial pressure 
and respiratory obstruction interact in a visdous cycle to exacerbate neurodevelopmental 
damage. These studies confirm that raised intracranial pressure is a significant feature of 
syndromic craniosynostosis. The causes of raised intracranial pressure in these individuals 
remain highly contentious. However, vault constriction through premature sutural fusion is 
thought to play a fundamental role (Renier et al., 1982).
1.2.4: Surgical Options for Craniosynostosis
Therapeutic intervention for craniosynostosis involves surgery as the mainstay and 
surgical procedures are performed for a number of indications. The timing, extent and type 
of procedure is determined on the basis of the severity and location of the cranial 
deformity. Early surgery would undoubtedly be desirable in order to correct deformity and 
prevent functional problems as previously described. However, continued abnormal growth 
and ossification would in a high proportion of cases lead to relapse and further, possibly 
earlier episodes of surgery (Hayward et al., 2004). The planning of surgery tends to fall 
into two categories: Those procedures carried out electively for psychosocial wellbeing 
and elective functional problems such as severe malocclusion and those which can be 
considered as being performed on a “crisis intervention” basis to alleviate or prevent 
progressing functional deficits. Concerns over increased intracranial pressure strongly 
influence the timing and staging of surgical intervention. This latter group is for the vast 
majority associated with syndromic cases with multiple suture involvement or 
pansynostosis, although raised intracranial pressure and its sequelae, can occur in single 
suture craniosynostosis (Renier et al., 1982; Gault et al., 1992).
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1.2.4.1: Vault Expansion Procedures
The purpose of early calvarial surgery in syndromic craniosynostosis is two-fold; 
firstly lowering of raised intracranial pressure and venous hypertension by immediate 
expansion of the intracranial volume and secondly, removal or release of fused sutures to 
allow further unconstrained growth of the brain. Furthermore, combined fronto-fadal 
advancement procedures (Ortiz-Monesatrio, 1978) may be required at an early stage to 
produce an increase in intracranial volume, simultaneous with an advancement of the 
facial skeleton for protection of exposed cornea and improvement in respiratory function, 
by opening of the nasopharyngeal airway (Polley et al., 1995; Britto et al., 1999).
Surgical procedures for individuals with complex craniosynostosis include cranial 
vault expansion or fronto-fadal advances. Vault expansion can be accomplished either as 
a staged procedure or in a single stage. There are proponents of each technique and no 
individual approach has been proven superior in a validated way. However, most authors 
favour a two stage procedure with either primary anterior or posterior vault decompression, 
followed by counterpole vault expansion (Marchac et al., 1995; McCarthey et al., 1995; 
Hayward et al., 2004). Others, less commonly, advocate a complete single stage calvarial 
vault expansion (Persing et al., 1981; Zuccaro et al., 1996).
Recently the technique of distraction osteogenisis has been added to the 
armamentarium of the craniofadal surgeon (McCarthey, 1992; Cohen et al., 1999; 
McCarthey et al., 2001). This has allowed larger and more stable advances of the 
craniofadal skeleton to be achieved with concomitantly fewer serious side effects such as 
life threatening infection (Cohen et al., 1999; Shin et al., 2003). However, while this 
technique has significant advantages, this has also led to the simultaneous creation of 
large bony defects overlying the brain (Bradley et al., 2006 and personal observations), 
which are filled with a thin fibrous scar joining the dural surface to pericranium or galeal 
aponeurosis (Dahlin et al., 1991; Ripamonti, 1992) (Fig 1.5). However, there is also a 
period of soft tissue interposition prior to successful regeneration of long bones through 
distraction osteogenisis. Why bone does not regenerate as completely in distracted cranial 
bones as it does in long bone is not fully understood. There is evidence that distraction 
osteogenisis in long bones proceeds when cells are stressed (Kanno et al., 2005; Cho et 
al., 2007) which in evolutionary terms, links to the fact that long bones are undergoing 
significant stresses during normal function, whereas the cranium is a protective vault 
compiled of normally unstressed bony plates.
Of further importance may be the fact that cranial bone is derived from 
neuroectodermal origin and forms in membrane without going through a cartilaginous
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precursor. The recent work by Leucht et al., (2008), who have highlighted the potential 
clinical importance of fundamental differences in expression of genes such as the Hox 
patterning genes between mesenchyme derived and neuroectoderm derived 
osteoprogenitors, may provide vital clues to direct the future manipulations aimed at 
resolving the problem of cranial bone regeneration.
Figure 1.5: Post fronto-facial advance for child with Crouzon syndrome
A: Lateral skull view of 3-D CT scan showing a two year old boy with Crouzon syndrome 
one month before surgery. This demonstrates the relative mandibular prognathism which 
is a result of poor forward and downward growth of the orbito-maxillary complex due to 
suture fusions of the neuro and viscerocranium.
B: Similar view 2 months post surgery. Monobloc osteotomies were performed followed by 
a one week period to allow callus formation and soft tissue healing before daily distraction 
of the fronto-facial skeleton by 1mm for 25 days. A further four week period of 
consolidation is necessary before frame removal. Arrow b* points to bony regeneration 
which has occurred in the vicinity of the skull base and mid-facial bones. Arrow b 
demonstrates the absence of bone regeneration of the cranial vault. Minimal further 
regeneration of bone would be anticipated in the vault regions in a child of this age or 
older. (Great Ormond Street Hospital for Children)
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1.2.5: The surgical problem.
The precedent and to a lesser extent the subsequent review, has been carried out 
with the focus on reconstruction of the craniofacial skeleton, as it relates to the conditions 
and surgical challenges encountered by the craniofacial surgeon. However, scenarios 
involving replacement of bone are also a frequent and sometimes everyday occurrence for 
orthopaedic surgeons, neurosurgeons, otolaryngologists and oral surgeons. The review 
therefore has relevance to all of the surgical specialties involved in bony reconstruction. 
This is manifest in the broad source of the review material, drawn from all of the above 
specialties and the basic scientific literature.
By the very nature and geometry of vault expansion, what all surgical approaches 
have in common is that defects will be created between the cut edges of the expanded 
bone. Moreover, spaces may be created between the dura and the dural surface of the 
calvarial bone (Wolfe et al., 1993). These spaces may eventually be obliterated by the 
expanding brain. However, this remains a potential cause of poor bone repair, as the 
dural-bone interface has been shown in animal studies to be the source of greatest bone 
regeneration (Hobar et al., 1993; Gosain et al., 2003). These studies also demonstrated 
that regeneration is significantly poorer in mature animals. This is consistent with findings 
in humans, where the capacity of children over the age of 2 to regenerate calvarium is very 
limited (Sirola, 1960; Bradley et al., 2006). This may be linked to the findings that 
immature dural cells are capable of producing greater amounts of growth factors 
compared with mature cells. (Greenwald et al., 2000).
The knowledge that calvarial defects do not heal in all but the youngest children, has 
necessitated the repair of defects with a number of alternatives. This is required for a) 
protecting individuals from the risk of cerebral injury, b) stabilisation and prevention of 
relapse in the “craniotomised" bony fragments and c) optomising aesthetic outcome by 
restoration of contour defects.
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1.2.6: Current techniques for calvarial defect reconstruction
Historically, autologous bone grafts, allografts, and a variety of alloplastic 
biomaterials have been used for the repair of cranial defects (Koenig et al., 1995; Gosain 
et al., 1999). However, problems related to graft availability, donor site morbidity, 
unpredictable graft resorption (Fig. 1.6), long term growth, long-term biocompatibility, 
immunogenicity, and biomechanical integrity, have all limited the success and 
applicability of these methods (Gosain & Persing, 1999; Pou, 2003), Moreover, because 
alloplastic materials remain as permanent foreign bodies, their use in pediatric patients is 
limited by concerns about their influence on the growing craniofadal skeleton, induding 
the possibilitiy of non degradable materials being translocated to the endocranial surface 
(Fearon et al., 1995).
1.2.6.1: Autologous Bone Graft
Several techniques and material options for the reconstruction of calvarial defects 
exist. The choice made should take into account many factors induding surgical site, risk 
of infection, previous surgeries, indication for surgery and patient age, to account for the 
need for future growth (Moreira-Gonzales et al., 2003). The most commonly used 
technique available for reconstruction of calvarial defects is the autologous free bone graft. 
Autologous grafting for craniofadal defects was first reported by Muller in 1890 to restore a 
skull defect by harvesting bone from the cranium (van Wyck, 1989). Since then and 
despite drawbacks, autologous grafts have remained popular and are considered by most 
spedalists to be the gold standard in the absence of the “ideal” bone substitute (Citardi & 
Friedman, 1994; Kirschner et al., 2002). The most commonly utilised donor areas indude 
cranium, rib, and iliac crest grafts (Guyuron et al., 1988; Prolo & Oklund, 1991). They have 
the advantage of bringing potentially osteogenic tissue to the defect and in-growth of 
adjacent fibro-vascular tissue (Gladstone et al., 1995; Jackson et al., 1987). However, 
they are not vascularised tissues in themselves and the degree to which they are 
incorporated is variable. Cranial bone grafts have the advantage of being situated at the 
site of primary surgery, thereby avoiding the need for a further donor site. Often large 
amounts of bone can be harvested by splitting of the calvarial graft into an inner and outer 
cortex. However, this technique is dependent on there being a well developed, age related 
diploe between cortices to allow feasible splitting (Koenig et al., 1995). Unfortunately, this 
is seldom the case in individuals with craniosynostosis who need surgery at an early age.
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Bone grafts from all donor sites are prone to unpredictable but significant levels of 
resorption (Moreira-Gonzales et al., 2003), although cranial bone grafts are accepted as 
being the most reliable (Whitaker et al., 1979, Tessier 1982; Jackson et al., 1986; 
D’Adonna and Nowzari, 2000). The reliability of cranially derived graft may be linked to the 
recent findings of Leucht et al., (2008), who have shown in mice that mandibular defects 
regenerate more effectively when grafted with bone from a neuroectodermal origin. 
Suggesting that skeletal stem cells have ‘positional memory, which influences how the 
cells behave when grafted into ectopic locations.
In addition to resorption or loss due to infection, complications associated with graft 
harvest can involve persistent cerebro-spinal fluid leak, epidural or subdural haematoma, 
contour deformities of the cranial vault, and permanent neurologic impairment (Kline & 
Wolfe 1995; Zins et al., 1995). Iliac crest grafts are readily available, but they have been 
associated with persistent postoperative pain, herniation of abdominal contents, 
haematomas, and neuropathy of the lateral femoral cutaneous nerve (Fowler et al., 1995; 
Russell & Block, 2000). Split rib grafts provide bone which is malleable to a degree and 
which complies well with skull form and in keeping with other autologous donor sites, it 
seldom fails due to infection. However, harvest involves a secondary donor site which can 
cause severe post operative pain or pneumothorax (Munro & Guyuron, 1981). In common 
with iliac grafts, rib grafts have been reported as undergoing a greater degree of resorption 
than cranial grafts (Zins & Whitaker, 1983; Hardesty & Marsh, 1990; Donovan et al., 1993), 
although recent studies in rabbits have found no difference in resorption volume between 
endochondral (iliac crest) and membranous (mandible) sources, when cortical bone was 
utilised, concluding that bone architecture dictates resorption and not embryological origin 
(Ozaki & Buckman, 1998).
1.2.6.2: Bone-Fibrin Composite
Where small defects are to be filled or where extensive surgery has produced 
significant quantities of bone dust or small bone fragments which can be morselised, 
defects can be filled by a bone pate, created by mixing the residual bone with 
commercially available fibrin glue (Anderl et al., 1987; Matsumoto et al., 1998). While this 
utilises bone which might otherwise be wasted, there are no studies confirming the long 
term outcome of a morselised bone composite, although a high resolution CT scan study, 
has confirmed the complete resorption of bone dust replaced during cranioplasty in all 
patients (O’broin et al., 1997)
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1.2.6.3: Bone Allografts
Allogenic bone is non-vital bone taken from one individual and transferred to another 
individual of the same species. Bone allografts exist in three main forms; a) fresh frozen,
b) freeze dried and c) demineralised bone matrix (DBM). Due to concerns regarding 
transmission of viral and PRION infection, only DBM continues to have a significant role to 
play in the clinical setting. Demineralised bone matrix is produced by demineralisation of 
freeze dried bone, a process which not only removes any inherent structural strength but 
also renders the material incapable of transmitting infection (Mellonig et al., 1992). Urist 
(1965), demonstrated in the 1960s that DBM induced the formation of bone in non- 
osseous tissue such as muscle. This ability to induce osteogenisis in cells, not of the 
osteogenic lineage is termed osteoinduction. It has subsequently been shown that this 
osteoinductive ability is due to the availability of bone morphogenic proteins (BMPs) 
following the demineralisation process (Urist et al., 1984; Wozney et al., 1988). DBM has 
been shown to provide complete bone healing of critical-sized defects in rabbits (Lindholm 
et al., 1993) and dogs (Oklund et al., 1986). Despite the fact that commercial formulations 
of DBM have been available since 1991, recent studies have reported great variability and 
inconsistency with the levels of BMPs present and ability of the material to heal bony 
defects (Maddox et al., 2000; Russell et al., 2000). DBM is used widely for a number of 
dental (Callan 2000, Babbush 2003) otolaryngological (Leatherman & Domhoffer, 2004) 
and orthopaedic indications, particularly spinal scenarios (Ludwig & Boden, 1999; Vaccaro 
et al., 2002; Price et al., 2003). However, the take-up in craniofacial practice appears 
limited, although Chen & Wang (2002), have reported favourable results in 10 consecutive 
patients with an average 33 months follow-up.
1.2.6.4: Polymethylmethacrylate
Polymethylmethacrylate (PMM) or PMM hybrid cements are widely used and 
considered to be one of the most consistently accepted options for reconstruction in the 
fully grown skull (Blum et al., 1997; Lara et al., 1998). They are however, not resorbed, 
incorporated or replaced by bone and do not adapt with the growing skull. They are difficult 
to model during polymerisation which involves a highly exothermic reaction (peak temps of 
81 °C), potentially causing thermal necrosis to the underlying tissues (Stelnicki & 
Ousterhout, 1996). Giant cell foreign body reactions have been described (Constantino et 
al., 1992) and may cause loosening and fragmentation, necessitating removal. Removal 
due to infection is not common unless associated with the sinuses or multiple procedures 
(Manson et al., 1986).
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1.2.6.5: Titanium
While autologous bone remains the preferred method of reconstruction for cranial defects, 
the reconstruction of large defects becomes more difficult owing to the availability of 
appropriate bone stock. In these circumstances defects can be reconstructed with 
prefabricated titanium plates (Fig. 1.6) or mesh (Simpson, 1965). Until the early 1990s this 
technique had the disadvantage of requiring a two stage procedure in order to construct an 
accurately fitting prosthesis, the first stage allowing an accurate impression of the defect to 
be obtained. This problem has since been overcome by the ability to model the titanium 
prosthesis from 3-Dimensionally reformatted CT scans and stereolithographic models 
(Joffe et al., 1992, 1999). Titanium is inert and does not produce a significant foreign body 
reaction and reports of removal due to displacement or infection are few (Joffe et al., 1999; 
Kamyszek et al., 2001). They are however not suitable for use in the growing skull.
Figure 1.6: Bone resorption and prefabricated titanium plate reconstruction
A: A 17 year old with Apert syndrome underwent recontouring of the frontal region with split 
calvarial grafts.
B: Six months following surgery and associated with a chronic staphylococcal infection of the 
bone, the majority of grafted bone has resorbed, creating a further significant contour defect 
and resulting in only soft tissue protection for the brain. C: Lateral view (patient supine) of 
exposed skull. The brain is protected and contour defect reconstructed using a prefabricated 
titanium plate due to risk of further resorption and further graft availability. (Great Ormond 
Street Hospital for Children)
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1.2.6.6: Calcium salt compounds
In the search for bioinert, osteoactive, easily applied and adaptable alloplastic 
materials, ceramic forming, calcium salt compounds, used separately or in combinations, 
have gained popularity (Burstein et al., 1999; Gosain et al., 2002; Durham et al., 2003; 
Eppley, 2003). Commercially produced hydroxyapatite [CaioCPO^eOHJ is chemically 
similar to the mineral component which accounts for 70% of the mineralised tissue in 
mammals. Furthermore, it is naturally occurring, tissue compatible, radiolucent and readily 
available.
Biologically, hydroxyapatite and other ceramic compounds are meant to substitute for 
the mineral phase of bone and are purely osteoconductive, although they can be 
combined with autologous cancellous bone to provide osteogenic potential (Ohgushi et al., 
1989; LeGeros 2002). Their ability to support osteoconduction seems to be dependent 
upon porosity, which appears to be important in allowing diffusion of nutrients, cellular 
attachment and tissue ingrowth (LeGeros, 2002). Typically, these bioceramics degrade by 
a combination of mechanisms; a) simple physicochemical dissolution and b) osteoclastic, 
resorption (LeGeros, 1993; Pietrzak & Ronk, 2000). Tay et al., (1999), recommend that the 
use of these materials should be limited to the filling of bony defects in which the 
surrounding host environment is conducive to bony healing.
Comparison of studies reporting the use of these compounds is difficult, as they 
relate to a large number of different formulations, studied within different species, 
observing differently sized defects. Of the many studies which exist, reports have been 
mixed. Animal experiments have reported generally favourable findings (Kirschner et al., 
2002). Moreira-Gonzales et al., (2003), reported good results with the use of 
hydroxyapatite granules for augmentation in the maxillary-mandibular region. The same 
authors reported that hydroxyapatite paste for reconstruction of human calvarial defects 
produced an immunoguided delayed inflammatory reaction that leads to thinning of the 
skin and exposure of the material, making secondary repair difficult. High levels of 
loosening, fracture, infection and extrusion have also been reported. (Matic & Manson, 
2004),
The most challenging surgical cases in terms of bony reconstruction are those with 
syndromic craniosynostosis. Since the aetiology which underlies the majority of these 
conditions is abnormal signalling via the fibroblast growth factor receptor (FGFR) group of 
receptors and their ligands the fibroblast growth factors (FGFs), it follows that any attempts 
at cell based tissue engineering strategies, are likely to be influenced by these mutations 
and interactions also.
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1.3: Fibroblast growth factors and receptors
1.3.1: Fibroblast growth factors
The fibroblast growth factors (FGFs) are a family of ligands which bind and activate 
fibroblast growth factor receptors. The FGF family consists of structurally related low 
molecular weight polypeptides of which 22 have been identified in mammals (Omitz & Itoh,
2001). Features of FGFs include a homologous central core of 140 amino acid residues 
which form a compact 0-barreI, similar in structure to interleukins 1a and ip  (Smallwood et 
al., 1996), with a strong affinity for heparin and heparan sulphate proteoglycan molecules 
(Schlessinger et al., 1995). Most FGFs are readily secreted from cells. However, the most 
ubiquitous factors, FGF1 and FGF2 lack a secretory amino acid signal sequence and are 
not secreted, but enter the extracellular matrix and cellular surfaces by a mechanism 
independent of the endoplasmic reticulum-Golgi pathway (Mignatti et al., 1992).
Fibroblast growth factors are capable of inducing a wide variety of effects, such as 
angiogenesis, chemotaxis, cell survival, proliferation and differentiation in 
neuroectodermal, epithelial and mesodermal cell types (Basilico & Moscatelli, 1992; 
Szebenyi & Fallon, 1999). Studies together with analyses of the role played by FGFs in 
specific developmental systems and the analyses of the expression patterns of FGFs in 
different tissues and cells, demonstrate that FGFs play critical roles during most stages of 
mouse development and organogenesis (Omitz & Itoh, 2001). Their pattern of expression 
is highly variable ranging from the widely expressed FGF2 (Bikfalvi et al., 1997) to the 
highly restricted expression of FGF4 (Niswander & Martin, 1992). However, we know that 
the expression of FGFs and their receprtors, is temporally and spatially regulated which is 
of importance during craniofacial ossification (Delezoide et al., 1998).
1.3.2: Fibroblast growth factor receptors
Fibroblast growth factor receptors (FGFRs) are members of the Immunoglobulin (Ig) 
superfamily of receptors that have been shown to play a key role in developmental 
processes induding proliferation, migration and differentiation of tissues as well as being 
expressed at high levels during embryogenesis (Peters et al., 1994).
First discovered in the mid 1980s (Olwin et al., 1986), four FGF receptors (FGFR1-4) 
have been characterised. The general structure of FGFRs is illustrated in Fig. 1.7. The 
extracellular (ligand-binding) domain of FGFR is composed of three immunoglobulin (Ig) 
like domains, designated Igl, Igll and Iglll, stabilised by disulphide bridges. These 
intramolecular disulphide bridges result from an interaction between two highly conserved
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cysteine residues, which stabilise the loop conformation. Situated between Igl and Igll is a 
region of 4-8 acidic amino acid residues, called the ‘acid box’ and a positively charged 
region in Igll that serves as a binding site for heparin. Also in this region is the ‘cell 
adhesion molecule’ (CAM) homology domain which is a stretch of 20 amino acids that 
shares sequence homology with NCAM and N-Cadherin. FGFRs have a single 
transmembrane domain (TMD) (Jaye et al., 1992) and, with the exception of the as yet 
uncharacterised FGFR5 (Kim et al., 2001), a ‘split’ intracellular tyrosine kinase domain 
separated into two parts by a 14 amino acid insert.
1.3.3: FGFR isoforms
An important feature of the FGFR family of receptors is that a variety of FGFR 
isoforms are generated by alternative splicing of FGFR transcripts. The different FGFR 
isoforms indude FGFRs with an extracellular domain composed of either two or three Ig- 
like domains, soluble secreted FGFR forms, as well as alternative splidng in the third Ig- 
like domain (Iglll) that profoundly alters ligand-binding specifidty (Miki et al., 1992). The 
alternative splidng in Iglll exists in FGFR1, 2 and 3, but not in FGFR4. It has been shown 
that exon 7 of FGFR2 gene encodes for the N-terminal half of Iglll (designated ‘a’), while 
exons 8 and 9 alternatively encode for the C-terminal half of Iglll. and are thus designated 
as ‘b’ and ‘c’ forms of FGFR, respectively (Fig. 1.7). Splice variants alter receptor function, 
and in several cases, lead to different ligand-binding specificities. Structural and fundiona! 
diversity amongst FGFR isoforms, combined with numerous receptor ligands of which 
fibroblast growth fadors (FGFs) are the most important, results in the potential for 
extremely complex and diverse FGFR-ligand interadions (Omitz & Itoh, 2001). It has been 
shown that the FGFR2b isoform is exdusively expressed in epithelial cells and that the 
FGFR2c is expressed exdusively in mesenchymal cells (Orr-Urtreger et al., 1993). The 
lineage-specific expression of the lllb and lllc isoforms of FGFRs enables interadion 
between the epithelial and mesenchymal layers during development in response to 
different ligands.
1.3.4: FGFR I ligand specificity
The extracellular regions of FGFRs are involved in ligand binding. Loops II and III 
and the interlinker region between them are required for conferring specificity upon the 
interaction between the receptor and FGF (Plotnikov et al., 1999). Omitz et al., in 1996, 
showed that mitogenic responses to FGF signalling were highly specific, and dependent
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Figure 1.7: General structure and isoforms of FGFRs
FGFR isoforms generated by alternative splicing of FGFR transcripts. The two forms of 
FGFR are generated by alternative splicing of exons 8 and 9. The C-terminal half of Iglll is 
encoded by exon 8 to generate the FGFR-lllb isoform while the C-terminal half of Iglll 
when encoded by exon 9 generates the FGFR-lllc isoform. TKD= tyrosine kinase domain, 
TMD= transmenbrane domain (Adapted from Morriss-Kay & Wilkie 2005)
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upon the combination of ligand and FGFR isoform. Table 1.4 shows the specificities of 
FGFRs and FGFs based principally on this study.
Upon ligand binding, receptor dimerisation brings the cytoplasmic domains of the 
receptors in close vicinity of each other providing the opportunity for receptor trans- 
autophosphorylation, subsequent tyrosine kinase activation and initiation of downstream 
signalling pathways (Yarden and Ullrich, 1988).
The binding of FGFs to their receptors and subsequent dimerisation is dependent 
upon the low affinity, co-binding of heparan sulphate containing proteoglycans (Ornitz et 
al., 1992; Spivak-Kroizman et al., 1994).
FGFR Isoform Ligand Specificity
1b FGF1,2,3,10
1c FGF1,2,4,5,6
2b FGF1,3,7,10,22
2c FGF1,2,4,6,9,17,18
3b FGF1 and 9
3c FGF1.2,4,8,9,17,18,23
4 FGF1,2,4,6,8,9,16,17,18,19
Table 1.4: Ligand specificities of FGFR isoforms
FGF ligand binding specificity determined by thymidine incorporation. Adapted from Ornitz 
et al., (1996); Xu et al., (2000); Yamashita et al., (2002); Umemori et al., (2004)
1.3.5: FGFR expression
In the earliest stages of the normal human developing skull and before ossification, 
FGFR1 expression is present in the entire head mesenchyme. FGFR2 is expressed in the 
epidermis and preosteogenic mesenchymal condensation and low levels of FGFR3 are 
found in basal head mesenchyme and epidermis. Approximately half way through 
gestation, sutures appear at the periphery of osteogenic centres and FGFR1 and FGFR2 
are expressed at high levels in the osteogenic fronts of the sutures where only low levels 
of FGFR3 are found, (Delezoide et al., 1998). Studies in mice by Rice et al., (2003), found
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mRNA for FGFRIc was detected weakly in osteoblastic cells in the developing calvarial 
bones. FGFR2c transcripts were detected at high levels in differentiating osteoblasts at the 
sutural osteogenic fronts of the calvarial bones. FGFR2b transcripts were detected in the 
cranial base where FGFR3b and FGFR3c were also localised. FGFR4, which has not 
been found to be a source of mutations for craniosynostosis, was detected minimally in 
calvarial cartilage. These distribution patterns are important in explaining the link between 
FGFR mutations and phenotype expression of individual craniofacial syndromes (Britto et 
al.. 2001).
1.3.6: Mutations in syndromic craniosynostosis
As previously described in this chapter, the severest forms of craniosynostosis are 
associated with abnormalities of the molecular genetics which are summarised in 
Table1.5. The recent discoveries of mutated genes that cause syndromic 
craniosynostosis, and the subsequent molecular investigations into these mutations, have 
greatly enhanced our understanding of the biological events that underlie them.
In 1993 a breakthrough came when the first mutation to be associated with 
craniosynostosis was found in the MSX2 gene (Jabs et al., 1993). Subsequently, 
mutations in various locations of the FGFR2 gene were found in children with a clinical 
diagnosis of Crouzon syndrome (Reardon et al., 1994). Since then Crouzon, Apert, 
Pfeiffer, Jackson Weiss and Beare-Stevenson syndromes have all been shown to arise as 
a result of mutations in FGFR2 (Jabs et al., 1994; Muenke et al., 1994; Wilkie et al., 
1995,). Mutations in FGFR1 and FGFR3 can also occur in rarer forms of Pfeiffer syndrome 
and Crouzon patients respectively (Muenke et al., 1994; Schell et al., 1995; Pryzlepa et al.,
1996). Muenke syndrome, the commonest and the mildest of the syndromic 
craniosynostoses is caused by a mutation of FGFR3 which is more commonly the site of 
mutations causing achondroplasia. To date, no causal mutations have been reported in 
FGFR4 (Gaudenz et al., 1998) or in FGFR5 (Kim et al., 2001). The similarity in clinical 
phenotype of cases with Apert syndrome, reflects its restricted genotype compared to that 
of the other syndromes including Crouzon, Jackson-Weiss and Pfeiffer which exhibit an 
overlapping clinical phenotype. It is noteworthy that Apert syndrome is associated with 
increasing paternal age (Moloney et al., 1996) and implicates the involvement of 
spermatogenesis in mutagenesis.
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Mutations in TWIST, a basic helix-loop-helix transcription factor have been identified 
in individuals with Saethre-Chotzen syndrome (Howard et al., 1997; El Ghouzzi et al.,
1997). The mechanism for mutated TWIST activity is not clearly understood, although 
most of the mutations result in a non-functional protein and are likely to result in 
haploinsuffidency (Wilkie, 1997). Yousfi et al., (2001), found that this produced altered 
osteoblast function in cultured human calvarial cells which may be linked to alteration of 
FGFR expression (Rice et al., 2000; Funato et al., 2001). This has been confirmed by 
Guenou et al., (2005), who have demonstrated that TWIST haploinsuffidency 
downregulates Fgfr2 mRNA expression, which in turn reduces Runx2 and downstream 
osteoblast-specific genes in human calvarial osteoblasts. Thus, providing evidence for a 
role of FGFR2 in the altered osteoblast phenotype induced by TWIST mutations in 
Saethre-Chotzen syndrome. More recently, Connemey et al., (2008), have shown that 
TWIST happloinsuffidency alters the TWIST heterodimers/homodimer ratio, effecting 
sutural patency by altering suture responsiveness to FGF signalling. In contrast to the 
majority of mutations in the TWIST gene, all FGFR mutations are in-frame mutations which 
code for functional proteins and are due to missense mutations, deletions, insertions or 
splice events. Although many mutations have been reported, there is marked dustering of 
mutations at particular locations in the FGFR genes. Namely, at the interlinker region 
between Igll and Iglll, the membrane end of the 3rd immunoglobulin domain and the 
transmembrane domain (Wilkie, 1997). Homologous mutations have been identified at 
equivalent positions in more than one FGFR. For example, in the interlinker region 
between Igll and Iglll, Pro252Arg substitution of FGFR1 causes Pfeiffer syndrome, 
Pro253Arg substitution in FGFR2 causes Apert syndrome, and Pro250Arg substitution in 
FGFR3 causes Muenke craniosynostosis (Muenke et al., 1994; Wilkie et al.,, 1995; and 
Bellus et al., 1996). Interestingly, it has also been identified that single mutations such as 
the C278F missence mutation of the FGFR2, can manifest as either Crouzon, Pfeiffer or 
Jackson-Weiss syndrome (Meyers et al., 1996; Passos-Bueno et al., 1997). Moreover, the 
same syndrome can be caused by mutations in different genes as exemplified by 
mutations in both FGFR1 and FGFR2 causing Pfeiffer syndrome. The mechanism by 
which the same genotypes cause different phenotypes is still uncertain. It may be due to 
unidentified polymorphisms within FGFRs or a complex temporal interaction between 
receptor regulation and ligand availability within different domains (Wilkie et al., 2006).
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Gene
FGFR1 Pfeiffer Igll - Iglll interlinker
FGFR2 Crouzon
Pfeiffer
Apert
Jackson-Weiss 
Beare Stevenson
Ig III -  mainly the creation of unpaired 
cysteine residues
As for Crouzon, sometimes the mutations are 
identical (e.g. C278F)
Igll-lglll interlinker 
As for Crouzon
Creation of new cysteine residues
FGFR3 Muenke syndrome 
Achondroplasia 
Crouzon (with a.n.) 
Thanotophoric dysplasia I 
Thanatophoric dysplasia II
Igll-lglll interlinker (P250R) 
Transmembrane 
Transmembrane 
Creation of cysteine residue 
Tyrosine kinase domain
Table 1.5: Craniofacial syndromes associated with mutations in FGFRs
Abbreviations: Ig: Immunoglobulin, a.n.: acanthosis nigricans. (Adapted from Wilkie, 2005)
There is evidence that mutations cause constitutive activation of receptors (Neilson & 
Friesel, 1995; Galvin et al., 1996; Mangasarian et al., 1997; Robertson et al., 1998). This 
activation is brought about by a number of effects including a) alteration in the number of 
cysteine residues allowing covalent cross linking with another mutant receptor and 
receptor dimerisation in the absence of FGF (Kannan and Givol, 2000), b) destabilisation 
of the disulphide bridge leading to alternative intermolecular bonds (Burke et al., 1998),
c) formation of transmembrane hydrogen bonds leading to conformational change and 
dimerisation (Webster and Donoghue, 1996) or d) increased ligand affinity of reduced 
ligand dissociation, leading to prolonged receptbr signalling (Anderson et al., 1998). (Fig. 
1.8)
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^ l g  like loop domain, [*]ActdBox/CAM domain, Q  Transmembrane domain,
Qryrosine kinase domain, ^Mutation site, Trans-phosphorylation of receptors,
''j  HSPG molecule, H...H hydrogen bond, C -C ‘free’ cysteine residues, Ligand.
Figure 1.8: Schematic representation of FGFR mutations
A. General structure of FGFR showing mutation foci
B. Effects of mutations in syndromic craniosynostosis. a) normal FGFR activation, b) 
intermolecular disulphide bridge formation secondary to unpaired cysteines, c) hydrogen 
bond formation in transmenbrane domains d) mutations leading to increased affinity or 
reduced dissociation of FGF ligand. (Adapted from Anderson et al., 1998; Burke et al., 
1998; Green et al., 1996; Kannan & Givol, 2000; Webster & Donohue, 1996)
- 4 3 -
1.3.7: FGF/FGFR interactions and osteogenisis
Bone development is dependent on the expression of members of the FGF family 
expressed locally during bone formation. FGF2, FGF4, FGF9, FGF18 and FGF20 
transcripts are found in cranial and sutural mesenchymal cells and osteoblasts (Gonzalez 
et al., 1996; Kim et al., 1998; Britto et al., 1998; Rice et al., 2000; Ohbayashi et al., 2002; 
Hajihosseini and Heath, 2002), suggesting that they may be involved in regulating calvarial 
osteogenisis. Recent data indicates that FGF18 is becoming recognised as an important 
coordinator of osteogenisis via FGFR2 and FGFR3 and will be reviewed separately. FGF 
expression is also dependent on the temporo-spatial expression pattern of FGFRs 
(Powers et al., 2000). FGFR1 and FGFR2 are expressed in mesenchymal cells during 
condensation prior to deposition of bone matrix, at early stages of long bone development 
(Orr-Urtreger et al., 1991) and are also expressed in the cranial suture (Delezoide et al., 
1998). Later in development and postnatally, FGFR1 and FGFR2 are found in pre­
osteoblasts and osteoblasts together with FGFR3 (Iseki et al., 1997; Delezoide et al., 
1998; Kim et al., 1998). The coordinate actions of FGFs on gene expression in osteoblasts 
is not only dependent on FGFR expression, but also on the affinity and specificity of FGF 
binding to the various alternative splice forms of FGFRs (Omitz et al., 1996). FGFR2lllc is 
expressed in early mesenchymal condensates and later in sites of endochondral and 
intramembranous ossification where it was recently found that in mice, the recessive 
phenotype of Fgfr2lllc(-/-) is characterised initially by decreased expression of bone 
transcription factor RunX2 (previously Cbfa) and retarded long bone ossification, 
suggesting that Fgfr2lllc is a positive regulator of ossification (Eswarakumar et al., 2002). 
Furthermore, FGFs bind cell surface heparan sulfate proteoglycans acting as low-affinity 
co-receptors that interact with FGF binding and signalling (Omitz, 2000; Schlessinger,
2000). Some of these proteoglycans, including syndecans are expressed in bone (Solursh 
et al., 1990) and may affect the osteoblast response to FGF during osteogenisis (Molteni 
et al., 1999). Given this mix of interacting molecules, it is likely that subtle changes 
occurring in the expression or localisation of any number of them, may induce variable 
functional effects on FGF signalling and osteoblast gene expression in vivo. Moore et al., 
(2002), have shown that there is a gradient of FGF2 expression, which is greatest at the 
suture, lessening in the surrounding mesenchyme, suggesting FGF2 may be driving 
proliferation at the sutures to keep them patent.
This group further found that blocking FGF2 activity prevents osteogenisis in a 
concentration dependent manner, consistent with previous findings that over-expression of 
FGF2 in mice induces abnormal bone formation (Coffin et al., 1995), whereas FGF2
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perturbation inhibits it (Montero et al., 2000; Greenwald et al., 2001). There is also good 
evidence that at the osteoblast level, the effect of FGFs is dependent on the stage of 
cellular maturation: and this will be discussed more fully in chapter 5.
1.3.8: FGF18 in osteogenisis
FGF18 is a recently investigated member of the FGFs, having been isolated in the 
rat and mouse in 1998 (Ohbayashi et al., 1998; Hu et al., 1998). The human FGF18 gene 
has been localized to chromosome 5q34 (Whitmore et al., 2000). It is highly conserved 
with a 99% identity match with the amino acid sequence, while the nucleotide sequence is 
90% conserved between humans and mice. It is involved in specification of left-right 
asymmetry (Ohuchi et al., 2000) and in the development of the intestinal tract (Hu et al.,
1998), brain (Ohuchi et al., 2000) and lung (Whitsett et al., 2002). A role in endochondral 
and intramembranous bone formation has been demonstrated in rodents and chicks 
(Ellsworth et al., 2002; Liu et al., 2002; Ohbayashi et al., 2002). Hajihosseini et al., (2002), 
found that FGF18 is strongly expressed in mouse coronal sutures, dorsal rims of the 
parietal bones and in the cranial base and that these regions directly abut with zones of 
osteopontin expression. It is interesting that of the FGFs so far targeted in mice, only those 
lacking FGF18 have demonstrated a phenotype affecting calvarial development: 
Ohbayashi et al., (2002) demonstrated FGF18 expression in differentiating osteoblasts 
and osteogenic mesenchyme, between the osteogenic fronts in calvarial bones and in the 
perichondrium of developing long bones. FG FIS'' mice illustrated delayed ossification 
characterised by widened metopic, coronal and sagittal sutures, delayed suture closure 
and decreased calvarial mineralisation. Proliferation within the calvarial osteogenic 
mesenchyme was also decreased.
FGF 18 shows strong binding affinity for FGFR3c and FGFR2c, as well as strong 
mitogenic activity for FGFR3c, modest for FGFR2c and not at all for FGFR1, FGFR4 or 
any of the b spliced variants (Xu et al., 2000). Both FGFIS"'' and FGFR3*7* mice display a 
similar although not identical long bone phenotype suggesting that while FGF 18 signalling 
through FGFR3 is important in chondrogenisis, FGF18 must also signal through other 
FGFRs (Liu et al., 2002). More recently Liu et al., (2007), have emphasised the role of 
FGF 18 in the control of mesenchymal vascularisation around centres of endochondral 
osteogenisis. Since FGFR1 and FGFR2 are the predominant FGFRs expressed in the 
calvarial bones (Iseki et al., 1999; Rice et al., 2000), it is likely that these FGFRs are the 
target for FGF18 in calvarial osteogenisis.
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The MC3T3-E1 murine cell line treated with FGF18 show a dose dependent increase 
in proliferation through ERK activation and inhibition of matrix synthesis and differentiation. 
These effects were comparable to the effects produced by FGF2 and it has been 
postulated that it might compensate for FGF2 in skeletal development (Shimoaka et al.,
2002).
1.3.9: FGF/FGFRs and osteoblast gene expression
The number of ligands and receptors acting on osteoblast are many and complex. 
However, FGF/FGFR interactions play an important part in modifying the expression of 
multiple genes that characterise the osteoblast phenotype. In osteoblastic cell cultures, as 
is the case for many other proteins, the effects of FGF signalling on osteocalcin (OC) 
expression are complex and depend on the cell type. Indeed, FGF1 inhibits OC gene 
expression in rat calvarial cells (Tang et al., 1996), but enhances its expression in bovine 
bone cells (Schedlich et al., 1994). Direct regulation has been reported in mouse calvarial 
cells, where FGF2 effects OC expression by acting on specific elements in the OC gene 
(Schedlich et al., 1994, Newberry et al., 1996), FGF2, FGF4 and FGF8, or transfection 
with a vector expressing a mutant FGFR2 that is constitutively activated in the presence of 
FGF ligand, was found to stimulate Runx2 expression in osteoblasts (Zhang et al., 2002; 
Kim et al., 2003). FGF signalling effects the expression of proteins involved in cellular 
communication and adhesion including the connexins and cadherins which will be 
discussed in more detail later in the chapter. FGFs interact with other growth factor 
signalling pathways and may thereby regulate osteoblast function. For example, FGF2 
up-regulates TGFp expression in osteoblasts in vitro (Noda & Vogel 1989). Conversely, 
TGF0 regulates FGF2 and FGFR expression in osteoblastic cells (Sobue et al., 2002). 
Additionally, FGF2 increases insulin-like growth factor-l (IGF-!) gene expression in vitro 
(Zhang et al., 2002) and in vivo (Power et al., 2002). Recent data indicate that FGF2 and 
FGFR2 inhibit the expression of the bone morphogenic protein (BMP) antagonist noggin in 
the patent cranial suture, resulting in premature suture fusion (Warren et al., 2003), thus 
indicating that FGF signling can control cranial suture fusion indirectly through BMP 
signalling. It is therefore likely that the biological activities of FGFs in bone depend not only 
on the balance between FGF and FGFR expression, but also on the presence of other 
signalling molecules. In addition, FGFs regulate genes that are involved in matrix 
resorption by increasing the expression of extracellular collagenase (Hurley et al., 1996, 
Varghese et al., 2000). These studies suggest that FGFs may modulate bone matrix 
breakdown by regulating collagenase expression and activity. Taken together, activation of
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FGF/FGFR signalling seems to regulate genes involved in most of the steps of 
osteogenesis. These finding would also suggest that genes may participate in regulating 
cell progression from osteoprogenitor cell to osteoblast death
1.4: Cellular bone biology 
1.4.1: Bone Cells
Bone is a constantly changing tissue which necessitates the presence of cells both 
for deposition and resorption. Calvarial bones ossify by the direct secretion of extracellular 
matrix, by osteoblasts, into mesenchymal condensations, forming centres of ossification. 
Osteoblasts are the predominant cell of bone deposition and are derived from 
mesenchymal cells which become preosteoblast prior to becoming functioning osteoblasts. 
Osteoclasts, which are derived from the monocyte/macropghe lineage, play an equally 
important role in bone growth and remodelling by their function of resorption (Sommerfeldt 
& Rubin 2001). They are regulated by the acidified microenvironment in addition to being 
under hormonal control by numerous factors, both pro-resorbative such as vitamin D3 and 
corticosteroid and anti-resorbative such as oestrogen and calcitonin (Boyle et al., 2003). 
Osteocytes are found, throughout mature bone enclosed within lacunae. They are the 
most common cell type in bone, forming an intercommunicating, syncitial network. Their 
role in osteogenisis and skeletal health has until recently been unclear. However, it is now 
appreciated that osteocytes are highly responsive to circulating hormone levels and 
cytokine (Bringhurst, 2002), and there is now growing evidence to support the hypothesis 
that the osteocyte is the bones mechanoreceptor (Noble et al., 2003).
1.4.2: Osteoblast differentiation and function
Osteoblasts are channelled through a path of commitment from mesenchyme to 
become mature osteoblasts. This journey from pluripotent mesenchymal cell to fully 
differentiated and functioning osteoblast is a process which involves a variety of 
hormones, cytokines and growth factors (Roelen, 2004). Osteoblasts are principally 
responsible for the deposition and regulation of extracellular matrix proteins and the 
expression of genes required for mineralisation and interaction with osteocytes and 
osteoclasts to regulate bone turnover. Molecules important for development of the 
osteoblastic phenotype include, Runx2 a transcription factor required for osteoblast 
differentiation and bone formation (Ducy et al., 1997). Absence of Runx2 in knock-out
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mice causes a complete absence of osteoblasts and osteogenisis (Komori et al., 1997, 
Otto et al., 1997). In humans, mutations within the Runx2 gene cause cleidocranial 
dysplasia (Lee at al 1997; Mundlos et al., 1997), characterised by short stature, widely 
patent inter-parietal and metopic regions and dental anomalies.
Osterix (Osx) is a recently identified zinc-finger containing transcription factor, that is 
expressed in all developing bones and appears necessary for osteogenisis. Osx null mice, 
do not deposit bone matrix and membranous mesenchymal cells cannot differentiate into 
osteoblasts. These cells do, however, express Runx2. In contrast, Osx is not expressed in 
Runx2 null mice, suggesting that Osx acts downstream of Runx2 (Nakashima et al., 2002).
Mature osteoblasts are morphologically indistinguishable. However recent in-situ 
studies in rat calvaria show that they are not a homogeneous class of cells, but are instead 
a molecularly diverse group of subpopulations based on the expression patterns of specific 
markers. These can be divided into two categories; those that are expressed by all 
osteoblasts, irrespective of their position in the calvaria, including, alkaline phosphatase 
and those such as the matrix proteins osteopontin, osteocalcin and bone sialoprotein 
which are differentially expressed only in subpopulations of osteoblasts (Candeliere et al.,
2001). This work complements previous, similar findings of osteoblast subpopulations 
within bone nodules of cultured rat osteoblasts (Malaval et al., 1994). The mRNA 
expression of some of the important markers of osteogenisis will be studied in this work.
1.4.2.1: Type 1 Collagen
Synthesised by fibroblasts and odontoblasts, type 1 collagen is principally the 
product of osteoblasts during the laying down of bone matrix and is the most abundant 
protein in bone, accounting for approximately 90% of bone matrix (Bilezikian et al., 1996). 
It is a trimeric molecule composed of two a1 chains and a a2 chain, which are in 
themselves made from polypeptide sequence repeats. These allow the formation of a triple 
helix which gives rise to a highly ordered fibrillar structure, important for tensile strength 
within mineralised tissues. Mutations within the genes coding for collagen I a chains lead 
to osteogenisis imperfecta, characterised by fragility and deformities of bone and dentine 
(Penttinen et al., 1975). Ascorbic acid is required for normal fibrillar crosslinking, which in 
turn is necessary for expression of the osteoblast phenotype and expression of alkaline 
phosphatase, osteocalcin (Franceschi et al., 1994; Wenstrup, 1996; Xiao et al., 2002) and 
for optimal cell adhesion and migration (Masi et al., 1992). Studies indicate that interaction 
of type I collagen with alpha2 integrin, is a crucial signal for the induction of osteoblastic 
differentiation and matrix mineralisation (Xiao et al., 1998; Reyes et al., 2004)
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Pathologically increased secretion of type 1 collagen by calvarial osteoblasts has 
been demonstrated in craniosynostosis associated with mutations of FGFRs (Bodo et al., 
1996; Lomri et al., 1998; Baroni et al., 2002).
1.4.2.2: Alkaline Phosophatase
Alkaline phosphatase (ALP) is a glycoprotein phosphohydrolase which exists in four 
isomeric forms encoded by different genes. The ALP associated with bone metabolism is 
tissue non-specific. This is found as a membrane bound enzyme in many tissues including 
some preosteoblasts and all osteoblasts (Candeliere et al., 2001). The function of ALP in 
bone formation is not entirely dear. However, it is thought to play a role in mineral 
maturation, as humans carrying mutations for ALP suffer from variable degrees of 
hypophosphatasia, a condition characterised by poor bone mineralisation (Weiss et al., 
1988). ALP is an early marker of the osteoblast (Whyte et al., 1994) phenotype, with 
expression which is inversely related to cellular proliferation increasing as cellular 
maturation progresses (Fedarko et al., 1990; Cowls et al., 1998).
Alkaline phosphatase activity requires normal type 1 collagen secretion (Wenstrup et 
al., 1996) and decreased levels of ALP have been demonstrated in the calvarial 
osteoblasts of patients with craniosynostosis associated with Crouzon syndrome 
(Ratisoontom, 2003).
1.4.2.3: Osteocalcin
Osteocalcin is a highly conserved, noncollagenous matrix protein found in bone, and 
other mineralised tissues (Ulrjch et al., 1987) and is amongst the most abundant of the 
bone matrix proteins. (Gerstenfeld et al., 1987). The functions of osteocalcin, suggested by 
an analysis of genetically engineered osteocalcin-deficient (“knockout”) mice includes, 
bone mineral maturation and inhibition of bone formation. Osteocalcin knockout mice have 
an accelerated rate of bone formation without changes in osteoblast or osteoclast number 
(Ducy et al., 1996). It is highly expressed by mature osteoblasts, usually as a late marker 
of osteoblast differentiation and is commonly examined in studies of osteogenisis. Raised 
OC levels have been demonstrated in craniosynostosis associated with mutations in the 
FGFRs (Lemmonier et al., 2001; Tanomoto et al., 2004) whilst decreased levels have 
been expressed in other craniosynostoses, associated with mutations in the TWIST gene 
(Yousfi et al., 2001).
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1.4.3: Coordinate expression profile of osteodifferentiation markers
Osteoblastic cell cultures, both primary and cell line, demonstrate a coordinate 
pattern of gene expression for molecules associated with the osteoblast lineage. The 
pattern of expression is dependent on the cells progressing through recognised stages 
from proliferation to terminal differentiation usually leading to mineralisation. Generally, the 
differentiation sequence is defined by an increase in collagen synthesis, acquisition and 
increase in alkaline phosphatase activity, followed by expression of several non- 
collagenous bone matrix proteins, such as osteopontin, bone sialoprotein and finally 
osteocalcin as the latest marker of the mature osteoblast (Quarles et al., 1992; Heersche 
et al., 1992; Choi et al., 1996). However, discrepancies in this expression profile have been 
reported and it should be borne in mind that whilst the general pattern exists across 
species, expression patterns are species specific; for example osteocalcin is expressed at 
a later stage of differentiation than ALP in the rat calvaria, whereas it parallels expression 
of ALP in chick calvaria (Stein & Lian 1993; Gerstemfeld et al., 1987). Within osteoblast 
lines, expression of different levels of the same marker are even observed (Heersche et 
al., 1992; Malaval et al., 1994; Smith et al., 2000), indicating considerable plasticity and 
functional heterogeneity of the osteoblast phenotype; for example within the MC3T3-E1 
osteoblast line which shall be examined more fully later, subdones of cells were identified 
in which expression of ALP was highly variable (Wang et al., 1999).
1.4.4: Cell adhesion and communication
As well as regulating the expression of genes characterising the osteoblast 
phenotype, FGF/FGFR signalling controls osteogenisis indirectly, via the expression of 
genes involved in osteoblast function, induding, amongst others, those of cell adhesion 
and communication channel proteins. These are required for cell-cell and cell-matrix 
interaction, communication and adhesion (Francheschi, 1999).
1.4.4.1: N-Cadherin
Cell-cell adhesions are mediated by adherens junctions containing cadherins. These 
are transmembrane glycoproteins acting with intracellular partners known as catenins 
which in turn interact with intracellular proteins (Yamada & Geiger, 1997). The cadherin 
family is composed of several calcium dependent molecules of which N-cadherin is one. 
Human osteoblasts were first shown to express N-cadherin by Cheng et al., (1998), who
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demonstrated that cadherins were critical for the expression of Bone Morphogenic Protein 
(BMP)2.
During the early stages of intramembranous bone formation, cadherins play an 
important role in the condensation of mesenchymal cells prior to ossification (Hall & 
Miyake, 2000). Osteoblasts in human and mouse cranial sutures and preosteoblasts and 
osteoblasts in the foetal human cranial sutures are known to express N-cadherin 
(Tsutsumimoto et al., 1999; Lemmonier et al., 2000). In human calvarial osteoblasts, 
N-cadherin neutralising antibodies have been shown to down-regulate the expression of 
alkaline phosphatase, type I collagen and osteocalcin (Hey et al., 2000). Lemmonier et al., 
(2001) and Lomri et al., (2001), have demonstrated over-expression of N-cadherin, 
mediated by Protein Kinase C, in osteoblasts from the coronal suture of fetuses with A pert 
syndrome carrying an activating mutation for FGFR2. This resulted in increased cell-cell 
adhesion and over-expression of osteodifferentiation markers in days 0-7 of confluent 
primary cell cultures.
1.4.4.2: Connexin 43
Intercellular communication is a fundamental requirement of skeletal tissue and is 
thought to control several physiological functions of bone cells, including, the coordination of 
tissue responses to mechanical stimulations (Duncan & Turner, 1995), sensitivity to 
hormones and growth factors (van der Molen et al., 1996) and the progression of 
differentiation (Lecanda et al., 1998). This communication is mediated by the transfer of 
small molecules and ions through transmembrane channels called gap junctions which are 
abundant in bone cells (Stanka, 1975; Doty, 1981) and have been demonstrated in cultured 
osteoblasts including MC3T3-E1 cells (Yamaguchi et al., 1994).The principal functional 
components of gap junctions are the connexins. These comprise a closely related 
group of hexameric proteins that associate to form cell-cell adhesion channels which 
assemble in gap junctions (Makowski et al., 1977; Beyer et al., 1990). When the 
connexin of one cell is in contact with a similar structure on a neighbouring cell, a 
transcellular channel is formed (Civitelli, 1995). The most abundant connexin in human 
and MC3T3-E1 osteoblasts is connexin 43(Cx43) (Civatelli et al., 1993; Yamaguchi et 
al., 1994). The gene is located on human chromosome 6q22. Mutations within the gene 
cause Oculo-digital-dental dysplasia, characterised by ocular, nasal, limb and dental 
deformities (Paznekas et al., 2003). The expression of Cx43 is associated with elevated 
levels of metabolic coupling (Jorgensen et al., 1997) and with a high degree of cellular 
differentiation (Schiller et al., 1997; Li et al., 1999). Over-expression of Cx43 has resulted in
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increased expression of osteocalcin in MC3T3-E1 cells (Lecanda et al., 1998), whilst Cx43- 
null mice display globally delayed ossification, osteoblast dysfunction and craniofacial 
abnormalities characterised by poor membranous bone ossification (Lecanda et al., 2000). 
Cx43 has also been implicated in altered cell motility and adhesion; Xu et al., (2001), have 
reported that neural crest cells deficient in Cx43 displayed poor motility and delayed neural 
crest migration has been observed by Huang et al., (1998). Gramsch et al., (2001), 
reported enhanced proliferation, bone nodule formation and mineralisation of the UMR 
osteosarcoma cell line overexpressing Cx43. FGF2 treatment has been shown to down- 
regulate Cx43 dependent cellular communication in astroglial cells (Reuss et al., 1998) 
and in MC3T3-E1 cells (Shiokawa-Sawada et al., 1997).
1.5: Bone engineering
1.5.1: The “Ideal” biomaterial
There is a strong need for bone substitution materials in craniofacial reconstruction 
and surgery in general. Currently, standard autologous bone grafting remains the default 
“best option” for bony reconstruction of the craniofacial region, although frequently this is 
not feasible and several allograft options, along with their potential problems, do exist. 
However, primary bone grafting fails in up to 20% of cases for a number of reasons 
(Younger & Chapman, 1989) and harvesting requires a donor area often at a secondary 
site. Thus, in addition to potentially increasing the operative time, this also increases the 
potential complications as reviewed in section 1.2.6.1. It would be desirable therefore, to 
try and eliminate these associated problems by creation of a bone graft substitute. An 
engineered bone substitute that can mimic the native structure and replace the mechanical 
and biological functions of the natural tissue being replaced would be ideal. This “ideal” 
would be a mechanically appropriate, biocompatible, bioresorbable scaffold, capable of 
supporting sufficient numbers of functioning cells (Langer & Vacarrti, 1993), capable of 
regenerating bone.
The search for this ideal synthetic bone substitute has been long and has 
generated numerous and ongoing studies (Rose & Oreffo, 2002). Initial attempts to 
produce materials with this aim, had as their main objective, the provision of implants 
which were physically suitable and which did not involve unacceptable host toxicity. This 
principally meant materials which were inert and did not produce a foreign body reaction. 
This resulted in more than 50 prosthestic implants being introduced into clinical use in the
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1960s-70s. None of which however, attempted to allow or induce bone regeneration 
(Hench, 1980).
More recently, work has focused on the two material properties which seem 
fundamental to creation of the “ideal”. Firstly, the creation of biodegradable materials and 
secondly the creation of materials which either permit bone regeneration by supporting 
osteoblast growth (osteoconductive), or actively stimulate bone regeneration by inducing 
cells to differentiate down the osteoblast lineage to form bone (osteoinductive). The 
classic example of the latter being the induction of ectopic bone within muscle following 
the intramuscular injection of demineralised bone matrix (DBM) (Urist, 1965).
Biodegradable materials offer several physical advantages over metals and other 
non-degradable materials currently in use as orthopaedic or craniomaxillofacial implants. 
These are best described in terms of avoiding the reported disadvantages inherent to non 
degradable materials such as titanium. These include growth disturbance (Resnick et al., 
1990; Lin et al., 1991; Eppley et al., 1993), plate migration (Fearon et al., 1995), the need 
for subsequent removal (Beals & Munro, 1987; Schmidt & Perrot, 1998) compatibility with 
future imaging needs, long-term palpability and thermal sensitivity (Orringer et al., 1998).
Numerous naturally occurring, biodegradable compounds have been studied in an 
attempt to create scaffolds including collagen (Mizuno et al., 1997), chitosan (Lee et al., 
2000), alginate (Shang et al., 2001), agarose (Mauck et al., 2003) and fibrin (Karp et al., 
2004). While these are degradable and biologically derived, their utility has been 
questioned on the basis that they provide poor mechanical strength and degradation rates 
can prove inconsistent (Gombotz et al., 1993). Synthetic alternatives which provide 
mechanical strength have therefore been studied and developed, including 
polycarbonates, polyesters, polyorthoesters, polyanhydrides, polyurethanes and
polyphophosphazenes (Gunatillake & Adhikari, 2003). As a result of these developments, 
several have been licensed for clinical use.
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1.5.2 Biomaterial options 
1.5.2.1 Polyesters
One of the most extensively studied biodegradable, polymeric materials, are the 
group known as the polyesters, of which polylactic acid (PLA) and polygiycolic acid (PGA) 
are the two most commonly encountered. They have been used for a number of clinical 
applications including resorbable sutures, drug delivery systems and fixation devices such 
as rods, pins screws and plates (Ashammakhi & Rokkanen, 1997, Middleton & Tipton,
2000). They have also been studied for tissue engineering applications (Hollinger, 1983; 
Wong & Mooney, 1997), particularly bone engineering (Ishaug-Riley et al., 1998; Burg et 
al., 2000).
1.5.2.2 Polylactic acid (PLA, L-PLA)
Polylactic acid is a naturally occurring compound produced from readily renewable 
recourses such as com and sugarbeet, which when polymerised to form polylactic acid is 
used in a wide range of industrial applications where natural degradation is a requirement 
(Drumright et al., 2000). Polylactic add exists as two optical isomers, a poly-L-lactide and 
a poly-D-lactide. The poly-L isomer is a semicrystalline polymer with a high melting point 
(178°C) and glass transition temperature (65°C). These properties impart high tensile 
strength and a prolonged degradation time (3-5 years) to materials constructed from it.
There are few reports of the use of L-PLA, although successful outcomes have 
been reported in craniomaxillofacial surgery (Bos et al., 1987, Waris et al., 1994). However 
the long degradation time has been assodated with chronic foreign body tissue reactions 
to PLA crystal remnants (Bergsma et al., 1993). Thus the long degradation time appears to 
have negated the advantages of a resorbable material. However, polymerisation of a poly- 
D, poly-L isomer blend (PLA), gives rise to an amorphous lower melting point (60°C), 
weaker compound with a correspondingly shorter degradation time (12-16months) (Gilding 
& Reed, 1979). This blend gives rise to a degradation profile which theoretically should be 
less likely to cause chronic reactions. Haers & Sailer, (1998) and Turvey et al., (2002), 
have reported 10 and 55 cases respectively with good mandibular and maxillary fixation 
with minimal complications following osteotomies. Serio et al., (2001), have used PLA 
plates and screws in 15 children undergoing cranioplasties and reported good clinical 
results with no complications at 8 year follow-up.
1.5.2.3 Polyglycolic acid (PGA)
Like PLA, polyglycolic acid is formed by polymerisation of glycolic acid to produce a 
semicrystalline structure with a melting point reported to be in the range of 225-230°C and 
a glass transition temperature between 35-40°C. There are no isomeric forms (Gilding & 
Reed, 1979). PGA has the greatest flexural strength of the polyesters but undergoes the 
most rapid degradation with the majority of its strength lost by 6 weeks and complete 
volume loss by approximately 9 months (Imola et al., 2001). A major medical application of 
PGA came in 1970 with its introduction as a braided, resorbable suture known as Dexon 
(American Cynamide Company), (Bender & Brouwer, 1975), which is still in current use, 
testifying to its long term safety and biocompatibility. However, given the relatively rapid 
degradation of PGA, its clinical use as a single constituent for the manufacture of rigid or 
semi-rigid fixation devices has not been reported, although their successful use as a 
“membrane” for supporting orbital contents in orbital floor repairs, where minimal 
mechanical loading is involved, has been reported (McVicar et al., 1995).
1.5.2.4 Polylactic-co-glycolic acid copolymers (PLGA)
Copolymerisation of PLA and PGA disrupts the crystallinity of these monomers, 
leading to an amorphous network with a degradation rate dictated by the monomer ratio. 
The ratio of monomers used in the copolymerisation process allows the physical properties 
of the polymer to be manipulated, which in turn alters the degradation properties of the 
polymer (Gopferich, 1996). The first commercial use of this copolymer range was in 1971 
with the resorbable suture material Vicryl (Ethicon inc.) composed of 8% PLA and 92% 
PGA (Aston & Rees, 1976).
Commercially available fixation devices blend approximately 80% PLA with 20% 
PGA, to reflect the combination of degradation and structural strength required. The 
copolymer is largely amorphous and has a degradation profile between PLA and PGA 
Clinically, It has been reported as providing successful rigid bony fixation, retaining 70% of 
its initial strength for 6-8 weeks and has disappeared between 12-16 months after 
implantation (Tatum et al., 1997; Peltoniemi et al., 2002). Eppley et al., (2004), 
retrospectivelly reviewed a multicenter experience of 1883 cases of craniosynostosis in 
which PLGA plates/screws were used. Significant infectious complications occurred in 0.2 
percent, device instability primarily resulting from postoperative trauma occurred in 0.3 
percent, and self-limiting local foreign-body reactions occurred in 0.7 percent of the treated 
patients. The overall re-operation rate attributable to identifiable device-related problems 
was 0.3 percent. A further retrospective multicentre study of 165 cases (Ashammakhi et
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al., 2004) stated that PLGA plates were safe and effective although noted an overall 
complication rate of 7.2% not all of which were directly attributable to the fixation device.
The degradation process takes place in two steps during which the polymer or 
copolymer is converted back to its monomer acids. Firstly tissue fluid diffuses into (non­
crystalline) regions of the polymer matrix, cleaving the ester bonds; the second step starts 
after the amorphous regions have been eroded, leaving the crystalline portion of the 
polymer susceptible to hydrolytic attack by random hydrolysis and tissue esterases. The 
degradation product, glycolic acid, is non toxic and this then excreted directly in urine or 
enters the citric add cyde after which it is excreted as water and carbon dioxide. 
(Drumright et al., 2000).
1.5.3 Bioactive glasses
The bioactive glasses are a group of biodegradable and biocompatible materials, 
originally developed by Hench in the 1960s (Hench et al., 1971). The structure which is 
manufactured in several formulations, depending on the percentage of S i02, consists of 
silica, caldum, sodium and phosphate. This develops a hydroxyapatite layer when 
exposed to tissue fluids, which has been shown to be osteoconductive (Hench et al., 
1971). More recently, Yuan et al., (2001), have demonstrated the limited osteoinduction of 
ectopic bone in the musde of dogs implanted with bioactive glass.
Bioactive glasses have been shown in microarray analysis of primary human 
osteoblasts to activate genes assodated with bone formation within a few hours of 
exposure to bioactive glass dissolution products in a concentration dependant manner 
(Xynos et al., 2001). Bielby et al., (2004), have shown that murine embryonal stem cells 
cultured in the presence of bioactive glass dissolution products will develop down the 
osteoblast lineage to express markers of bone differentiation and form mineralised bone 
nodules.
Although glasses demonstrate good compressive strength, they are very brittle and 
have poor tensile strength. This makes them unsuitable for fixation purposes but has 
shown them to be effective in dinical applications where tensile forces are absent or 
minimal induding grafting of periodontonal bone defects (Larmas et al., 1995), filling of 
frontal sinuses (Peltola et al., 1998), reconstruction of orbital floor fractures (Aitasalo et al.,
2001) and maxillary sinus augmentation (Turunen et al., 2004).
In an attempt to utilse a strengthened formulation of bioactive glass for bone tissue 
engineering, work in our laboratory has shown that a composite scaffold consisting of 
bioactive glass and PLGA co-polymer, supports growth and progression of bone
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differentiation of ceil lines and primary osteoblasts carrying mutations for craniosynostosis. 
(Santos-Ruiz et al., 2007).
1.5.4 Bio-material composites
The ability of materials to induce significant regeneration of new bone appears from 
the literature to be limited. Hence the hypothesis that cells on polymer scaffolds could give 
rise to organised tissue was developed from the observations of Vacanti, (1988) that; 
a) all tissues undergo constant remodelling, b) dissociated mature cells can reorganise 
themselves into their native histological structure when placed in appropriate culture 
conditions, c) this reorganisation is limited by lack of a template to guide restructuring and
d) the volume of tissue that can be implanted is restricted by gas and nutrient 
requirements.
Material scaffolds have to date principally acted as carriers and support structures 
on which osteoblasts must be able to survive and produce bone, although as will be 
discussed later, strategies are being developed to enhance this interaction. In this bio­
composite approach, a scaffold is seeded with osteogenic cells. The interaction which 
ensues and subsequent success of the approach, will be dependent upon the chemical 
and surface properties of the material, the cell type, and the implant environment.
1.5.5 Surface and chemical properties
The primary interaction between cell and material, involving attachment and 
spreading is likely to be highly influential in further proliferation and differentiation and is 
therefore of great importance. The initial short term adhesion will involve physical forces 
such as ionic and van der Walls forces, followed by longer term molecular interactions 
including the material surface, ECM proteins and cytoskeleton proteins (Anselme et al., 
2000) which are likely to act in concert to induce signal transduction to ultimately regulate 
gene expression. Initial interaction and subsequent cellular growth is affected by levels of 
surface free energy of different materials (Schakenraad et al., 1986) and also by differing 
ionic charges between cell types which affects the ability of cells to attach and spread on 
solid substrata (Schakenraad et al., 1988). In addition, cells do not interact with bare 
materials either in-vivo or in-vitro, and surface energy and charge effects the adsorption 
and structural arrangement of tissue fluid proteins on a material (Chesmel et al., 1995; 
Boyan et al., 1996; Shelton et al., 1998). The cellular adhesion properties of fibronrctin 
(FN) were altered by the surface properties of materials, affecting the ability of endothelial 
cells and fibroblasts to spread and adhere (luliano et al., 1993; Altankov et al., 1997).
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El-Amin et al., (2003), have demonstrated that PLGA surfaces are more hydrophilic 
than a PLA surface and that human osteoblast adhesion to PLGA was significantly higher 
than on PLA surfaces. However, this difference became less marked as incubation time 
increased post-plating, concluding that cellular adhesion was also dependent on either the 
chemical composition that differs between PLGA and PLA, or the accumulation of 
degradation products including lactic acid. These authors also found that cells grown on 
PLGA produced higher levels of ECM molecules and cytoskeletal organisation than seen 
on PLA or tissue culture plastic. It is possible to surmise from these findings that the 
different formulations produce varying concentrations of breakdown products which may 
differentially effect cellular function.
The surface roughness of materials also causes cells to react differently. Osteoblasts 
have been shown to spread and form continuous layers more readily on smooth surfaces 
(Naji & Harm and, 1990; Anselme et al., 2000). A smooth surface also appears to benefit 
proliferation of osteoblasts with appropriately decreased levels of OC and ALP when 
grown on hydroxyapatite or titanium surfaces (DeSantis et al., 1996)
1.5.6 Scaffold modification
Each biomaterial has its own characteristic advantages and disadvantages. For this 
reason and in an attempt to optimise physical and regenerative capabilities, workers in the 
field have sought to combine properties by producing composite materials. Indeed, natural 
bone matrix is an organic-inorganic composite of collagen, matrix proteins and apatites 
and it could be postulated that composite materials are the obvious choice for bone 
engineering. For example, in an attempt to make glasses structurally more suitable for 
bone engineering, material composites of bioactive glasses or apatites and polyesters 
have been developed (Kikuchi et al., 1997; Marcolongo et al., 1998; Kellomaki et al., 
2000). Moreover, it has been discovered that the alkaline dissolution products of glasses 
and the acidic degradation products of polyesters, can neutralise each other to create a 
physiological environment for optimised cell survival (Lu et al., 2003)
The three dimensional (3-D) structure of scaffolds has been considered to be an 
important part of scaffold design for bone engineering (Yamamoto et al., 1997; Griffith 
2002; Hutmacher, 2000). The scaffold should have a high porosity and interpore 
connectivity, to allow a large number of cells to penetrate the scaffold and to allow the 
efficient diffusion of nutrients and metabolites to and from the cells (Vacanti et al., 1988). 
This has led to the development of numerous scaffold forming techniques including solvent 
casting and particulate leaching (Lu & Mikos 1994; Ma & Choi, 2001), gas foaming (Hams
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et al., 1998), freeze-drying (Whang et al., 1995) electro-spinning (Renejer & Chun, 1996; 
Boland et al., 2001; Yoshimoto et al., 2003), phase-separation (Nam & Park, 1999) and 
rapid-prototyping (Landers et al., 2002).
Further innovative methods of formulating and producing scaffolds with variable 
physical characteristics have been described, which can for example successfully trap and 
release osteogenic enhancers, principally recombinant proteins, such as BMP-2 and TGF- 
81 (Tielinen et al., 1999; Oldham et al., 2000). Recently, pre-osteoblasts have been grown 
on scaffolds which have incorporated DNA plasmids on PLA based, electrospun nano­
fibers, promising a flexible, biodegradable carrier capable of transfecting adjacent cells 
(Shea et al., 1999). Materials incorporating antibiotics have been reported (Overbeck et 
al., 1995; Zhang & Zhang, 2002); of particular potential benefit, carriers of antibiotics 
against Staphylococcal aureus species, the species having the greatest infective risk for 
implanted materials (Kim et al., 2004). However, difficulties have been reported when 
incorporating pharmaceuticals or co-materials. These stem from alterations to the material 
properties of the carrier, including weakening of constructs upon addition of antibiotics and 
the addition of bioactive glasses to polyesters (Tianen et al., 2002, Leinonen et al., 2002).
The surface nature of a material can directly affect cellular attachment, proliferation 
and phenotype, which ultimately will affect the ability of a system to regenerate new bone 
(Yamamoto et al., 1997). For example, polyesters are poorly hydrophilic, which greatly 
effects cell adhesion onto the surface and penetration into the scaffolds (Mikos et al., 
1994). Furthermore, there are no cell recognition sites on the
surfaces of most tissue scaffolds which leads to poor cell affinity and potentially failed 
tissue engineering. (Liu et al., 2004). In recognition of this, surface modification is an area 
which has received considerable attention in the quest to optimise osteogenisis. This can 
be achieved by physico-chemical modification of the material surface or coating of the 
material.
1.5.7 Substrates adhesion
Cell-protein-surface interactions are critical to the development of biotechnological 
applications including biomaterials and tissue engineering. In many of these applications, 
cells interact with proteins synthesised and secreted by cells or adsorbed from 
physiological tissue fluid. Cellular interaction with ECM constituents provides signals that 
control cell survival, proliferation and phenotypic expression (Werb et al., 1989; Adams & 
Watt, 1990). Therefore, extracellular matrix components are likely to be important in 
regulating the survival and function of osteoblasts (Meredith & Schwartz, 1997), (Fig 1.9).
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Osteoblast differentiation is partially dependent on adhesion to bone matrix proteins 
such as typel collagen, laminin and fibronectin (Damsky, 1999; Franceschi, 1999; 
Zimmerman, 2000). These interactions between matrix proteins and osteoblasts are 
mediated in part by a group of transmembrane glycoproteins known as integrins (Plow et 
al., 2000) and more specifically the 81 integrin subunits (Gronthos et al., 2001), which 
have been shown to mediate early osteoblast differentiation (Moursi et al., 1997) and 
which represent the primary mechanism of cell-ECM interaction across all cell types. 
(Hynes, 1992). Many bone ECM proteins including FN and laminin have chemotactic or 
adhesive properties, notably because they contain an Arg-Gly-Asp (RGD) sequence 
which is specific to the fixation of cell membrane receptors such as integrins which contain 
RGD recognition domains (Takada, 1997). Modification of PLA films by attaching RGD 
peptide to the surface has led to improved cellular attachment and spreading (Cook et al., 
1997; Quirk etal., 2001).
1.5.7.1 Fibronectin
Fibronectin is widely expressed by multiple cell types and is critically important in 
vertebrate development, as demonstrated by the early embryonic lethality of mice with 
targeted inactivation of the FN gene (George et al., 1993). Although FN molecules are the 
product of a single gene on chromosome 2, the resulting protein can exist in multiple forms 
that arise from alternative splicing of a single pre-mRNA that can generate as many as 20 
variants in humans (Kosmehl et al., 1996) which are tissue and function dependent (Xia & 
Culp, 1994; Sinkin et al., 1995; Price et al., 1998). It is a large dimeric ECM glycoprotein 
which has been shown to regulate adhesion, migration and differentiation of an array of 
mesenchymal cells (Yamada et al., 1992).
The FN molecule is a dimer of similar or identical subunits crosslinked by a pair of 
carboxyl-terminal disulphide bonds. Fibronectin interacts with cell surface receptors and 
other ECM components via well defined domains. The amino-terminal domain of FN binds 
to collagen, while the carboxy-terminal domains and central cell binding domains which 
include the Arg-Gly-Asp (RGD) sequence, have sites for interaction with cell surface 
receptors, including selectins, cadherins, immunolgobulins and integrins (Ruhoslahti & 
Pierschbacher, 1987, Damsky &Werb 1992; Hynes, 1992).
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Figure 1.9: Interaction of extracellular matrix protein with intracellular signalling and 
cell functions via membrane receptors.
This diagram schematically represents the role of ECM protein binding and the influence of 
downstream effects via multiple signalling pathways (adapted from van der Flier and 
Sonnenberg 2001, Lee & Juliano, 2004)
Fibronectin is a main ligand for integrins and specifically the a5G1 subunit which only 
binds FN (Werhle-Haller & Imhof, 2003). Varner et al., (1995), demonstrated that human 
colonic cells overexpressing integrin a5R1 showed growth arrest which could be reversed 
by ligation of this receptor with fibronectin. Activation of the intracellular FAK and ERK2 
signalling pathways in CHO cells is directly proportional to the level of FN-integrin binding 
(Asthagiri et al., I999). This has been confirmed by Carvalho et al., (2003), who
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demonstrated that enhanced adherence of chicken calvarial osteoblasts to FN, stimulated 
FAK translocation from the nucleus to the cytoplasm, with a concomitant increase in 
expression of osteopontin. Moursi et al., (1996), showed that the addition of anti- 
fibronectin antibodies to cultures of osteoblasts from fetal rat calvaria at confluence 
reduced subsequent formation of mineralised nodules to less than 10% of control values 
and suppressed the expression of osteocalcin and alkaline phosphatase. The same 
authors subsequently showed that this effect was mediated through a decrease in 
fibronectin-integrin interaction (Moursi et al., 1997). Yang et al., (2001), demonstrated 
increased attachment, spreading and differentiation of osteoprogenitors derived from 
human bone marrow cultured on PLGA scaffolds and PLA membranes treated with FN 
and the RGD peptide. The attachment and proliferation of MC3T3-E1 osteoblasts onto 
polystyrene (Stephansson et al., 2002) and dimethylsiloxane, a synthetic polymer (Toworfe 
et al., 2004) has been enhanced by FN coating. Moreover, it has been shown that 
disrupting the osteoblast-fibronectin interaction can induce massive apoptosis in 
differentiated osteoblasts (Globus et al., 1998). It is therefore apparent that FN is crucial 
for expression of the osteoblast phenotype and that cellular attachment, proliferation and 
differentiation might be the subject of FN manipulation.
1.5.7.2 Laminin
Laminins are a family of glycoproteins that make up an integral part of the structural 
scaffolding of basement membranes in almost every animal tissue. Each laminin is a 
heterotrimer of which twelve exist in mammals, assembled from a, 6 and y chain subunits, 
which are secreted and incorporated into cell-associated extracellular matrix (Sasaki et al., 
1988). Like fibronectin, the subunit chains can be alteranively spliced to produce multiple 
isoforms (Colognato & Yurchenco, 2000). Laminins bind to other matrix macromolecules, 
and have unique and shared cell interactions mediated by integrins, and other receptors 
(Henry et al., 2001). Through these interactions, laminins critically contribute to cell 
differentiation, cell shape and movement, maintenance of tissue phenotypes, and 
promotion of tissue survival. Targeted disruption of laminins causes a wide spectrum of 
developmental faults depending on subunit specificity, from early embryonic lethality with 
defects in placental vessels, anterior neural tube closure, kidney and limb development 
(Miner & Campbell, 2002) to central and peripheral nerve defects, muscular dystrophies 
(Sunada et al., 1995) and epidermolysis bullosa (Christiano & Uitto, 1996).
Lundgren et al., (1985), found that after 2 weeks of culture, myocytes seeded on 
dishes coated with laminin formed a denser monolayer than those cultured on uncoated
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plastic dishes. These also exhibited spontaneous contraction. Carvalho et al., (2003), 
demonstrated enhanced adherence and osteopontin expression of chicken calvarial 
osteoblasts cultured on laminin coated polystyrene. They also concluded that of several 
substrate coatings studied, laminin was the most efficient enhancer of osteoblast 
attachment. Roessler et al., (2001), found that bonding of MC3T3-E1 cells to titanium 
dental implants was enhanced by a linear adhesion peptide developed from the laminin 
sequence. Interestingly, microarray gene expression studies of MC3T3-E1 cells by Beck et 
al., (2001), identified high levels of expression of laminin receptor 1. These reports 
suggested that laminin could be a further potential modifier of the osteoblast phenotype.
1.5.8 Cell Strategies
The bio-material composite model for tissue engineering requires a source of cells 
with which to seed material scaffolds. Just as the ideal material should possess certain 
characteristics, so an ideal profile for any cell type utilised, exists. They should be non- 
immunogenic, easily and rapidly expandable in culture and accessible with minimal donor 
morbidity and risk (Warren et al., 2004). Cells used may be drawn from a range of 
sources, including primary tissues or cell lines such as the murine, calvaria derived 
MC3T3-E1 osteoblast like cell line. This line which will be discussed more fully in chapter 4 
has been well characterised in terms of its temporal expression of osteoblast related 
proteins and has been widely used in studies of osteogenisis.
Primary tissues may be autologous (from the same individual), syngenic (from a 
genetically identical individual), allogenic (from a different individual of the same species) 
or xenogenic (from a different species). However, the use of xenogenic or allogenic cells is 
limited by the need for host immunosupression, although techniques to render cells 
immunologically “invisible" may make them a clinical reality for the future.
An area of research which is rapidly developing, involves the potential use of 
embryonal stem cells, although ethical issues and ongoing medico-political debate 
regarding the further development and implementation of this source, renders them 
currently inaccessible (Zoloth, 2002; Walters, 2004). Therefore, cells derived from bone 
marrow aspirates are the most likely therapeutic candidates for host derived cells. They 
are capable of developing cell lineages producing adipose, muscular and cartilaginous 
tissues as well as bone (Prockop, 1997). Shen et al., (2002), has used systemically 
administered bone marrow derived cells to enhance healing of long bone fractures in mice. 
The remarkable potential to use cells from liposuction of fat, a readily available source, has
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also been reported when Zuk et al., (2001), demonstrated the multi-lineage potential of 
human derived adipose cells.
A further potential source of cells in patients would be those derived from the site of 
surgery. This would require subsequent enzymatic digestion and culture expansion of 
osteogenic cells in much the same fashion that cells are currently derived for research. 
This approach however, would only be feasible on ethical grounds, for individuals having 
planned multi-staged procedures.
1.6 Hypothesis and study strategy
The need for reconstruction of bony defects following surgery in children with 
syndromic craniosynostosis has been established. Very little is known about the 
behaviour, interactions and ability of osteoprogenitors carrying FGFR mutations to produce 
viable bioscaffolds, which would appropriately regenerate bony defects.
The working hypothesis for the study was that
Osteoprogenitors carrying mutations for craniosynostosis could be grown on bioresorbable
scaffolds to regenerate bony calvarial defects.
The ultimate long term goal of regenerating critical size cranial bone defects, of which this 
study would be an initial part, would require several steps.
In the first instance, the study involved working exclusively with the MC3T3-E1 cell 
line. An important first step was to further characterise the osteogenic phenotype of this 
line, transfected with the FGFR2-C278F mutation for craniosynostosis and wild type 
human FGFR2. This would help clarify whether this model was a suitable one in which to 
progress the further work required toward the long term clinical aim.
To accomplish this, the examination of mRNA expression of matrix proteins 
produced by the osteoblast phenotype was undertaken using RT-PCR. Subsequently 
genes which may have been significantly regulated by the mutation, given the observed 
behaviour and morphological appearance of the mutated line were studied. An indirect 
immunohistochemistry technique was utilised to assess proliferation of the cell lines.
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Having observed and further characterised the effect that the mutation was having on 
the phenotype, these findings directed the attempt at pharmacological manipulation of the 
mutated cells, in order to revert or rescue them towards the wild-type (Chapter5). It was 
then appropriate to study the growth of these cells on a bioabsorbabie scaffold, whilst 
exploring potential substrates to enhance osteogenisis. (Chapter 6)
A novel, composite material incorporating an expanded formulation of 
polylactide-co-polyglycolide combined with a bioactive glass had been pledged at the 
beginning of the project. Unfortunately as the study reached the stage where it was 
feasible to proceed to investigate cellular behaviour on the scaffold, it was not made 
available. Therefore, following discussion with study supervisors, it was elected to 
substitute this novel material with PLGA plates (80:20, PLA:PGA) (Bionx, Tempere, 
Finland), which were already being used for craniofacial reconstruction/fixation in our 
institution and which were therefore readily available.
Towards the end of the study, the first formulation of this novel material became 
available and only initial pilot studies of cellular growth on this material were possible.
The research questions which were to be answered in an attempt to fulfil those first 
steps were therefore:
•  Did the stably transfected FGFR2-C278F cell line proliferate then differentiate to 
express markers appropriate to an osteoblastic phenotype and subsequently 
mineralise.
•  Could this cell line attach, proliferate and mineralise on a bioabsorbabie membrane 
in an attempt to assess its usefulness as a model for future study of bio-composite 
bone engineering in craniosynostosis.
•  Could the attachment growth and differentiation of these mutated osteoprogenitor 
cells on bioresorbable scaffolds be optimised for osteogenisis.
- 6 5 -
Chapter 2: Materials
The manufacturers of all materials used are detailed below. The region and country 
of the manufacturer is given with the product description. Where the same manufacturer 
has supplied multiple items, the region and country will be shown once. Subsequent 
references to the same manufacturer will show only the country of manufacture.
2.1: Murine cell lines
MC3T3-E1 pre-osteoblasts and MC3T3-E1 cell lines stably expressing either Human 
Fibroblast Growth Factor Receptor 2 (referred to subsequently as “wild-type”- WT) and a 
mutated form of the receptor (referred to subsequently as “C278F") coding for the C278F 
missense mutation (Oldridge et al., 1995), were used. Transfection had been carried out in 
pcDNA3 plasmid (Invitrogen, Carslbad, California) by electrocorporation and selected 
using 200pg/ml of Zeomydn to establish stable cell lines (Santos-Ruiz et al., 2007). All 
lines were stored in liquid nitrogen and thawed as required.
2.2: Tissue culture media and equipment
Alpha modification of Eagle’s minimal essential medium with ribosides and 
deoxyribonudeosides (a-MEM) and Dulbecco’s caldum, magnesium and sodium 
bicarbonate-free phosphate buffered saline (DPBS), L-Glutamine, Penidllin/streptomydn 
solution (100,000 units per ml), and foetal calf serum (FCS) were all supplied by Gibco 
BRL (Paisley, UK). Bovine or calf serum (FBS and FCS, respectively) are the most widely 
used growth supplements for cell culture, primarily because of their high levels of growth 
stimulatory factors and low levels of growth inhibitory factors. Maintaining successful and 
consistent cell fermentations can be difficult, as FBS and FCS are complex natural 
products and may vary from lot to lot even from a single manufacturer. Moreover, the 
quality and concentration of both bulk and specific proteins can affect cell growth. 
Therefore, batches of FCS were tested at the start of the project and a single batch 
ordered and used throughout, in all cultures.
Dexamethasone, b-glycerophosphate and ascorbic acid were purchased from Sigma- 
Aldrich (Gillingham, UK).
Trypsin -EDTA for cellular dissociation was purchased from Sigma-Aldrich (UK).
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Tissue culture grade Petri-dishes, multiple well plates and other plastics were 
supplied by Philip Harris (Stoke, Staffordshire, UK), Nunc Inc (Roskilde, Denmark) and 
Helena Bioscience (Sunderland, UK).
2.3: Substrate coating agents
Laminin (L2020), and fibronectin (F2006) for coating of surgical plates and culture 
dishes were obtained from Sigma-Aldrich (UK).
2.4: Growth factors
Human recombinant FGF18 (F7301) was purchased from Sigma-Aldrich (UK)
2.5: Bioabsorbabie membranes
Surgical grade poiyglactide plates used for craniofacial fixation were purchased 
from Bionx Implants Ltd (Tempere, Finland). Two formulations of Bioglass/PLGAw 
composite membrane were a gift from Bionx Implants Ltd.
2.6: Primary antibody
Anti-phospho-Histone H3 (mitosis marker) rabbit polyclonal IgG was obtained from 
Upstate Biotechnology (Buckingham, UK). In all experiments, the antibody was used at a 
dilution of 1 in 400. The immunogen used for the antibody production was a KLH- 
conjugated peptide corresponding to amino adds 7-20 of the human histone H3, which 
recognises the phosphorylated form of histone H3 in vertebrate species
2.7: Secondary antibody
Goat anti-rabbit immunoglobulin was obtained from DAKO Ltd (UK). In all 
experiments, the antibody was used at a dilution of 1 in 100.
2.8: Sera as blocking agent
Goat serum was obtained from DAKO Ltd (UK).
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2.9: Other immunohistochemical detection reagents
StreptavadinABComplex/HRP (ABC duet kit), used for the labeling and signal 
amplification of secondary antibodies used in H3 staining was purchased from DAKO Ltd 
(UK). Diaminobenzidine tetrahydrochlorodihydrate (DAB) tablets, Triton X100 and 
paraf6rmaldehyde(PFA) were obtained from Sigma-Aldrich (UK). Alkaline phosphatase 
activity was detected by NBT/BCIP purchased from Roche, (Basel, Switzerland). The 
combination of BCIP (5-Bromo-4-Chloro-3'-lndolyphosphate p-Toluidine Salt) and NBT 
(Nitro-Blue Tetrazolium Chloride) yields an intense, insoluble black-purple precipitate when 
BCIP is hydrolyzed by alkaline phosphatase to form an intermediate that undergoes 
dimerisation to produce an indigo dye.
2.10: Microscopy and image capture
Cultured cells were observed under a Zeiss SV11 inverted microscope, using 
objective lenses of 2.5x, 10x and 32x and photographed using a Yashika 108 multi 
program 35mm single lens reflex camera and Kodak TMax 160 colour reversal film or 
Fujichrome T64 colour reversal film. BrightfiekJ microscopy was performed on a Zeiss 
Axk>vert135 microscope (Carl Zeiss, Germany) using objective lenses of 2.5x, 10x, and 
20x . Digital images were captured electronically using a Hamamatsu digital camera 
(C4742-95, Hamamatsu Photonics KK, Japan), and opened into Openlab software version
3.05 (Improvision, Coventry, UK). Images were saved in formats compatible with Adobe 
Photoshop version 6.0 (Adobe Systems Europe, Edinburgh, UK). Images taken on colour 
reversal film were scanned digitally using an Epson Film Scan 200 slide scanner and the 
associated Twain 32 software (Epson, Hem el Hempstead, UK). Images were processed 
using Adobe Photoshop version 6.0 where necessary (Adobe Systems Europe, UK) and 
saved to a Macintosh G3 computer.
2.11: Cell Tracker probes
5-CWoromethytfluorescein diacetate (CMFDA) vital cell-tracking dye was obtained 
from Molecular Probes (Invitrogen, USA).
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2.12: Mineral detection
Alizarin red, Silver nitrate and sodium thiosulphate were purchased from Sigma- 
Aldrich (UK).
2.13: General laboratory reagents
The general reagents used for experimental procedures were Analar grade 
supplied by BDH Ltd (UK) unless otherwise stated. Sigma-Aldrich (UK) supplied 
diethylpyrocarbonate (DEPC), ethidium bromide, orange G, paraformaldehyde (PFA), citric 
acid and hydrogen peroxide. Phosphate buffered saline (PBS) tablets were purchased 
from Oxoid (Hampshire, UK).
2.14: Gel electrophoresis and molecular size markers
Agarose powder was supplied by Gibco BRL (UK). Agarose gels were run in the 
Horizon horizontal gel electrophoresis system (Gibco BRL, UK). 1Kb ladders for RNA 
analyses were either from Gibco BRL (UK), or Bioline (London, UK). Trisma base, glacial 
acetic add and EDTA (used to make Tris acetate EDTA electrophoresis buffer-TAE) were 
purchased from Sigma Aldrich (UK). Gel images were captured using Alphalmager™1200 
computer software (Alpha Innotech Corporation, San Leonardo, Ca., USA).
2.15: Reagents and equipment for RT PCR
Reverse transcriptase, random hexamer primers, deoxynucleoside triphosphates 
(dNTPs), RNA inhibitor, magnesium chloride and 10x buffer set, and Taq polymerase were 
purchased from Promega (Southampton, UK). Thermostable PCR tubes were purchased 
from Elkay Laboratory Supplies Ltd. (Hampshire, UK). PTC-1000 thermal cyder machine 
was from MJ Research Inc. (Boston MA, USA).
2.16: Restriction Enzyme
Following a restriction site search using the Promega search resource at:
www.promeqa.com/quides/re quide/research.asp?search=seq. the restriction enzyme 
Bbsl was purchased from New England Biolabs (Hertfordshire, UK) to confirm the 
presence of the C278F mutation.
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2.17: Oligonucleotides
Oligonucleotides were custom synthesised by Genosys (Cambridge, UK). The 
oligonucleotides presented in Table 2.1 were each designed from published records of 
cDNA using the Pubmed nucleotide enquiry facility on:
www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=10090 
The appropriate sequence was then used to design the oligonucleotide forward and 
reverse primers with the aid of PRIMER3 software, based centrally at Massachusetts 
Institute of Technology on: http://fokker.wi.mit.edu/primer3/input-030.htm
2.18: Centrifuges
Samples were centrifuged in a Heraeus Biofuge 13R (Heraeus instruments, UK) 
a Sigma 113 microfuge (Sigma, Osterode, Germany).
AlkP
Forward
Reverse
AF285233
192-211
595-576
403bp 56°C
5’ ATGGGCGTCTCCACAGTAAC 3* 
5’ TTATCCGAGTACCAGTCCCG 3’
Coll
Forward
Reverse
U08020
293-212
576-557
283bp 56°C
5’ GCTTCAGTGGTTTGGATGGT 3’ 
5’ AGAGCCTCTAGCTCCTTGGG 3’
Cx43
Forward
Reverse
M61896
143-162
602-621
468bp 56°C
5’ GGGTGATGAACAGTCT GCCT 3’ 
5’ GAGAGGAAGCAGTCCACCTG 3’
FGF18
Forward
Reverse
NM8005
190-209
457-438
267bp 56°C
5’ CCTGCACTTGCCTGTGTTTA 3’
5’ AGCCCACATACCAACCAGAG 3’
GapDH
Forward
Reverse
L26492
151-170
547-528
396 bp 55°C 
5* ACTCCACTCACGGCAAATTC 3’
5’ GTCATGAGCCCTTCCACAAT 3*
hFGFR2
Forward
Reverse
Z 71929 
413-432 
1042-1023
630bp 56°C
5’ ATGGTGCGGAAGA111I GTC 3’ 
5* TAGAATTACCCGCCAAGCAC 3’
NCad
Forward
Reverse
M31131
634-653
939-920
306bp 56°C
5’ CGGTTTCACTTGAGAGCACA 3' 
5’ CACAGTGATGATGTCCCCAG 3*
OC
Forward
Reverse
L24431
51-70
264-245
214bp 60°C
5’ TGAGGACCCTCTCTCTGCTC 3’ 
5’ GCGTCTGTAGGCGGTCTTTA 3’
Table 2.1 : Oligonucleotide sequences of primers used for reverse transcriptase 
polymerase chain reaction (RT-PCR)
The accession number is underlined. Bold characters indicate the expected product size in 
base pairs, italics indicate the position of the primer sequence relative to the position of the 
corresponding base pairs in the cONA sequence. Primer annealing temperatures used are 
shown to the right of the base pair number. All primers are murine cDNA sequence derived 
other than hFGF
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Chapter 3: Methods
3.1: Cell Culture
3.1.1: Sterile technique and culturing
All tissue culture plates, bioabsorbabie membranes, dishes, pipettes, containers and 
solutions used were sterile. All aliquotting and preparation of plates was performed under 
a laminar flow tissue culture hood which had been switched on at least 30 minutes prior to 
use, and cleaned with 70% industrial methylated spirit (IMS)/dH20. Clean nitrile gloves 
were used during all procedures, and these were regularly sprayed with 70% IMS and 
changed periodically. Instruments were flamed in 100% IMS, under the laminar flow hood, 
and allowed to cool before use. Manipulation and washing of Bionx plates was carried out 
under sterile conditions throughout
All media and additives prepared and aliquotted into Falcon tubes and dishes were 
kept under the laminar flow hood prior to seeding, splitting or feeding of cultures. Cells 
were harvested for passage or RNA extraction as follows: Medium was removal from 
flasks, adherent cells were washed twice with warmed phosphate buffered saline (PBS) 
and released with 0.5% trypsin-EDTA. Cultures were maintained in a humidified incubator 
in a mixture of 95% air and 5%C02 at 37°C. Unless stated otherwise, cells grown for 30 
day osteodifferentiation cultures were grown in T-25 flasks, seeded at 12,000 cells/cm2. 
Cells grown for pre-confluent studies were seeded at 5000 cells/cm2 in T-75 flasks to 
maximise biomass for RNA extraction. Unless otherwise stated, all cells for preconfluent 
studies were cultured in standard medium to maximise proliferation (aMEM, 10%FBS, 
2mM L-glutamine, 100U/ml penicillin, 50pg/ml streptomycin) Cultures for differentiation 
studies were supplemented with 50pg/ml ascorbate and 10mM &-glycerol-phosphate when 
cells became fully confluent.
3.1.2: Freezing and Thawing
Freezing cells involved harvesting them as described above, suspending them at a 
concentration of 10°/ml in freezing medium containing 10% dimethyisulphoxide (DMSO) 
and 20% FBS, aliquoting 1 ml of cell suspension into cryotubes, slow freezing in a -20°C 
freezer, transferring and storing the cryotubes overnight at -80 °C and transferring them to 
a liquid nitrogen container the next day.
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To thaw frozen cells, vials were removed from liquid nitrogen storage and 
immediately placed in a 37°C water bath. The cell suspension was transferred by pipette 
to a 15-ml falcon tube and 5 ml of warm medium was added slowly to the tube and mixed 
by gentle repeat aspiration. Aliquots of cell suspension were transferred to flasks 
containing additional medium and cultured under standard condition. Complete medium 
changes were performed after 12 hours of culture and subsequently every 48 hours.
3.1.3: Cell number and viability
Medium from plates, wells or flasks was removed; adherent cells were washed twice 
with (PBS) and released with 0.5% trypsin-EDTA solution. Cell number and viability were 
determined by haemocytometer count and trypan blue exclusion according to accepted 
conventions for cell counting in grids, namely, viable cells crossing the upper and right 
hand grid lines are counted and those on the lower and left hand lines are excluded (Fig. 
3.1)
Not
counted
Figure 3.1: Haemocytometer cell counting convention
3.2: Vital cell tracking
Cells difficult to visualise under bright field microscopy were treated with a vital, 
intracellular, fluorescent dye to allow observation under ultra-violet light. Live cells were 
labelled with CellTracker Green (CMFDA), according to the manufacturer’s instructions. 
Cells were incubated at 37°C for 45min in labelling solution (1 pM CMFDA in prewarmed, 
serum-free medium), followed by a 45 minutes incubation in normal medium (without 
CellTracker). Cells were gently washed with PBS. Labelled cells were put back into the 
incubator in normal medium for observations at 520 nm wavelength.
Counted
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3.3: Cellular proliferation assay
One of the first steps in ceil division is the replication of DNA during S-phase of the 
cell cycle. Cellular proliferation in cultured cells can be assessed using various techniques. 
Direct counting of mitotic cells in haematoxylin and eosin (H&E) stained sections can be a 
difficult and time-consuming process. It is especially difficult to distinguish between cells in 
prophase and cells undergoing pycnosis or apoptosis in H&E-stained samples. High 
magnifications have to be used to distinguish the cycle phases and large numbers of cells 
must be counted to obtain statistical validity. This has led to the development of specific 
techniques and markers to immunologically identify cell division.
The anti-phosphorylated-H3 antibody is one such method, which recognises histone 
H3 after it becomes phosphorylated when the chromosomes condense during cell division. 
This technique has been shown to be a sensitive and reliable method for assessing cells 
undergoing mitosis (Brenner et al., 2003).
This assay utilises the well established technique of immunohistochemistry, which 
relies on the highly specific binding properties of mammalian antibodies to recognise 
protein epitopes in fixed cell culture or tissue sections (Polack & van Noorden, 2003).
The indirect technique for detection of the targeted epitope was used (Fig. 3.2). This 
method requires a primary and a secondary antibody as well as a visualisation marker to 
allow counting of the proliferating ceMs.The primary antibody is usually an IgG raised 
against the epitope of choice, in a mammalian species different from the sample species. 
The secondary antibody is obtained from a different species to that of the primary antibody 
and conjugated with peroxidase to allow signal detection (Fig 3.2A) in combination with an 
avidirvbiotin amplification complex and visualisation compound such as diaminobenzidine- 
tetrahydrochloride (DAB) (Fig. 3.2B). Further important steps to block endogenous 
peroxidase (Fig. 3.2C), charged proteins and non-specific antigens (Fig. 3.2D-E) are 
carried out to reduce false positive detection and minimise background staining.
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Figure 3.2: Indirect method of immunohistochemical antigen detection
A: The primary antibody binds the targeted epitope which in turn is bound by peroxidase 
conjugated secondary antibody. The peroxidase activity is detected by colour development 
by incubation with a substrate such as DAB. B: Amplification steps using avidin-biotin 
complex can be included to strengthen the signal prior to DAB exposure. C: Hydrogen 
peroxide is used to block endogenous peroxidase activity within the tissues. D: Charged 
proteins and non-specific epitopes may react with primary antibody, leading to background 
staining. E: Treatment with protein-rich serum blocks these non-specific epitopes to 
provide a “clean” signal.
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3.3.1: Cellular Fixation
Cell cultures were washed once with PBS and fixed by cold 4% paraformaldehyde 
(PFA) in PBS for 30 minutes at room temperature. The PFA was removed and the cells 
washed with cold PBS for 10 minutes, 3 times by placing on a rocker-table agitator.
3.3.2: Blocking
Endogenous peroxidase activity was then quenched by incubation of the cells with 
3% hydrogen peroxide (H2O2 ) in 10% methanol in PBS at room temperature for 20 
minutes. The H2O2  was removed and the cells washed for 5 minutes, 3 times in PBS. Non­
specific proteins and charged compounds were then blocked by saturating the cells in a 
10% solution of goat serum in PBS for 45 minutes at room temperature. The serum was 
removed and the cells washed 3 times in PBS at room temperature.
3.3.3 Application of primary antibody
The cells were coated and incubated with a layer of anti-phosphorylated-H3 antibody 
at a dilution of 1:400 in PBS overnight at 4°C. Negative controls were treated similarly 
without the addition of primary antibody. The following day, samples were thoroughly 
washed and agitated on a rocker-table 3 times with 0.5% Triton in PBS, to ensure only 
specifically bound primary antibody remained, prior to application of the secondary 
antibody. The cells were washed a further 3 times in PBS to remove traces of Triton.
3.3.4: Application of secondary antibody
The ceils were then incubated for 45 minutes at room temperature with goat anti- 
rabbit IgG diluted to 1:100 in PBS. They were then washed 3 times with PBS before 
detection of the secondary antibody.
3.3.5: Antibody detection
Avidirvbiotin-peroxidase complex was prepared from an ABC kit according to the 
manufacturers instructions, diluted with PBS and allowed to stand for 30 minutes. It was 
then added to the samples for 30 minutes before removal and washing with PBS. This 
amplification kit confers a fourfold increase in the levels of peroxidase available for 
development. Visualisation of the peroxidase tag was then detected by colorimetric 
changes due to precipitation of its substrate diaminobenzidine-tetrahydrochloridehydrate 
(DAB) which was made up into 5ml solutions with MilliQ water according to manufacturer’s
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instructions and filtered through a 0.4 pm pore filter. Half a mililrter of DAB was added to 
each well and allowed to develop for a fixed period for all wells as ascertained by pre­
testing. The DAB solution was removed and wells washed for 5 minutes in PBS before 
image capture.
3.3.6: Proliferation count
Once the plates had been processed, triplicates of four random areas per well were 
captured digitally, downloaded and stored as TIFF image files onto a Mac G3. The total 
number of cells per field and the number of H3 positive nuclei for that field were counted 
using the Openlab software point counting option. Briefly, the computer mouse was used 
to ‘dick’ on each cell. Each ‘dick1 labelled the cell with a mark and a number, so that the 
user could see which cell, and how many, had been counted for any particular field of 
view. To optimise objectivity of H3 counting, the gain/contrast control on the software was 
then adjusted to exdude visualisation of cells not positive for H3 and the counting process 
was repeated (Fig. 4.6A). This system was adopted to reduce counting error. The counts 
were tabulated using Microsoft Excel software, where the H3 positive cells were expressed 
as a percentage of the total cell count, using the following equation:
Mitotic Index = number of H3 positive nuclei
total number of cells in field
The data was separated into controls and FGF18 treated cells and transferred into SPSS 
(10.0) for statistical analyisis. Proliferation rates were analysed for statistical significance 
using analysis of variance between groups (ANOVA) and post hoc tests were carried out 
using Bonferroni’s method.
3.4: Growth factor treatment
Human recombinant fibroblast growth factor (FGF) 18 was obtained from Sigma- 
Aldrich (U.K.) and used for the treatment of cultured cell lines. Concentrations of FGF 18 
between 10'1°M and 10~®M were first prepared to ascertain a treatment range for 
experimentation. The level of foetal calf serum (FCS) required to maintain viability of the 
cells during experimentation was determined at 24 and 72 hours post treatment, using 
FGF18 at a concentration of KT®M.
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For experiments, triplicate samples of cell lines were seeded at 12,000 cell/cm2 in 
normal culture medium. This was replaced after 12 hours following washing in PBS at 
37°C, by experimental medium containing 2% FCS and FGF18 at differing concentrations.
Proliferation assays using anti-phosphorylated-H3 were carried out as described in 
section 3.3 and a mitotic index calculated for each treatment condition
3.5: Bioabsorbable membranes
Bioabsorbable fixation plates or composite membranes provided by Bionx (Finland) 
were removed from sterile packaging and manipulated under the tissue culture hood at all 
times. Materials were divided for experimentation into equal portions, marked and cut with 
a scalpel blade (Figure 3.3). The materials were placed in tissue culture wells and the 
wells seeded with cells at the experimental concentration. For experiments lasting several 
days, cells were allowed to attach for 12 hours before gently washing the materials with 
PBS at 37°C to remove unattached cells and placed in a fresh well and medium to allow 
only cells originally attached to the material to be included. Medium was changed every 48 
hours. For measurement of seeding efficiency with membrane coatings, the material was 
removed from its original well, gently washed in PBS at 37°C and cells detached with 
warmed 0.5% trypsin-EDTA. Cells were counted as described in section 3.1.3. Staining for 
markers of mineralisation was carried out as described in section 3.7.
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Figure 3.3 : Commercially available resorbable bone fixation plates
A. BioSorbPDX, co-polymer, Polyglycolic(20%)/Po!ylactate(80%) plates supplied as sterile 
packed implant. 800pm thick with 1.5mm screw holes.
B. Supplied plates were divided by sharp, sterile scalpel to provide single hole 
fragments of 5mm diameter. Scale bar = 5mm
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3.6: Membrane coatings
Pre-treatment of culture dishes and bioabsorbable membranes with fibronectin or 
laminin was performed by adding 0.5ml of 0.01% solutions of laminin or fibronectin to 
tissue culture wells to allow total surface wetting, followed by removal of the excess. 
Dishes were then allowed to air dry for 1 hour under the tissue culture hood, prior to 
seeding of cells. PLGA bioabsorbable plates were coated by immersion into a solution of 
either laminin or fibronectin at the above concentration, allowed to drip excess for 2 
minutes then transferred to a culture plate to air dry before transferring to the centre of a 
fresh culture well prior to the seeding of cells. Cells were released for collection or 
counting as described in section 3.1.3.
3.7: Staining for mineralisation 
3.7.1: Von Kossa
This method relies upon the principle that silver ions can be displaced from solution 
by carbonate or phosphate ions due to their respective positions in the electrochemical 
series. The argentaffin reaction is photochemical in nature and the activation energy is 
supplied from strong visible light Since the demonstrable forms of tissue carbonate or 
phosphate ions are invariably associated with calcium ions, this method can be considered 
as demonstrating sites of tissue calcium deposition. Cultures were washed 3 times in PBS 
for 2 minutes on a rocker-table. Cells were then fixed with 4% PFA in PBS for 30 minutes 
and washed 3 times with 10mM Tris-HCI, pH 7.2. Fixed cells were incubated with 5% 
silver nitrate for 1 hour under a halogen lamp, washed 3 times in PBS and then treated 
with 5% sodium thiosulphate. Cells were imaged using bright field microscopy and images 
captured on colour reversal film.
3.7.2: Alizarin Red S
Following removal of medium, plates were gently washed with PBS 3 times and fixed 
with 4% PFA for 30 minutes, The PFA was removed and the plates washed again 3 times 
with PBS. Alizarin Red S stain was added at a concentration of 1% at pH 4.2 for 10 
minutes at room temperature, then washed 3 times with distilled water and once with PBS 
before visualisation with bright field microscopy and image capture with colour reversal 
film.
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3.7.3: Alkaline phosphatase
Alkaline phosphatase activity was detected by NBT/BCIP staining. Plates were gently 
washed once in PBS and then fixed with 4% PFA in PBS. They were then washed 3 times 
for 5 minutes in PBS at room temperature on a rocker-table and incubated for 10-30 
minutes at room temperature in 0.0375 M9/ml NBT + 0.0188 pg/ml BCIP dissolved in 100 
mM Tris-HCI buffer, pH 9.5, containing 5 mM MgCI2. All plates were developed for the 
same period of time. The reaction was stopped by washing 3 times in buffer followed by 3 
times in distilled water. Plates were then imaged using bright field microscopy and 
captured on colour reversal film
3.8: RNA analysis
All solutions for RNA work were made using diethyfpyrocarbonate (DEPC) treated 
water. DEPC is a potent inhibitor of ribonudeases (RNAse) which rapidly degrades RNA 
molecules. 1ml DEPC was added to 1L MilliQ water. This was incubated at 37 °C 
overnight to kill the RNAse. The DEPC in the treated water was finally degraded to ethanol 
and carbon dioxide by autodaving. All reagents used for RNA extraction were kept 
separate from other laboratory agents to reduce the risk of RNAse contamination. RNAse- 
free equipment was used throughout the procedure.
Total RNA was extracted from cultured cells using TRI-REAGENT™. TRI­
REAGENT™ promoted the formation of RNA complexes with guanidinium and water 
molecules, and inhibits hydrophilic interaction between the DNA and protein. The RNA 
was isolated in the aqueous phase, which was subsequently removed and purified.
3.8.1: RNA extraction from cultured murine lines
All tissue culture media was removed from the culture flasks or plates. One mililiter of 
0.5% trypsin-EDTA was added to each flask or plate and returned to a humidified tissue 
culture incubator, at 37 °C in 5% C 02 for 5 minutes. The samples were then gently 
agitated to aid release of the intact cells which were then collected after the addition of 5 
ml of PBS. This suspension was spun at 1000 G for 5 minutes. The supernatant was 
discarded, and all traces of liquid removed from the cells using a fine glass pipette. 1 ml of 
TRI REAGENT™ was added to the cellular pellet, and repeatedly pipetted for several 
minutes and vortexed to promote complete cell lysis. The sample was either stored at - 
80°C for later RNA extraction or left for 5 minutes at room temperature, treated with 200 pi 
chloroform, vortexed and centrifuged. Samples were left to stand at room temperature for
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15 minutes, in order to optimise the separation of RNA, DNA and proteins and then 
centrifuged at 12,000 rpm for 10 minutes at 4°C. The top aqueous layer containing the 
RNA was removed carefully by pipette and put into a separate Eppendorf tube. Five 
hundred microlitres of isopropanol was added to this in order to precipitate the RNA. The 
extract was centrifuged at 12,000 rpm for 10 minutes at 4 °C. The resultant RNA pellet 
was visualised, and the supernatant removed. The pellet was washed gently in 1 ml of 
75% ethanol in DEPC water and centrifuged at 12,000 rpm for 2 minutes. The supernatant 
was removed completely, and the last traces of liquid were left to evaporate from the pellet 
for several minutes before gently re-suspending the RNA in 20-50 pi of DEPC water. The 
concentration of RNA was then evaluated by measuring the absorbance at 260 nm 
wavelength using a Genequant spectrophotometer. The quality of RNA extraction was 
determined periodically throughout the study by running samples on agarose gel 
electrophoresis. Intact total RNA run on a denaturing gel will have dear 28S and 18S 
ribosoma! RNA bands (Figure 3.4 A) whereas degraded RNA demonstrates smeared, 
drawn-out bands. While crisp 28S and 18S RNA bands are indicative of intact RNA, visual 
assessment of the 28S:18S rRNA ratio on agarose gels is somewhat subjective because 
appearance of RNA bands is affected by electrophoresis conditions, amount of RNA 
loaded, and saturation of ethidium bromide fluorescence. Hence, the RNA quality was 
further determined periodically by a colleague testing samples in an Agilent Technologies 
2100 Bioanalyzer (Figure 3.4 B). This uses a combination of microfluidics, capillary 
electrophoresis, and fluorescence by the addition of an RNA specific dye, to evaluate both 
RNA concentration and integrity.
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Figure 3.4 Determination of RNA quality
A: Extracted RNA was run on a denaturing gel. Characteristic 18S and 28S bands of 
ribosomal RNA are clearly demonstrated.
B: 18S and 28S peaks are prominent and RNA concentration is determined by 
spectrofl uorescence.
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3.8.2: Reverse transcription polymerase chain reaction
The reverse transcription polymerase chain reaction (RT-PCR) is a powerful 
molecular technique that is widely used to assess gene transcription in whole embryos, 
tissues, or isolated cells. The technique allowed for highly specific and sensitive 
amplification of specific mRNA transcripts. RT-PCR was very useful in the detection of low 
amounts of mRNA, that would not be detected using other methods such as Northern 
blots. The RT-PCR method involved an initial reverse transcription (RT) step in which all 
mRNA transcripts were reverse-transcribed by a retroviral enzyme using specific primers, 
short random hexamers or oligo-dTs as primer templates (Fig.3.5). This process lead to 
the formation of a set of double helices, each made up of the original mRNA template, and 
its complementary strand of newly transcribed cDNA. Subsequently, the cDNA of interest 
was separated from the mRNA and amplified exponentially using gene-specific primers 
and a thermo-stable DNA polymerase enzyme (Fig.3.6).
3.8.2.1: Reverse transcription
Reverse transcription (RT) involved the synthesis of complementary DNA (cDNA) 
using single stranded RNA as a template, as illustrated in Figure 3.4. The Maloney murine 
leukaemia virus (M-MLV) reverse transcriptase was used for all RT reactions. Using 
RNAse-free equipment, 1 pg of RNA, made up to 10 pi with DEPC water, was added to 1 
pi of 100 pmol random hexamer primers (pN6) in a 0.5 ml microfuge tube. The tube was 
placed into a PCR thermal cycler and heated to 70 °C for 10 minutes. This step removed 
secondary mRNA structure. The reaction mix was cooled rapidly on ice. 9 pi of a mix 
containing 4 pi of 5x first strand buffer, 2 pi of 100 mM dfthiothreitol (DTT), 1 pi of 10 mM 
deoxynudeoside triphosphates (dNTPs), 1 pJ of RNAse inhibitor and 1 pi M-MLV RT (20 
U) was added. This was incubated at 42°C for an hour then heated to 95 °C for 10 minutes 
to destroy the RT enzyme. The RT products were stored at "20 °C until use.
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AAAAAA3’
1: Denature at 70 °C for 10 minutes, then cool at 4 °C
I
5'   AAAAA A3'
I
2: Add RT enzyme, primers, oligonucleotides and buffers
N6 N6 N6 N6 N6
i
AAAAAA3’
3: Primers anneal, and reverse transcriptase transcribes cDNA 
strands from the mRNA templates
5* ■ -  AAAAA3’
3’ ' "■  -  5'
Key
native mRNA strand 
AAAAAA3’ poly A tail of mRNA
---------------- denatured mRNA strand
N6 random hexamers 
---------------- cDNA strand
Figure 3.5: The reverse transcriptase reaction
1: Linearisation of extracted mRNA by denaturation. 2: Addition of reverse transcriptase, 
random hexamer primers, oligonucleotides and buffer to the reaction mixture. The primers 
become annealed to their complementary base pairs on the mRNA transcripts. 3: 
Transcription of complementary strands of cDNA for each mRNA molecule present in the 
extract.
(Adapted from Molecular Biology of the Cell, Alberts et al., 2002)
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Non linear cDNA 3 “ 5 primer
------------------------- Linear cDNA | 5’ to 3’ primer
Figure 3.6: The polymerase chain reaction.
A: The cDNA templates were heated to denature and separate the strands. B: Upon cooling 
the reaction mix, primers corresponding to the cDNA of the gene being studied annealed to 
the cDNA template. C: DNA polymerase then transcribed a complementary strand of DNA. D: 
Re-heating the mixture separated the strands. Upon cooling, more primers annealed to the 
newly transcribed strands, and the process of DNA replication began again (E). The process 
was repeated many times (F,G,H) ranging from 24 - 36 cycles resulting in amplification of 
cDNA strands transcribed. The process was finished with a ten minute polishing step. 
Samples were stored at 4 °C prior to gel electrophoresis. Adapted from Molecular Biology of 
the Cell, Alberts et al., (2002).
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3.8.2.2: Polymerase chain reaction
The Polymerase chain reaction (PCR) was used to amplify and detect specific cDNA 
molecules from the many that had been reverse-transcribed from the mRNA template 
during reverse transcription. This specificity was attained by the binding of primer pairs to 
the cDNA template of interest (Fig.3.6). The integrity of RNA used in each RT reaction 
was verified by amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a 
house keeping gene believed to be expressed in all cells at constant levels.
3.8.3: Primer design
Primers were designed from cDNA records published in original papers, or from an 
online ‘Pubmed Nucleotide Enquiry1 (Table 2.1). Primers consisted of 19-22 bases, and 
flanked specific regions of the cDNA of interest, usually spanning a region of 350 to 650 
bases. cONA sites were chosen to cross intron/exon boundaries, in order to detect 
potential contamination by genomic DNA. The expected product sizes for genomic DNA 
and cDNA would be very different allowing detection of genomic DNA contamination of 
the sample. Primers were selected to have approximately 55% guanidine or cytosine 
residues. Complementarity between primers was avoided to prevent the formation of 
primer dimers, which could disrupt the efficiency of the polymerase chain reaction. 
Generally, the primer concentration was 50 pM in a 50 pi reaction.
The primer annealing temperature can affect the stringency of primer/cDNA 
interaction. The optimal annealing temperature was calculated from the nucleotide 
composition of the primer using the following formula:
Annealing temperature (°C) = 4 (G+C) + 2 (A+T) -  5.
The temperature calculated was not always that used for the primers in this study, 
although it was a convenient starting point for optimising the temperature for each primer. 
Annealing temperatures were optomised by running a PCR for each set of nucleotides at 
1°C increments above and below the formulaic derived temperature. Annealing 
temperatures of primer pairs were kept the same, thus permitting annealing (and therefore 
transcription) at the same rate for each strand.
Having chosen the optimum annealing temperature for each primer pair, it was important 
that visualisation of bands under U-V light should be within the linear intensity spectrum for 
any particular gene being expressed. Therefore for every gene being studied, a linear 
range diagram was drawn using 5-cyde PCR increments. The mid-point between
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non-detection and maximum intensity was chosen as the number of cycles (n) for each 
individual gene being studied (Figure 3.6).
Figure 3.6: Linear range of band intensity for Osteocalcin (OC)
A: PCRs products observed under U-V light at 5 cycle increments
B: Band intensities are measured using Alphaease software and a linear range diagram
constructed. The mid-linear point is chosen as the number of PCR cycles for this gene
(n = 33 for OC)
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A ‘master mix’ of PCR reagents was made up at 4 °C prior to dispensing into separate 
tubes and the addition of cDNA. This was to ensure that all tubes had exactly the same 
proportions of PCR reagents. The master mix for a typical 25 pi reaction is given in Table 
3.1. Four microlitres of cDNA (50 pi reaction) or 2 pi cDNA (25 pi reaction) was then added 
to each tube. These were placed into a thermal cycler with a heated base and lid for DNA 
amplification. Table 3.2 illustrates a typical PCR cycle programme. Samples were kept at 
4 °C prior to band separation and detection using agarose gel electrophoresis.
DEPC water 15.9 pi
MgCI2 1.5 pi
MgCI2-free buffer 2.5 pi
dNTPs 2.5 mM 2.0pl
Forward primer 0.5 pi
Reverse primer 0.5 pi
Taq polymerase 0.1 pi
Table 3.1: PCR reagents
The reagents were first made up as a master mix, before addition to individual PCR 
reaction tubes. This maximised consistency of reagents between reactions. 2 pi cDNA was 
added in a 25 pi reaction mix and 4 pi cDNA was added per 50 pi reaction mix.
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Temperature Time Function
Cycle
number
(n)
1) 95 °C 5 minutes (denatures secondary structures)
2) 95 °C 30 s (separates cDNA strands)
3) 55-56 °C 30 s (primer annealing)
4) 72 °C 40 s (Taq transcribes cDNA)
5) 72 °C 10 minutes (completion of all cDNA strands)
Table 3.2: Normal thermal cycling programme
The thermal cycler follows steps 1 to 6, cycling ‘n’ times between steps 2 and 4, before 
advancing to the polishing step (5)
3.9: Mutation confirmation with restriction enzyme
Restriction enzymes, mostly purified from bacteria, recognise specific DNA 
sequences and cleave the DNA either within the sequence or at a specific site flanking that 
sequence. Therefore the number and size of the fragments produced by the digestion 
depend on the frequency and position of the restriction sites.
The restriction enzyme Bbsl was used periodically to confirm the presence and 
absence of the mutation within the C278F and WT cell lines respectively. Following 
amplification of the hFGFR2 gene, the RT-PCR products were then incubated with Bbsl at 
room temperature for 30 minutes. The products were run on agarose gel and imaged as 
described in section 3.10 and 3.11.
3.10: Agarose gel electrophoresis
Agarose gels for electrophoresis of amplified cDNA were made by heating 1.2 g pure 
agarose in 100ml tris-acetate-EDTA electrophoresis buffer (TAE) with 0.0025% ethidium 
bromide (1 pi /ml) for 1.5 minutes at full power in a 700 W microwave oven. The liquid gel 
was allowed to cool slightly, and poured into a gel mould. Appropriate sized combs were 
fitted, and the gel was left to set at room temperature for at least 1 hour. The finished gel 
was placed into an electrophoresis tank, containing 800 ml TAE and 0.0025% ethidium 
bromide. 2 pi of orange G solution (10 g sucrose, 50mg orange G, 5mg sodium azide in 20 
ml H20) was added to 12 pi PCR product.
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This mix was carefully loaded into the wells in sequence. A 1kb DNA ladder was put 
into the first well of each lane, so that the size of cDNA products could be determined. The 
voltage was set to approximately 100mV, and the current applied. The cDNA was left to 
migrate towards the anode through the agarose gel for an appropriate period 
(approximately 1 hour), to allow adequate separation of the 100Kb bands of the 
hyperladder.
3.11: Band detection and semi quantification
Ethidium bromide intercalates between molecules of DNA and is fluorescent under 
long wave ultra violet (UV) light. This permitted visualisation of the DNA bands. Large gels 
were divided into six to allow centralisation of groups within the UV imager. They were 
then exposed to UV and captured digitally using the Alpha-lmager and Alphaease 3.3 
software imaging system to allow measurement of band intensity and extrapolation as a 
semi-quantification of PCR product.
3.12: Statistical analysis
Statistical analysis was performed by entering data initially into Microsoft™ Excel 
spreadsheets and then uploading this data into SPSS (version 14.0) statistical package 
software (SPSS inc., Chicago) with appropriate statistical tests applied such as analysis of 
one way variance (ANOVA) with Bonferonnis’ post-tests for intergroup analysis. 
Bonferonnis’ method was chosen as it is a simple method, valid for equal and unequal 
sample sizes and is considered a powerful method for determining significant difference 
when the number of groups being compared is small. A value for P  < 0.05 was regarded 
as statistically significant All data are expressed as mean + standard error (SE).
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Chapter 4: Characterisation of osteoprogenitor cell lines
4.1: Introduction
Bone formation is a complex biological process which progresses through distinctive 
developmental stages, from commitment of mesenchymal derived cells into the 
osteoprogenitor lineage, followed by mitotic proliferation, through to expression of the 
osteoblast phenotype and ultimately as terminally differentiated osteoblasts producing 
mineralised extracellular matrix (Tonna, 1961; Owenm 1990; Aubin, 1995). Understanding 
the processes of proliferation and differentiation, in tandem with further comprehension of 
signalling pathways are fundamental to the understanding of normal osteogenisis and 
pathological osteogenisis, such as that seen in craniosynostosis. This has been advanced 
by the development of immortalised cell lines. These overcome the limitations of malignant 
cell lines, which fail to display the normal coupling of differentiation and growth arrest and 
of primary cell cultures in which data interpretation can be difficult, due to the presence of 
various cell populations and tendency to lose osteoblast characteristics following repeated 
subcultivation (Aronow et ai., 1990). Furthermore, stable cell lines provide an unlimited 
supply of material for study. This latter point is important, as the supply of primary bone 
from patients suffering from craniosynostosis is limited by the small numerical chance that 
any given individual mutation would present more than once for surgery to our institution, 
within the research period.
The MC3T3-E1 cell line, derived from newborn murine calvaria is a well established, 
stable cell line, which has been shown to display the osteoblast phenotype following 
repeated passages (Kodama et al., 1981). They proliferate until confluent then differentiate 
and can be induced to mineralise in a fashion which resembles membranous bone 
formation (Sudo et al., 1983). This line has been well studied and characterised in terms of 
phenotype and temporal pattern of expression of bone related proteins. Quarles et al., 
(1992), showed that sparceiy seeded MC3T3-E1 cells undergo marked cell replication 
without expression of alkaline phosphatase (ALP) or accumulation of significant 
mineralised extracellular collagenous matrix during days 1-9 in culture. During days 9-16, 
they undergo osteoblastic differentiation that is characterised by rising ALP activity and 
osteocalcin (OC) secretion. After day 16, the mineralisation of extracellular matrix marks 
the final phase of osteoblast phenotypic development (Fig. 4.1). This work has been
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largely confirmed by others, although the temporal stages and phases of marker 
expression can be variable depending on seeding density, clonal selection drift and 
numbers of passages (Choi et al., 1996; Beck et al., 1998; Wenstrup et al., 1996; Peterson 
2004). Moreover, within our laboratory (Petoit A., PhD), we have generated an MC3T3-E1 
cell line stably expressing the wild type human FGFR2 (WT) and to mimic the 
craniosynostotic phenotype, FGFR-C278F (C278F), a mutated human FGFR2, found in 
patients with Crouzon, Pfeiffer and Jackson-Weiss syndromes (Oldridge et al., 1995; 
Steinberger et al., 1996; Passos-Bueno et al., 1998). In this mutation, the cysteine at 
position 278 in the third immunoglobulin-like extracellular domain Ilia of FGFR2 is replaced 
by a phenylalanine, causing constitutive activation of the receptor as described in chapter 
1 .
Matrix Deposition
Proliferation
0 10 30
- —  ■»
Days post induction
Figure 4.1: Schematic representation of MC3T3-E1 development in culture
Plated osteoblasts initially undergo rapid proliferation with progressive deposition of 
extracellular matrix, followed by a time dependent decrease in replication with a 
concomitant increase in extracellular matrix deposition. Finally matrix mineralisation 
predominates (time-line from Quarles et al., 1992; Choi et al., 1996)
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In the context of our long term aims of developing autologous, engineered scaffolds 
for clinical use, the aim of the work described in this chapter was therefore to better 
characterise the behaviour of osteoprogenitors carrying this mutation for craniosynostosis 
and assess their viability as a model for studying the effect of FGFR2 mutations on cellular 
behaviour and osteogenisis. TNs would ideally inform the development of potential 
strategies to modify the behaviour of mutated cells if required.
4.2: Results
The three cell lines were grown under standard culture conditions or in the presence 
of mineralisation medium. They were assessed morphologically, for their ability to form 
ossification centres and mineralise and for the expression of cell-cell adhesion molecules, 
markers of osteodifferentiation and a fibroblast growth factor.
4.2.1: HFGFR2 expression
Prior to assessing the expression of all molecules being investigated, it was 
necessary to confirm that the cell lines were expressing the hFGFR receptors expected. 
This was performed by adding a restriction enzyme to the PCR amplified products of 
hFGFR2. The sequence 5’-GTCTGC-3’ is replaced by 5’-GTCTTC-3’ in the C278F cells. 
This is recognised by the Bbsl enzyme, creating two fragments. The results confirmed that 
both the WT and C278F cells produce the hFGFR2 product which is absent in the MC3T3- 
E1 cells. The restriction site enzyme cut the mutated hFGFR2, but not the wild type 
receptor product, confirming there was no significant cross contamination of cell lines and 
that the mutated hFGFR was expressing (Fig. 4.2).
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Figure 4.2: Confirmation of HFGFR2 receptor
RT-PCR for FGFR2 was performed on all three cell lines. Expression of hFGFR2 was 
detected as amplification of a 630 bp product. This was treated with the restriction enzyme 
Bbsl, digesting the product to 420 bp and 210 bp fragments. The samples were run on a 
2% agarose gel. L = DNA ladder to determine approximate length of amplified cDNA.
RE= Restriction enzyme Bbsl. Negative control (-ve) consisted of DEPC water in place of 
cDNA
4.2.2: Morphology
All cell lines were cultured in normal media as described until confluent and 
supplemented with ascorbate and 6-glycerol-phoshate thereafter and monitored daily for 
survival and growth. Initial cultures on plastic revealed that MC3T3-E1 and WT cells 
appeared to grow well on a medium change regime of every 3rd or 4th day. However, 
C278F cells did not thrive on this regime. There was notable early acidification of media 
indicated by a change in media colour. This required a change to an alternate day feeding 
regime, which was applied for all lines thereafter.
There were marked difference in the gross appearance and attachment behaviour 
between the lines: C278F cells carrying the craniosynostotic mutation appeared to adhere 
less well than either the untransfected MC3T3-E1 cells or the WT cells carrying the non­
mutated human FGFR2 receptor. MC3T3-E1 and WT cells attached evenly to plastic
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within 2-4 hours developing a fibroblastic, elongated morphology, typical of proliferating 
osteoblasts (Fig. 4.3 A-B) In contrast, C278F cells (Fig. 4.3 C) attached poorly at first, 
requiring 4-6 hours before significant attachment was observed. However, they 
subsequently grew at a rate which appeared similar to the growth of the other lines. This 
was confirmed by measures of plating efficiency (Fig. 4.4).
The mutated cells did not develop such an elongated or dendritic morphology and 
unlike the evenly distributed MC3T3-E1 and WT cells (Fig. 4.3 D-E), they formed 
aggregates (Fig. 4.3 F). Further proliferation demonstrated that MC3T3-E1 and WT cells 
reached confluence after 4-5 days of culture, whereas C278F cells never became fully 
confluent under normal conditions. There was an apparent high level of cellular death in 
the C278F cultures, heralded by the vacuolated appearance of cells and subsequent 
appearance of floating dead cells and cellular debris not seen in the MC3T3-E1 or WT 
cultures.
C278F cells aggregated and proliferated in distinct condensations which progressed 
to form multilayered nodules (Fig. 4.3 I). Nodular areas developed less obviously in the 
MC3T3-E1 and WT cultures (Fig. 4.3 G-H). During all phases of growth, although more 
prominently in the differentiating phase, the observed number of dead cells and cellular 
debris was greatest in the C278F cultures.
When cells were released from plastic, MC3T3-E1 and WT cells detached similarly. 
However, C278F cells detached more readily after approximately half the exposure period 
to trypsirv-EDTA. This raised the possibility that ceU-ceU and cell-substrate adhesion 
molecules may be functioning differently in mutated cells. It was also noted that the 
mutated cells appeared less tolerant to release from plastic by trypsinisation than the 
MC3T3-E1 and WT lines, with a visibly higher proportion of cells not surviving the process.
- 96 -
Figure 4.3: Morphology of MC3T3, WT and C278F cells
MC3T3-E1 (A,D,G) WT (B,E,H) and C278F (C,F,I) cells from a second passage post 
plating were seeded at 12,000 cells/cm2 and grown in aMEM containing 10% FCS 
until confluent (designated day 0). Medium was then supplemented with 50pg/ml (final 
concentration) ascorbate and 10 mM 8-glycerophosphate. Cells were imaged by 
phase contrast microscopy at 4 hours post plating (A-C), Pre-confluence(PC) (D-F) 
and 21 days post confluence (G-l). Arrows (F, I) indicate areas of nodule formation. 
Scale bars are 25pm in A-C and 200pm in D
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4.2.3: Plating efficiency
MC3T3-E1 cells showed the most efficient attachment. Mutated cells attached poorly 
in comparison with MC3T3-E1 and WT cells. This was statistically significant at 1, 2 and 4 
hours. However, mutated cells appeared to demonstrate “catch-up” growth when attached, 
suggesting their proliferative rate may be greater than that of the MC3T3-E1 or WT cells. 
At 4 and 8 hours for MC3T3-E1 cells and at 8 hours for WT cells, the number of cells 
attached was greater than 100%, reflecting that these cultures had undergone mitotic 
expansion beyond losses due to cell death and non attachment.
Figure 4.4: Plating efficiency of cell lines
Cells were plated at 12,000/cm2 in standard medium. Detached cells were counted at 1,2,4 
and 8 hours following seeding. Data are expressed as the mean + SEM for each group. 
Statistical differences among treatment groups were evaluated using analysis of variance 
(ANOVA) and the significance of differences was determined by post hoc testing using 
Bonferroni’s method. S = significant (p < 0.05 was considered significant)
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4.2.4: Cellular Proliferation
Initial observations of the behaviour of the cell lines and indications from measures of 
plating efficiency, suggested that despite poor early attachment, mutated ceHs exhibited 
“catchup” growth.
Studies have identified that FGF/FGFR signaling has profound effects on cellular 
growth and differentiation and therefore it might be expected that the C278F cells would 
exhibit altered proliferative characteristics compared to the wild-type.
To study proliferation in the C278 cells, the mitotic index was studied using anti- 
Histone-H3 antibodies. Monoclonal antibodies directed against histone H3 phosphoserine 
have been used to visualise mitotic chromosomal condensations to provide staining 
indices that correlate wen with simple mitotic indices (Chadee et a!., 1999, Hirata et ai., 
2004). The phospho-H3 antibody recognises histone H3 after it becomes phosphorylated 
on serine 10 when the chromosomes condense during prophase, (Strahl & Allis, 2000). 
Histone H3 remains phosphorylated until telophase, at which time it becomes 
dephosphoryterted by specific phosphatases (Cunningham, 2002).
This study revealed a greater mitotic index for C278F cells (Fig. 4.5) which became 
statistically significant at day 2 (Fig. 4.6).
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Figure 4.5: Phosphorylated histone 3 (p-H3) immunostaining of osteoblasts
Histone staining of mitotic chromosomal condensations of cell lines at 24 and 48 hours 
after plating in normal medium at 12,000 cells/cm2. Four random areas per well (triplicate 
samples) were counted to give 12 counts for each cell line and time point. A negative 
control (no primary antibody applied) for each time point was included (not shown). Images 
obtained by phase contrast microscopy. Scale bars = 50 pm
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Figure 4.6: Measurement of Mitotic Indices for MC3T3-E1, WT and C278F cell lines
A. Example (WT cells at 48hours) of method to count H3 positive cells. All cells (a) were 
counted using Openlab software “click counting” facility. This was repeated (b) following 
adjustment of gain and contrast levels to show only cells demonstrating H3 positivity. 
Images obtained by phase contrast microscopy. Scale bars = 50pm
B. Mitotic index expressed as % of positive cells/total cell count. Data are expressed as the 
mean + SEM for each group (n=12). Statistical differences among treatment groups was 
evaluated using SPSS (version14.0) (SPSS inc., Chicago, USA) software by analysis of 
variance (ANOVA) and the significance of differences was determined by post hoc testing 
using Bonfenroni’s method. S = significant (p < 0.05 was considered significant)
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4.2.5: Matrix mineralisation
The mineralisation of matrix proteins is of fundamental importance in osteogenisis as 
would be the ability of any potential cell based biomaterials to remineraltse in an 
appropriate manner when implanted.
Quarles et al., (1992) and Choi et a!., (1996), demonstrated that the MC3T3-E1 cell 
line start to produce calcified nodules at approximately day 16 in differentiation culture 
medium. Osteoblasts carrying mutations in FGFRs appear to mineralise matrix in a 
manner which is dependent upon the specific mutation involved (Fragale et al., 1999).
Cell cultures were stained for AMzarin-S Red and von Kossa to attempt to reveal 
areas of matrix mineralisation. In the case of Alizarin, a complex which displays a 
red/orange birefringence is formed between calcium and Alizarin via its suiphonated and 
hydroxyl groups. The reaction is not strictly specific for calcium, since magnesium, 
manganese, barium, strontium, and iron may interfere, but these elements usually do not 
occur in sufficient concentration to interfere with the staining. Furthermore, calcium-binding 
proteins and proteoglycans are also detected by this stain.
The von Kossa technique which is widely used, relies on the binding of positively 
charged silver ions with negatively charged phosphate and carbonate ions which act as a 
surrogate for calcium. These are observed as black/brown deposits. However, caution 
should be exercised in interpretation, as the presence of phosphate per se does not 
necessarily imply the presence of calcium or hydroxyapatite.
At 21 days post confluence, C278F cells were observed showing well developed and 
discrete calcified nodules (Fig. 4.7 C,Ffl) whereas much more limited nodule formation 
and calcification was seen in the MC3T3-E1 (Fig. 4.7 A,DtG) and WT (Fig. 4.7 B,E,H) 
cells, which demonstrated a more homogenous pattern of staining. All attempts to show 
mineralisation at 30 days were unsuccessful, due to detachment of the 30 day cultures 
during the fixation and staining process.
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MC3T3 E1 WT C278F
Fig 4.7: Alizarin S Red and von Kossa staining for mineralisation
MC3T3-E1 (A,D,G), WT (B,E,H) and C278F (C,F,I) Cells at 21 days post confluence, 
unstained (A-C), stained with Alizarin (D-F) and von Kossa (G-l). The mutated cell cultures 
(C,F,I) produced well developed nodules (Arrows) which stain for Alizarin S (AS) and von 
Kossa (vK) within a background of cells which did not reached full confluence. The 
MC3T3-E1 (A,D,G) and WT (B,E,H) cells exhibited very limited development of nodules 
with a more homogenous pattern of mineralisation. Images obtained by phase contrast 
microscopy. Scale bars = 200pm
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4.2.6: mRNA expression of osteodifferentiation markers 
4.2.6.1: Collagen 1a1
All lines expressed collagenlal from the pre-confluent stage through to day 30 (Fig. 
4.8). MC3T3-E1 cells expressed collagen at significantly higher levels from day 5-30. The 
expression of type I collagen in the C278F cells was not raised in comparison to the WT 
cells and both were significantly reduced in comparison to untransfected cells. Levels of 
expression remained at a consistent level throughout the study period in the C278F and 
WT lines with a tendency to decrease towards day 30 in the mutated cells, although this 
was not statistically significant. In contrast, levels in the MC3T3-E1 cells increased towards 
30 days, although again this was not statistically significant. The change from normal to 
mineralising medium at day 0 made no obvious difference to levels of expression.
MC3T3 WT C278F
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Figure 4.8: RT-PCR of Collagen 1a1 and GapDH expression in MC3T3-E1, WT and 
C278F cells
Col1a1 (284 bp) and GapDH (396 bp) band detection following agarose gel 
electrophoresis in buffer containing ethidium bromide. Samples were run from triplicated 
culture plates on a single large gel. cDNA bands were detected under UV light and 
intensity was determined with Alphaease (version3.3) (Alphalnnotech Corp., San 
Leonardo, Ca, USA) software. L = DNA ladder. Negative control (-ve) consisted of DEPC 
water in place of a cDNA sample
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Figure 4.9: Semiquantitative analysis of collagen 1a1 mRNA expression
Band intensity upon UV fluorescence is proportional to the quantity of ethidium bromide 
which intercalates with the cDNA. This should be proportional to the quantity of RNA at the 
start of the RT-PCR reaction thereby giving an indication of the levels of cellular RNA 
expression. However, gel electrophoresis is an end-product technique which cannot be 
assumed to quantify the PCR product in the exponential phase of amplification. In addition, 
ethidium bromide is an insensitive technique which is unable to resolve differences lower 
than approximately 10-fold. Attempts to make the technique as sensitive as possible 
include visualisation of the bands within the mid-linear range of band intensity as 
described in section 3.8.3. Band intensity was detected using Alphaease software and 
expressed as a ratio of Col1/GapDH for each sample point, (pc) = pre-confluent. The data 
are expressed as the mean + SEM for each group (n=3). Statistical differences among 
treatment groups were evaluated by analysis of variance (ANOVA) and the significance of 
differences between the groups was determined by post hoc testing using Bonferroni’s 
method. S -  significant (p < 0.05 was considered significant)
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4.2.6.2 Osteocalcin
Osteocalcin expression was significantly higher in the C278F pre-confluent and 
day 5 post-confluent cultures and decreased with time to levels similar to the MC3T3-E1 
and WT lines in which osteodacin levels showed a non significant tendency to increase 
after confluence.
\ r
d5 d10 d30
V  \ (
214bp -----
396bp—
■■ MC3T3-E1
WT
C278F
Figure 4.10: RT-PCR of osteocalcin (OC) and GapDH mRNA expression
Osteocalcin (214 bp) and GapDH (396 bp) band detection following agarose gel 
electrophoresis. Samples for each cell line were run on a single gel and divided for viewing 
and band intensity reading. A,B,C represent separate samples for each line and timepoint. 
pc = pre-confluent, L = DNA ladder. Negative control (-ve) consisted of DEPC water in 
place of a cDNA sample
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Figure 4.11: Semiquantitative analysis of osteocalcin mRNA expression
RT-PCR analysis of pre-confluent, day 5 -  day 30 post-confluent samples of all cell lines, 
(pc) = pre-confluent. Data are expressed as the mean + SEM for each group (n=3). 
Statistical differences among treatment groups were evaluated using analysis of variance 
(ANOVA) and the significance of differences was determined by post hoc testing using 
Bonferroni’s method. S = significant (p < 0.05 was considered significant)
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4.2.6.3 Alkaline phosphatase
Alkaline phosphatase was expressed in pre-confluent MC3T3-E1 cells and levels 
rose towards day 30. Consistently lower levels were seen in WT cells which did not 
express significantly until day 5. C278F cultures did not express until day 30 and at lower 
levels than the MC3T3-E1 or WT cultures. Levels were significantly different between all 
cell lines at days 6-30.
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Figure 4.12: RT-PCR of alkaline phosphatase (ALP) and GapDH mRNA expression
Alkaline phosphatase (386 bp) and GapDH (396 bp) band detection following agarose gel 
electrophoresis. Cell lines were run on separate gels and divided for viewing and band 
intensity reading. Faint expression observed at day 30 in C278F cells, pds = primer 
dimers. L = DNA ladder for determining approximate size of RT-PCR products. Negative 
control (-ve) consisted of DEPC water in place of a cDNA sample
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Figure 4.13: Semiquantitative analysis of alkaline phosphatase mRNA expression
RT-PCR analysis of pre-confluent, day 5- 30  post-confluent samples of ail lines, (pc) = 
pre-confluent. Data are expressed as the mean + SEM for each group (n=3). Statistical 
differences among treatment groups were evaluated using analysis of variance (ANOVA) 
and the significance of differences was determined by post hoc testing using Bonferroni’s 
method. S = significant (p < 0.05 was considered significant)
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4.2.7: N-Cadherin
MC3T3-E1 cultures showed significantly higher levels of N-Cadherin at all time 
points. There was no significant difference in the levels of expression between WT and 
C278F cultures.
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Figure 4.14: RT-PCR of NCadherin (NCad) and GapDH mRNA expression
NCadherin (306 bp) and GapDH (396 bp) band detection following agarose gel 
electrophoresis. Ceil lines run on separate gels and divided for viewing and band intensity 
measurement. L = DNA ladder for determining approximate size of RT-PCR products. 
Negative control (-ve) consisted of DEPC water in place of a cDNA sample
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Figure 4.15: Semiquantitative analysis of NCadherin mRNA expression
RT-PCR analysis of day 1 -8 post-plating samples of all lines (dayl -  4 cultures are pre­
confluent, day 8 cultures are confluent).
Data are expressed as the mean + SEM for each group (n=3). Statistical differences 
among treatment groups were evaluated using analysis of variance (ANOVA) and the 
significance of differences was determined by post hoc testing using Bonferroni’s method.
S = significant (p < 0.05 was considered significant)
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4.2.8: Connexin 43
Expression in ail lines was highest immediately after plating and decreased as the 
cells became confluent. C278F cultures expressed higher levels than WT at all time points 
(not statistically significant).
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Figure 4.16: RT-PCR of connexin 43 (Cx43) and GapDH mRNA expression
CX43 (468 bp) and GapDH (396 bp) band detection following agarose gel electrophoresis. 
Cell line samples run on single gels (note the changed well order) and divided for viewing 
and band intensity measurement. A,B,C represent separate samples for each line and 
timepoint L = DNA ladder. Negative control (-ve) consisted of DEPC water in place of a 
cDNA sample
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Figure 4.17: Sem[quantitative analysis of connexin43 mRNA expression
RT-PCR analysis of day 1 -8 post-plating samples of all lines and their GapDH (day 1 -  
day 4 cultures are pre-confluent, day 8 cultures are confluent). Data are expressed as the 
mean + SEM for each group (n=3). Statistical differences among treatment groups were 
evaluated using analysis of variance (ANOVA) and the significance of differences was 
determined by post hoc testing using Bonferroni’s method. S = significant (p < 0.05 was 
considered significant)
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4.2.9: FGF18
All lines expressed FGF18 at all time points throughout the culture period. Levels 
were significantly higher in pre-confluent and day 5 C278F cultures, dropping at day 10 
and rising again on day 30. MC3T3-E1 and WT cultures expressed FGF18 at similar levels 
from pre-confluent to day 10, with levels dropping in these cultures at day 30.
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Figure 4.18: RT-PCR of FGF18 and GapDH mRNA expression
FGF18 (267 bp) and GapDH (396 bp) band detection following agarose gel 
electrophoresis. All samples run on single gel and divided for viewing and band intensity 
measurement. L = DNA. Negative control (-ve) consisted of DEPC water in place of a 
cDNA sample
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Figure 4.19 : Semiquantitative analysis of FGF18 mRNA expression
RT-PCR analysis of pre-confluent, day 5- 30  post-confluent samples of all lines and their 
GapDH. (pc) = pre-confluent. Data are expressed as the mean + SEM for each group 
(n=3). Statistical differences among treatment groups were evaluated using analysis of 
variance (ANOVA) and the significance of differences was determined by post hoc testing 
using Bonferroni’s method. S = significant (p < 0.05 was considered significant)
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4.3: Discussion
4.3.1: Morphological development of cell lines
Initial observations of cellular growth in culture revealed the C278F ceils required a 
much more frequent feeding regime than non mutated cells. This might be explained by 
the recent findings of Hatch et al., (2006), who observed significantly higher levels of 
anaerobic metabolism within COS7 cells transfected with the FGFR-C278 mutation.
Importantly, an obvious difference in the morphology, attachment behaviour, growth 
and levels of cellular death of the mutated C278F cells compared to the MC3T3-E1 and 
WT cells was noted. C278F cells initially attached poorly compared to the MC3T3-E1 and 
WT cells, as confirmed by measures of plating efficiency. When mutated cells attached 
and began proliferating, their morphology consisted of a more rounded or cuboidal 
appearance than the other cell lines. Mutated cells did not reach confluence, but formed 
aggregates earty, which developed into multilayered nodules with cultures taking on an 
overall “woven” appearance. These observations were consistent with the findings of 
Petiot et al., (2002), who studied the effect of the C278F mutation in premigratory quail 
chick neural crest cells and in primary human cell cultures carrying different activating 
mutations of FGFR2 (Lomri et al., 1998; Santos-Ruiz et al., 2007). When cultures were 
treated with trypsin, mutated cells rounded and detached more quickly and demonstrated 
a greater tendency to attach to each other.
In considering the possible mechanisms to explain these findings it is worth first 
discussing the potential influences on cell shape. Two principle models of cellular shape 
exist. In the first, the cell is a balloon type structure in which the cell membrane influenced 
by external forces (e.g adjacent cells, matrix), contains a homogenous, viscous cytoplasm 
(Evans and Yeung 1989; Dong et al., 1991). This fails to explain however, the influence of 
internal microstructure. Hence, the “tensegrity” model popularised by Ingber, (1993), has 
become the predominant view with respect to cell shape and movement. In this model, 
cells generate their own internal tension or “prestress” in the actin filament and 
intermediate filament cytoskeleton. This is counter-balanced by both internal microtubule 
struts which withstand compression forces and by external ECM adhesions via cell surface 
adhesion receptors such as the integrins.
Consistent with the model, it has been shown that forces from the exteracellular 
environment acting through the cellular adhesion molecules, can be transmitted to the 
nucleus via the cytoskeleton to influence gene expression (Wozniak et al., 2000; Chen et 
al., 2001; Jalali et al., 2001; Wang et al., 2001). The mechanotransduction of these signals 
occurs through focal adhesion proteins such as Vinculin which connect directly to
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microfilaments and indirectly to microtubules and intermediate filaments (Alenghat et al., 
2000). This in turn activates integrin-associated signaling cascades such as focal adhesion 
kinase (FAK), extracellular signal-regulated protein kinase (ERK), and G-proteins. 
(Janmey et al., 1998)
The link between FGFRs and cytoskeietal transduction of signals has not been fully 
defined. However, Mehta et al., (2001), have documented the p-38(MAPK) dependant 
formation of actin plaques and cell membrane retraction upon treatment of prostate-DU145 
cells with FGF2. More recently, Sandilands et al., (2007), have shown in foetal mouse 
fibroblasts that ligand-induced activation of FGFRs is dependant on intact actin filaments 
to allow function of the Src/RhoB endosome shuttle which transfers FGFR from the 
cytoplasm to the cell membrane. More specifically with relation to craniosynostosis, micro- 
array studies of pericranial fibroblasts from patients with Crouzon syndrome have 
demonstrated the down-regulation of CofUin and Profilin (Carina et al., 2002). Cofilin is an 
actin-modulating protein that binds and depolymerises filamentous actin and inhibits the 
polymerisation of monomeric actin and is involved in the translocation of the actin-cofilin 
complex from cytoplasm to the nucleus, while Profilin is important for spatially and 
temporally controlled growth of actin microfilaments. These reports describe important 
interactions between FGFR signaling and the cytoskeleton to affect cellular shape and 
function and give further insight into the morphology and behaviour of the C278F cells, 
suggesting that potential down regulation of these proteins in the mutated cells leads to a 
decrease in prestress and subsequent rounding of the cells.
The tensegrity model also goes some way to explaining that cellular behaviours, 
including differentiation, motility, and contractility, can be altered by changing cell shape or 
ECM rigidity (Ben-Ze’ev et al., 1988; Opas, 1989; Mochitate et al., 1995; Lee et al., 1997; 
Parker et al., 2002). In general, spread cells grow, retracted cells differentiate and fully 
round or detached cells undergo apoptosis (Weaver et al., 2002), even when stimulated 
with optimal levels of growth factors and ECM attachment (Dike et al., 1999). Therefore, 
these findings may help to explain the observation that the more rounded, less well 
attached C278F cells had an apparently higher rate of cellular death suggesting that they 
maybe further down the differentiative path than MC3T3-E1 and WT cells.
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4.3.2: Cellular proliferation
Although C278F cells initially attached poorly, they appeared to undergo “catchup” 
growth upon measures of plating efficiency. This was confirmed by H3 proliferation studies 
which revealed a greater mitotic index for C278F cells, which became statistically 
significant at day 2. The finding of differential proliferation between the lines was not 
altogether surprising as Li et al., (1994), demonstrated that fibroblast proliferation is 
mediated through FGFR1 and FGFR2. Mansukhani et al., (2000), transfected the OB 1 
osteoblast cell line with an FGFR2 mutation for Apert syndrome (S252W) and Crouzon 
syndrome (C342Y) and found that both mutations conferred a two-fold increase in 
proliferation. Other authors however have reported differently. Lomri et al., (1998), found 
that osteoblast culture from patients carrying the S252W mutation for Apert syndrome 
have no alteration in their proliferation rate compared with aged matched controls. Fragale 
et al., (1999), reported decreased osteoblast proliferation in a patient with Apert syndrome 
(FGFR2/P253R) and Pfeiffer syndrome (FGFR2/C342R). However, Ratisoontom et al., 
(2003), have found that chicken calvarial osteoblasts transfected with the C278F mutation, 
exhibited significantly increased proliferation.
Ohbayashi et al., (2002), have shown that FGF18 is implicated in the control of 
osteoblasts proliferation/differentiation and hence the finding in this study that FGF18 is 
expressed at significantly higher levels within the C278F cells during early proliferation, 
may further explain the increased levels of proliferation within these cells.
Mutated cells failed to reach confluence prior to developing nodular condensations 
and despite the apparently higher levels of proliferation in the first two days post-plating, 
upon prolonged culture, there was no obvious increase in the total biomass of C278F cells 
when pelleted for splitting or freezing. This would suggest one of two phenomenons: 
Either, proliferation in this cell line was down-regulated to a greater degree by cellular 
communication as the cells became more confluent. Alternatively or in addition, C278F 
cells may have been undergoing a higher level of apoptosis which would have been 
consistent with the cellular morphology. Indeed, significantly raised levels of TUNEL (a 
marker of apoptosis) expression in C278F cells were confirmed by a co-worker in our 
laboratory (Dr Santos-Ruiz, unpublished data). This is consistent with papers in which 
osteoblasts carrying FGFR2 mutations exhibit increased apoptosis compared to wild type 
or control populations (Mansukhani et al., 2000; Lemmonier et al., 2001)
Another explanation of this apparently higher level of proliferation relates to the levels 
of confluence during the study: Despite seeding at the same cellular concentration and 
because of the previously described attachment behaviour and higher levels of cell death,
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the C278F cells were less confluent than the MC3T3-E1 and WT cells at both time points 
(Fig. 4.S). This gives rise to the possibility that measured differences in proliferation may 
have been due to a relatively lower level of proliferation within the non mutated lines, 
secondary to the phenomenon of contact inhibition. This may have become apparent by 
proliferation studies carried out beyond day 2 once C278F cells were denser. An 
alternative approach would have been to seed at different densities allowing for plating 
efficiency and early cell death, to provide cell cultures displaying equal confluence for each 
time point.
4.3.3: Expression of markers of osteodifferentiation and mineralisation
Although pathologically increased levels of type 1 collagen by calvarial osteoblasts 
has been demonstrated in craniosynostosis associated with mutations of the FGFRs 
(Bodo et al., 1996; Lomri et al., 2000; Baroni et al., 2002), the expression of type I collagen 
in the C278F cells was not raised in comparison to the wild type receptor and significantly 
reduced in comparison to untransfected cells.
Alkaline phosphatase was not expressed in the mutated cells until day 30 and then at 
significantly lower levels than the untransfected and WT cells, which first expressed in the 
pre-confluent and day 5 cultures respectively.
Franceschi et al., (1992, 1994), demonstrated that MC3T3-E1 cells expressing low 
levels of normal type I collagen, expressed lower levels of ALP and OC. In addition, 
Wenstrup et al., (1996), found that MC3T3-E1 osteoblasts require a normally structured 
collagen rich matrix for up regulation of ALP activity and that cells with disrupted collagen 
structure had down-regulation of ALP but up-regulation of OC, a pattern of expression 
demonstrated in earty cultures of C278F cells, possibly suggesting the presence of an 
abnormal collagen matrix in the mutated cells.
The finding that Coll and ALP were expressed at generally lower levels in the 
mutated cells was seemingly inconsistent with previous reports that typel collagen and 
ALP are upregulated in FGFR2 mutations in osteoblasts from patients with 
craniosynostosis, (Lomri et al., 1998; Fragale et al., 1999), although interestingly, the 
same authors noted that mineralisation was blocked in osteoblasts from patients carrying 
Crouzon/Pfeiffer mutations, yet accelerated in osteoblasts from patients with Apert 
mutations (P253R and S252W). It should be recognised however, that interpretation of the 
effects of FGFR mutations in patients with craniosynostosis are limited by the varying ages 
of patients and controls. Nevertheless, these findings are largely corroborated by
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osteoblast transfection studies; Mansukhani et al., (2000), reported that mutations 
producing constitutive activation of FQFR2, block ALP expression and mineralisation.
The fact that the C278F cells were forming prominent nodules and mineralising 
also seemed at odds with poor expression of ALP. However, during the course of this 
study, Ratisoontom et al., (2003), reported the downregulation of type 1 collagen and ALP 
in chick calvarial osteoblasts transfected with the C278F mutation. Furthermore, Wang et 
al., (1999), who have shown that there is good correlation between mRNA expression and 
protein transcription of ALP and OC in the MC3T3-E1 cell line, have questioned the 
correlation between osteodifferentiation markers and mineralisation, with the finding that 
MC3T3-E1 cells exhibit donal subpopulations with widely different expression patterns; 
some subdones mineralised without expressing ALP or OC, while other donal populations 
expressed ALP and OC but did not mineralise. In addition, Beck et al., (1998), showed that 
ALP expression could be dissociated from OC expression and mineralisation in MC3T3-E1 
cells by targeting with adenovirus E1A protein.
Osteocaldn is generally reported as the last marker of differentiation to express, 
typically appearing not before day 7 in MC3T3-E1 cultures and increasing as differentiation 
advances (Choi et al., 1996; Quarles et al., 1997). The finding that all cells expressed OC 
from the preconfluent stage with the mutated cells expressing OC maximally at this stage 
and decreasing with confluence and nodule formation was surprising. However, this was 
not an isolated finding, as Ratisoontom et al., (2003), have also reported their osteoblast 
lines expressing OC from the outset.
Whilst the differences in levels of expression of ALP and OC between the WT and 
mutated cells are likely, given the differing morphology and adhesion behaviour, to be due 
directly to downstream effects of the FGFR2 mutation, it is worth considering that they may 
be affected by one or a combination of factors not directly attributable to the mutation. The 
cell lines may be at different levels of maturation for a number of reasons including clonal 
drift into a phenotypically more differentiated cell line (Leis et al., 1997), selection of 
particular subdones (Wang et al., 1999) or the effects of multiple passaging, an effect 
which may be under emphasised in osteoblast research according to Chung et al., (1999) 
and Peterson et al., (2004).
A further consideration which makes comparisons with the findings of other authors 
difficult, is possibly the effect which different serum concentrations was having on the 
cultures: The presence and concentration of the numerous inductive, permissive or 
inhibitory hormones or cytokines will likely influence osteoblast specific gene expression 
and cell-matrix interactions. Both the qualitative and quantitative size of these effects
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cannot be known and true comparison and interpretation would only be possible by the 
omission of serum from the experiments.
4.3.4: Expression of markers of cell adhesion
The expression of cell-cell adhesion and gap junction molecules was examined 
based on the difference in morphology and attachment behaviour of the cell lines as 
previously described. The expression of Cx43 in all lines was highest immediately after 
plating and decreased as the ceils became confluent. C278F cultures expressed 
consistently higher levels than WT at all time points although this was not statistically 
significant This tendency however, may start to explain the dumping and cell-cell 
attachment behaviour observed in the mutated cells, as cellular coupling has been directly 
correlated with Cx43 expression in MC3T3-E1 cells (Yamaguchi et a!., 1994).
To date, there are no reports of Cx43 expression in either primary or cell line 
osteoblasts carrying FGFR mutations. The finding by Gramsch et al., (2001), that there is 
a correlation between Cx43 expression and increased levels of proliferation in the UMR 
osteosarcoma cell line would also be consistent with Cx43 expression and increased 
proliferation of the C278F cells, although extrapolation of findings in an osteosarcoma line 
to an osteoblast Nne may be problematic.
When N-cadherin expression was looked at, there appeared to be little difference in 
the expression levels between the wild type and mutated cells which both consistently and 
significantly expressed N-cadherin at a lower level than the untransfected cells. This is 
difficult to explain given the inter-cellular dumping behaviour of the cell lines. Moreover, 
Lemonnier et al., (2001), have reported the up-regulation of N-cadherin in human primary 
osteoblasts carrying the S252W mutation for Apert syndrome, although, as previously 
discussed with reference to osteodifferentiation markers, discordant findings for different 
mutations within the FGFR2 receptors may be antidpated (Lomri et al., 1998). This is not 
altogether surprising as the mechanism of receptor activation for the C278F Crouzon 
mutation involves ligand independent constitutive activation whereas the Apert mutations 
do not induce ligand independent dimerisation.
4.3.5: Expression of FGF18
FGF18 was expressed in all lines from pre-confluent culture until late differentiation 
at day 30. Levels of expression were similar in the MC3T3-E1 and WT cells at all time 
points, decreasing marginally towards day 30. However, the level of expression in the 
mutated cells was significantly raised by a factor of almost two in preconfluent cultures.
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These levels subsequently dedined at day 5 although remained raised with respect to the 
WT and MC3T3-E1. At day 10, levels had fallen to those seen in the MC3T3-E1 and WT 
cultures. Interestingly, transcript levels rose again in the late differentiated phase.
These findings would suggest that C278F cells were produdng raised levels of 
FGF18 in the proliferative phase, creating an autocrine enhanced prdiferative drive. As 
previously alluded to, Ohbayashi et al., (2002), have shown that FGF18 is implicated in 
stimulation of osteoblast proliferation via ERK activation. It can therefore be postulated that 
this up-regulation of the expression of FGF18 may be an attempt to regain functionality by 
a feedback response to down-regulation of the FGFRs, brought about by the constitutively 
active FGFR2-C278F. This would be consistent with work published after the completion 
of this study by Hatch et al., (2006), in which MC3T3-E1 cells transfected with the FGFR2- 
C278F receptor mutation showed increased receptor internalisation and degradation within 
the GokjhER-Complex and decreased surface expression.
The rise in levels at day 30 is more difficult to explain based on our knowledge to 
date of FGF18 interactions and effects. Possibly a higher level of cellular death within the 
C278F cells at late maturation, created a phase in which pockets of unoccupied matrix 
exist, allowing cells to resume proliferation.
Where statistical significance has been demonstrated, this should be read in the 
context that a Gaussian distribution was assumed for the distribution of data and sample 
sizes consisted of triplicates. This is small and indeed the smallest sample size which 
allows an analysis of variance (ANOVA) and intergroup post-hoc testing. This produces 
large standard errors which may prevent the identification of real as opposed to statistically 
significant differences. Furthermore, while the Bonferonni method was chosen for 
measures of significance because it is considered to be a simple method, good for 
comparing groups of less than approximately five, it should be recognised that it provides 
conservative measures of p-value which again may fail to demonstrate significant 
differences.
4.3.6: Summary
The basic morphological development of the three cell lines and the differences due 
to the mutation in the FGFR2 receptor has been highlighted. I have demonstrated altered 
adhesion, cell shape and enhanced early proliferation within the mutated cells. The 
differential expression of osteodifferentiation markers has been semi-quantified as has the 
expression of the functionally important cell adhesion molecules Connexin-43 and N- 
cadherin.
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The expression of Cx43 and FGF18, a ligand recently implicated in the control of the 
proliferative-differentiative balance in osteogenisis has been studied for the first time in 
FGFR2 mutated cells. It is interesting to speculate as to the molecular causes of the 
altered cellular morphology and why expression of a mutated FGFR2 receptor should 
affect the shape and attachments of cells both to themselves and tissue culture plastic. As 
alluded to, there is probably a complex interplay between cellular adhesion molecules, 
cytoskeleton, and the nucleus which affects cellular integration and function as predicted 
by the tensegrity model. This may become increasingly obvious and important when 
investigating the surface form of scaffolds for bioengineering. The obvious difference in 
attachment behaviour and shape of the mutated cells would justify further analysis of the 
nature of adhesion interactions between the cells, the ECM and the expression of 
cytoskeleta! structures. This would facilitate the determination of the fundamental 
relationship between cell adhesion and function and would have been a focus for future 
work on this cell model.
What these findings in conjunction with a review of the relevant literature highlights, 
is that it seems difficult to make broad inferences and apply them to specific cell types or 
mutations. The interaction of cell type, cell age, the multitude of signaling pathways along 
with the individual culture and experimental conditions, allow for only limited conclusions to 
be drawn from any particular set of findings. For example, the precise role which each 
single component of the extracellular matrix plays in determining the phenotype of any 
particular craniofacial syndrome is not at all dear.
Having described qualitatively and semi-quantitatively the difference in morphology 
and behaviour which the FGFR2-C278F(C278F) mutation was eliciting, It seemed relevant 
to attempt to modify or “rescue” the phenotype of the mutated cell line, to one which more 
resembled cells not carrying the mutation, with particular emphasis on facilitating maximal 
proliferative expansion. This would be a potential strategy for utilising mutated, autologous 
osteoprogenitors for bone engineering. Specifically, it would be informative to explore the 
effect of FGF18 treatment given the significantly raised levels of mRNA expression within 
the C278F cell line and the potential importance of this FGF raised in the recent literature.
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Chapter 5: Modulation of osteoblast behaviour
5.1: Introduction
In chapter 4, phenotypic study of the cell lines, revealed that in comparison to WT 
and untransfected MC3T3-E1 cells, FGFR2-C278F(C278F) mutated cells appeared 
morphologically and behaviourafly different. They demonstrated a more rounded/cuboidal 
appearance when attached to plastic with less well developed filopodia. Attachment 
behaviour was also markedly different, with C278F cells taking longer to attach to culture 
plastic and attaching in a manner which allowed a more rapid release by trypsin. Upon 
attachment mutated cells attached in clusters which subsequently took on a nodular 
appearance before they were able to reach full confluence. Proliferation studies revealed 
that once attached the mutated cells demonstrated an initially higher mitotic rate in the 
early pre-confluent stages of growth. Throughout all culture periods and conditions, the 
mutated cells subjectively demonstrated a higher proportion of cell death, which was 
consistent with unpublished data from our laboratory (Dr. Santos-Ruiz), confirming this 
mutation exhibited increased levels of apoptosis in standard culture conditions. While the 
expression of mRNA for osteodifferentiation proteins revealed that the appropriate markers 
were expressed, the temporo-spada! expression was different from that which would have 
been expected in cells expressing in the accepted progression along the osteoblast 
lineage. Specifically, the expression of high levels of osteocalcin in pre confluent cultures 
before the development of significant nodules and the subsequent falling levels were 
contrary to what was anticipated in osteoblasts (Aubin et al., 1995; Liu et al., 2003).
In considering development of bio-composites for bone engineering, the use of 
osteoprogenitors from patients with syndromic craniosynostosis and the ability to optimally 
expand them on a scaffold prior to terminal differentiation and mineralisation would 
theoretically be an ideal manipulation.
Fibroblast growth factor signalling plays an important role in cranial bone 
development and osteoblast function as alluded to in chapter 1. The biological effects of 
FGFs depend on stage of growth, and in vitro studies have shown that FGF1, FGF2, FGF4 
and FGF18 can potentiate the growth of proliferating calvarial osteoblasts (Canalis et al., 
1988; Tang et al., 1996; Hurley et al., 1995; Shimoaka et al., 2002) but not mature or 
differentiated osteoblasts (Mansukhani et al., 2000).
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Studies within our laboratory have confirmed that endogenous levels of FGF2 may 
constitute a mechanism to control proliferation in a concentration dependent manner 
(Moore et al., 2002) and analysis of FGF18 null mice has revealed a decrease in 
proliferation of osteogenic mesenchymal cells associated with delayed suture closure 
(Ohbayashi et al., 2002).
Differentiation also seems to be under the control of FGFs, as prolonged treatment 
with FGF2 promotes osteocalcin transcription and mineralisation in rodent and human 
osteoblasts (Newberry et al., 1998; Debiais et al., 1998). FGF18 inhibited differentiation 
and matrix synthesis in MC3T3 cells (Shimoaka et al., 2002). Proliferation and terminal 
differentiation of calvarial osteoblasts was decreased in FGF18 null mice (Ohbayashi et 
al., 2002) with a reduction in osteocalcin and osteopontin expression (Liu et al., 2002). In 
addition, apoptosis is influenced by FGF signalling, which again seems dependent on the 
stage of osteoblast differentiation. This is important as apoptosis is known to be a 
fundamental controller of osteoblast longevity and osteogenisis (Manolagas, 2000).
FGF2 treatment of neonatal mouse calvarial osteoblasts protected cells from 
apoptosis when starved of serum (Hill et al., 1997), whereas FGF1 treatment induced 
apoptosis in more differentiated osteoblasts and over-expression of FGF2 signalling in 
transgenic mice led to increased apoptosis in mouse calvaria (Mansukhani et al., 2000; 
Lemmonier et al., 2001). Mansukhani et al., (2000), also noted similar patterns of 
proliferation and apoptosis in osteoblasts constitutively activated by FGFR mutations. 
Interestingly, the effect of exogenous FGF treatment on cells carrying activating mutations 
for FGFRs has not been studied to a large extent, with only one report by Mansukhani et 
al., (2000), finding that OB1 osteoblasts transfected with an Apert FGFR2/S252W  
mutation, demonstrated a 22-54% increase in proliferation upon FGF1 treatment. Crouzon 
FGFR2/C342Y cells demonstrated only a minimal increase in proliferation upon treatment 
FGF1 treatment inhibited osteodifferentiation in these osteoblasts with no quantifiable 
difference between the groups. Treatment of differentiating, norvmutated OB1 cells with 
FGF1 induced apoptosis to levels seen in untreated mutated ceils.
Thus, FGF signaling of immature osteoblasts appears to reduce apoptosis and 
increase proliferation and cell numbers, whereas later stage signaling promotes apoptosis. 
Hence this apparently opposing effect is likely to be an important control mechanism in 
osteogenisis.
Taken together, along with the findings of Shimoaka et al., (2002), who reported that 
the mitogenic effects of FGF18 on osteoblasts were as strong as FGF2; the finding in 
chapter 4 that FGF18 was expressed at significantly higher levels in early and late cultures
-126-
of C278F cells, combined with the recent literature suggesting an important role for FGF18 
in the control of proliferation/differentiation, directed the study towards examination of the 
effect of FGF18 treatment on the ceil lines.
5.2: Foetal calf serum (FCS)
As seen in chapter 4, the growth of the C278F mutated cells relied on culture 
medium change more frequently than that required for the WT and untransfected cells. 
Likewise, the literature reviewed suggests that the concentration of serum in which cells 
are cultured, influences the response to growth factor treatment (Sachs et al., 1982; Allen 
et al., 1983). Foetal calf serum contains a variety of polypeptides that may "attach" to cells, 
inducing significant metabolic/morphologic changes. For example, bone marrow derived 
mesenchymal progenitor cells show a different behaviour in culture performed in the 
presence of FCS with or without heat inactivation (Bruinink et al., 2004). It is known that 
deprivation of serum or growth factors from the medium causes apoptotic death of cultured 
cells. Myc and p53 appear to be involved in the mechanism underlying such apoptotic cell 
death, but the precise mechanism is still unknown (Packham et al., 1995; Elliott et al., 
1995). Components of serum, such as growth factors other than FGFs highlighted 
previously, can cause attenuation of apoptosis in cell cultures, for example, epidermal 
growth factor (EGF) has been shown to protect cultured cells against apoptosis induced by 
serum deprivation (Tong et al.„ 1999). In addition, increasing MC3T3-E1 cell number has 
been shown to be linearly proportional to serum concentration up-to 4 days in culture 
(Masayuki et al., 2000) and the effect of exogenous FGF2 treatment on MC3T3-E1 cells is 
dependant on serum concentration. It was necessary therefore, to ascertain the lowest 
concentration of FCS which would sustain the cells during the treatment period and avoid 
the masking of effects solely due to FGF 18.
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5.3: Results
5.3.1: Assessment of FGF18 concentration effect
In the first instance, the study observed the effects of FGF18 treatment on the cell 
lines and established that the concentrations used, were in the correct range to observe an 
effect. These initial doses were chosen based on the findings of Shimoaka et al., (2002). 
Initial studies were carried out in 10% serum in keeping with the experiments in chapter 4, 
in order that any observed differences could be attributed to the FGF18 treatment.
Cellular behaviour observed in culture is shown in figure 5.1. MC3T3-E1 cells and 
WT cells just reached monolayer confluence at 48 hours post plating without treatment 
(Fig. 5.1 A,B), whereas C278F cells displayed their typical non confluent appearance (Fig. 
5.1 C) as observed in chapter 4. Cells treated for 36 hours with FGF18 at [10~10 M], 
particularly when observed directly through the microscope, appeared more densely 
packed in the case of the MC3T3-E1 and WT lines (Fig. 5.1 D,E).
The mutated cells took on a different morphology to that seen in standard culture 
when treated with FGF18 at [1(T10 MJ: Whilst still not fully confluent there were fewer and 
smaller voids on the culture dish (Fig. 5.1 F), indicating that the treatment had probably 
increased the cell population and/or altered cellular motility and attachment. When treated 
with a ten fold higher concentration of FGF18 [10~9 M], there was a multilayered 
appearance and increase in cellular density in the MC3T3-E1 and WT lines (Fig. 5.1 G,H), 
compared to cells treated with FGF 18 [10'1° M].
Treatment of the mutated cell line with FGF18 [10~9 M] (Fig. 5.1 I), produced a 
surprising result in that the appearance of the cultures was indistinguishable from the 
untransfected and wild-type cell lines. Full confluence had been achieved and there was 
no evidence of clustering behaviour.
These initial observations appeared to be consistent with the findings of Shimoaka et 
al., (2002), with respect to the MC3T3-E1 cells. Thus, treatment of the mutated C278F 
cells with FGF18 altered the characteristics of the line to one which took on the 
appearance more in keeping with the behaviour of the untransfected and WT cells. This 
observation suggested that FGF18 treatment might be a candidate for “rescuing” the 
behaviour of mutated cells in any potential bone engineering application.
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Figure 5.1: Treatment of osteoprogenitor lines with FGF18 for 2 Days
Cultures were plated at 12,000 cells/cm2 in standard medium containing 10% FCS. 
Medium was replaced after 12 hours with standard medium (A-C), standard medium 
supplemented with FGF18[10'1°M] (D-F) or standard medium supplemented with 
FGF18[10'9 M] (G-l). Cultures were imaged at 48 hours following the commencement of 
treatment. Medium was changed every 24 hours. MC3T3-E1 (A,D,G) and WT (B,E,H) 
cells have just reached confluence without treatment(A,B) - Treated cells are more 
densely packed and start to appear multilayered (D,G and E,H). C278F cells(C,F,l) are 
partially confluent in clusters without treatment (C), almost fully confluent with 
FGF18 [101°M] (F) and fully confluent when treated with FGF18 [10-9] (I). Images 
obtained by phase contrast microscopy. Scale bar = 200 pm
-129-
-130-
MC3T3 WT C278F
-ve
FGF18
[1 o-10]
FGF18
[10*]
5.3.2: Effects of foetal calf serum
The effect of foetal calf serum (FCS) concentration on the cell lines prior to 
quantification of the FGF18 effects was studied. The concentration of FGF18 chosen was 
[10r9 M] as this had appeared to “normalise” the proliferation of the mutated cells in section 
5.3.1.
MC3T3-E1, WT and C278F cells were observed at 24 and 72 hours with or without 
the addition of FGF18 [1(7® M] in the presence of 10%, 1% or no FCS. The results are 
shown in Figure 5.2.- 5.7. At 24 hours post treatment the MC3T3-E1 cells grown without 
FGF18 supplementation (Fig. 5.2 B,D,F) looked unstressed and showing progressive 
confluence from no FCS (Fig. 5.2 B) to the 10% FCS (Fig. 5.2 F) which were near full 
confluence. When cells were treated with FGF18 (Fig. 5.2 A,C,E), the cells growing 
without FCS (Fig. 5.2 A) appeared to be more confluent than the equivalent cells without 
FGF 18. However, they also appeared more “stressed” with a greater number of dead cells 
suggested by the pattern of light diffraction. The cells growing in 1% FCS (Fig. 5.2 C) were 
fully confluent although once again there was a suggestion that a greater degree of cell 
death had occurred. Cells grown in 10% FCS (Fig. 5.2 E) were fully confluent and looked 
healthy.
When observed at 72 hours, the MC3T3-E1 cells growing in 1% and 10% FCS were 
fully confluent with (Fig. 5.3 c,e) and without (Fig. 5.3 d,f) FGF 18 supplementation. Cells 
grown without FCS and without FGF18 (Fig. 5.3 b) looked healthy but still not fully 
confluent. Whereas cells grown without FCS but with FGF 18 (Fig. 5.3 a) had changed 
very little from the 24 hour appearance, looking non confluent and demonstrating signs of 
stress and cellular death.
WT cells at 24 hours post treatment grown without FGF18 supplementation (Fig. 5.4 
B,D,F) looked unstressed and showed progressive confluence from no FCS (Fig. 5.4 B) to 
just fully confluent in the 10% FCS condition. When cells were treated with FGF18 (Fig.
5.4 A,C,E), cells growing without FCS (Fig. 5.4 A) appeared to be undergoing a high level 
of cell death and appeared much less healthy than in the equivalent group without FGF 18. 
This appearance was significantly improved when grown in 1% (Fig. 5.4 C) and 10% (Fig.
5.4 E) FCS which were near confluence and confluent respectively. At 72 hours without 
FCS or growth factor (Fig. 5.5 b), WT cells appeared healthy but had not reached 
confluence, in contrast cells without FCS and treated with FGF18 (Fig. 5.5 a) were 
surviving poorly with high levels of cellular death and few viable cells remained. Cells 
growing in 1% and 10% FCS with or without growth factor supplementation (Fig. 5.5 d,f
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and c,e) were all confluent, although cells growing in 1% FCS with FGF18 added (e) 
demonstrated a higher level of cell death.
When mutated cells were observed at both time points, it was apparent that they 
tolerated the absence of FCS poorly. At 24 hours without FGF18 (Fig. 5.6 B,D,F) 
approximately half of the visible cells were dead if no FCS was present (Fig. 5.6 B). When 
FGF18 was added, no viable cells were seen (Fig. 5.6 A). Cell survival was improved in 
the presence of 1% FCS (Fig. 5.6 D,C), however, the presence of FGF18, again conferred 
a high level of cell death (Fig. 5.6 C). With 10% FCS similar cell numbers were observed 
although ceils treated with FGF18 (Fig. 5.6 E) appeared more stressed. At 72 hours only a 
few viable cells were seen in the cultures without FCS or growth factor (Fig. 5.7 b), when 
growth factor had been added only cellular debris was seen (Fig. 5.7 a). When 1% FCS 
was added (Fig. 5.7 d) cell survival was greatly enhanced. When FGF18 was also added 
(Fig. 5.7 c) a greater number of ceils were observed, although a higher level of cellular 
stress was also noted. In the presence of 10% serum without FGF18 (Fig. 5.7 f) C278F 
cells took on their subconfluent appearance, whereas when treated with FGF18 (Fig. 
5.7,e) they became fully confluent, although multiple dead cells were apparent
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Figure 5.2: Effects of foetal calf serum and FGF18 on MC3T3-E1 cell growth at 24 h
Cells at 24 hours with FGF18I10'9] (A,C,E) or without treatment (B,D F), without serum (A,B), 
with 1% (C,D) or 10% (E,F) serum
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours with 
the treatment medium. Cultures were imaged by phase contrast after 24 of treatment. Scale 
bar = 200 pm
- 13 3 -
+FGF18 -ve
No FCS
1 % FCS iiiSil d 7 SISlil
10% FCS
Figure 5.3: Effects of foetal calf serum and FGF18 on MC3T3-E1 cell growth at 72 h
Cells at 72 hours with FGF18H0'9] (a,c,e) or without treatment (b.d.f), without serum (a,b), 
with 1% (c,d) or 10% (e,f) serum
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours 
with the treatment medium and every 24 hours thereafter. Cultures were imaged by phase 
contrast after 72 of treatment. Scale bar = 200 pm
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Figure 5.4: Effects of foetal calf serum and FGF18 on WT cell growth at 24 h
Cells at 24 hours with FGF18H0'9] (A,C,E) or without treatment (B,D F), without serum (A,B), 
with 1% (C,D) or 10% (E,F) serum
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours with 
the treatment medium. Cultures were imaged by phase contrast after 24 of treatment. Scale 
bar = 200 pm
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Figure 5.5: Effects of foetal calf serum and FGF18 on WT cell growth at 72 h
Cells at 72 hours with FGF18[10-9] (a,c,e) or without treatment (b,d,f), without serum (a,b), 
with 1% (c,d) or 10% (e,f) serum
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours 
with the treatment medium and every 24 hours thereafter. Cultures were imaged by phase 
contrast after 72 of treatment. Scale bar = 200 pm
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Figure 5.6: Effects of foetal calf serum and FGF18 on C278F cell growth at 24 h
Cells at 24 hours with FGF18[10_9] (A,C,E) or without treatment (B,D F), without serum (A,B), 
with 1% (C,D) or 10% (E,F) serum
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours with 
the treatment medium. Cultures were imaged by phase contrast after 24 of treatment. Scale 
bar = 200 pm
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Figure 5.7: Effects of foetal calf serum and FGF18 on C278F cell growth at 72 h
Cells at 72 hours with FGF18H0'9] (a,c,e) or without treatment (b,d,f), without serum (a,b), 
with 1% (c,d) or 10% (e,f) serum
Cells were seeded at 12,000/cm2 in normal medium. Medium was replaced after 12 hours 
with the treatment medium and every 24 hours thereafter. Cultures were imaged by phase 
contrast after 72 of treatment. Scale bar = 200 pm
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5.3.3: Proliferation effects of FGF18 treatment
Treatment with FGF18 produced an obvious increase in cell numbers amongst all 
cell lines, but most strikingly in the mutated cells, allowing them to grow to full confluence 
which until this stage, had not been observed. This apparent proliferative enhancement 
was quantified using anti-phosphohistone3 (pH3) as described in chapter 4.
Observations from the previous section revealed that the mutated cells required FCS 
to survive. While the addition of 1 % FCS obviously improved the survival of mutated cells, 
they continued to show a high degree of cellular stress, particularly in the presence of 
growth factor. Therefore further observations of cellular growth with different 
concentrations of FCS in the presence of FGF18 were performed and it was elected to 
carry out the experiment with all cultures growing in 2% FCS. This concentration allowed 
all lines to grow, without showing excessive signs of cellular stress.
Treatment with FGF18 increased the proliferation of all cell lines. This effect was 
greatest in the first 24 hours of treatment and a visual impression of this is gained by 
comparison of day 1 and day 2 staining in Figures 5.8 and 5.9. This was confirmed by 
analysis of the mitotic indices, calculated for each line and time point as shown in Figure 
5.10. Proliferation was significantly enhanced in a concentration dependent manner most 
notably for the WT and C278F lines. On day 1 this effect was greatest for mutated cells, 
producing a 2.4 fold increase in proliferation at [1 0 ^ ] compared to a 1.9 fold increase for 
both MC3T3-E1 and WT cells. At day 2 the effect was less obvious and there was no 
statistically significant difference in the increase between lines.
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Figure 5.8: Effect of FGF18 on proliferation using anti-pH3. Day 1
Cells were seeded in triplicate at 5000/cm2 in normal medium. Medium was replaced after 12 
hours with treatment medium containing 2% FCS in the absence (A-C) of FGF18 or 
supplemented with FGF18[10'9M] (D-F) or FGF18[10'8M] (G-l). Cultures were 
immunostained for anti-pH3 after 24 hours of treatment and imaged by phase contrast for 
measurement of mitotic index using Openlab software “click counting” facility, (gain/contrast 
adjusted images not shown). Scale bar = 50 pm
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Figure 5.9: Effect of FGF18 on proliferation using anti-pH3. Day 2
Cells were seeded in triplicate at 5000/cm2 in normal medium. Medium was replaced after 12 
hours with treatment medium containing 2% FCS in the absence (a-c) of FGF18 or 
supplemented with FGF18[10'9M] (d-f) or FGF18[10'8M] (g-i) which was changed after 24 
hours. Cultures were immunostained for anti-pH3 after 48 hours of treatment and imaged by 
phase contrast as before. Scale bar = 50 pm
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Figure 5.10: Effect of FGF18 on mitotic index.
Graphic representation of mitotic index, assessed by anti-pH3 staining
A. Day 1. Ratio of anti-pH3 positive cells as proportion of total cell count for MC3T3-E1, 
WT and C278F cells.
B. Day 2.
Data are expressed as the mean + SEM for each group (n=12). Statistical differences 
among treatment groups were evaluated using analysis of variance (ANOVA) and the 
significance of differences between groups was determined by post hoc testing using 
Bonferroni’s method. S = significant (p<0.05 was considered significant)
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5.4: Discussion 
5.4.1: Effect of FCS
During initial observations of cell culture in chapter 4, it was observed that the 
mutated cells seemed more dependent on serum supplementation than did the MC3T3-E1 
or WT ceils. This was further emphasised whilst optimising culture conditions before 
quantifying the effects of FGF18 treatment MC3T3-E1 cells tolerated serum starvation 
well as did WT cells in the absence of FGF18, whereas C278F cells did not tolerate serum 
starvation. The addition of FGF18 in the absence of serum had a severely deleterious 
effect on WT and C278F cell survival, in contrast to reports by Hill et al., (1998) and 
Debiais et al., (2004), that FGF2 rescues serum starved mouse primary calvarial 
osteoblasts and human primary osteoblasts respectively.
The addition of 1% FCS rescued the behaviour of WT cells. However 2% FCS was 
required in order to normalise the appearance of C278F cells. It became apparent that in 
conditions of low or absent FCS, FGF18 treatment was causing cell death, whereas the 
addition of FGF18 at higher concentrations of FCS, enhanced cell numbers. This was 
seen most obviously during the preliminary finding that C278F cells reached full 
confluence in the presence of 10% FCS and FGF 18 [10*9M], This had not previously been 
observed in the C278F cells. In addition there was no evidence that the cells were forming 
nodules early. The effect also appeared to be dependent on FGF18 concentration, as the 
addition of FGF at [1C10M] modified the appearance of C278F cells towards confluence.
Taken together, these observations suggested that FGF18 acting alone was driving 
cell death, but that in the presence of other growth factors and serum components, was 
enhancing cell survival either by increasing proliferation, reducing apoptosis or a 
combination of both. In addition, the absence of clustering and early nodule formation 
suggested that cell function was being affected. These observations might be explained in 
part and would be consistent with the tensegrity model. Such that low serum 
concentrations provided suboptimal levels of absorbed extracellular matrix proteins 
including fibronectin for example, for integrin associated attachment. The mutated cells 
therefore attach poorly, remain round and undergo apoptosis.
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5.4.2: Effects of FGF18
Quantification of the proliferative effect of FGF 18 in 2% FCS, revealed a 
concentration dependent increase in cellular mitosis for all cell lines. This was significantly 
greater at day 1 for the mutated cells than for the MC3T3-E1 and WT cells. However, the 
overall magnitude of increase was not seen to the same degree as Shimoaka et al., 
(2002), who carried out treatment in 10%FCS. This suggests that other growth factors 
present in the serum work in synergy with the FGF18 to influence proliferation. 
Furthermore, when cells were serum starved or at very low concentrations of FCS, the 
degree of cell death, possibly apoptotic in nature, was visually much greater in the mutated 
cells. It can be postulated that this response of the C278F cells suggests that the lack of 
cellular attachment and spreading via the ECM, in combination with a substance which 
under different conditions is mitogenic, is causing cellular death. This observation is 
consistent with both the more rounded appearance of the mutated cells in this study as 
predicted by the tensegrity model and the findings by Mansukhani et al., (2000), who 
observed that more mature cells respond to FGF treatment by undergoing apoptosis.
The observed concentration effect on proliferation differs from previous findings for 
FGFs, particularly FGF2, where it has been found that at low concentrations, FGF2 
promotes proliferation and at higher concentration proliferative arrest and differentiation is 
observed (Iseki et al., 1999; Moore et al., 2001; Sarkar et al., 2001). This study was unable 
to examine the effect of concentrations higher than 1(7® Molar. Had this been possible it 
would have been interesting to assess whether cells switched from proliferation to 
differentiation upon treatment with FGF18 at higher concentrations.
The mutation carried by the C278F cells causes ligand independent constitutive 
activation of the receptor (Robertson et al., 1998) and should therefore not respond to 
exogenous FGF. Moreover, it is possible that the constitutively activated FGFR2 creates a 
negative feedback, causing down-regulation of the receptor, a theory which has 
subsequently been supported by the recent findings of Hatch et al., (2006), as discussed 
in Chapter 4. It is therefore likely that the early increase in proliferation by FGF18 in the 
mutated cells is caused by the activation of other endogenous wild type FGF receptors, 
which may have differentially up-regulated expression secondary to the autocrine influence 
of the mutated FGFR2 receptor. It would therefore have been informative to look at the 
expression profiles of the FGFRs following FGF18 treatment.
In addition to increased proliferation, the full confluence of mutated cells without the 
tendency to form nodules prematurely was observed and it is tempting to speculate that 
treatment with FGF 18 is affecting cell-cell interaction and adhesion. Further studies
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examining the expression of some of the likely candidates should be considered in future 
work.
5.4.3: Sum m ary
In this chapter, it was observed that at low serum concentrations or in the absence of 
serum, FGF18 treatment was associated with cell death and that this was seen to the 
greatest degree in cells carrying the C278F mutation. When serum concentration was 
increased to a level which supported normal cell survival, treatment with FGF18 increased 
proliferation and this effect was greatest in pre-confluent cultures of C278F cells. In 
addition, treatment with FGF18 at concentrations at or above [1(T10M] “normalised* the 
appearance of the C278F cultures by allowing the cells to become fully confluent without 
early clustering. The effect of FGF18 treatment on the expression of osteodifferentiation 
and cellular attachment proteins would have been a natural further extension of this study.
Having observed that behaviour of the mutated cells could be influenced by 
modification of the culture environment in a manner which seemed beneficial to the 
expansion of the cellular population, it was also necessary as part of an integrated 
approach, to look for substances which might act as an appropriate scaffold, on which to 
transfer osteoprogenitors to surgical sites requiring bony regeneration.
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Chapter 6: Bioabsorbable Membranes 
& Substrate Attachment
6.1: Introduction
The development and widespread introduction of internal metallic bone fixation over 
the past 25 years has been one of the most significant advances in craniomaxillofadal 
surgery since the basic concepts of secure bone fixation and primary bone healing were 
introduced several decades previously. With the extensive use of fixation technology in 
paediatric craniofacial surgery in particular, it is now apparent that there are several 
potential postoperative complications that may occur as discussed in chapter 1. Given the 
young age at which the paediatric craniofacial procedures are performed, some patients 
will require device removal in their lifetime (Rubin & Yaremchuck, 1997). More 
significantly, the development and bone apposition/resorptive pattern of skull growth, 
creates the potential for growth restriction and eventual translocation of metal fixation 
devices to the endocranial surface (Munro et al., 1993). The tips of screws against the 
dura or juxtaposed to the cerebral cortex impose a risk of creating an injury to the brain 
surface and seizure focus, (Fearon et al., 1995). The use therefore, of resorbable devices 
in an attempt to prevent the associated complications, has been the subject of much study 
and clinical evaluation.
The first published clinical use of resorbable devices was in 1972 by Cutright and 
Hunsuck, who used non load-bearing polylactide sheets for orbital floor repair. 
Subsequently, more complex patterns including screws and fixation plates were introduced 
into clinical practice in the late 1970s and early 1980s. (Sedel et al., 1978; Rokkanen et al., 
1985). Resorbable devices are now commonly used for procedures requiring bone fixation 
and having been used successfully and safely in this context, there has been a natural 
endeavour to extend their application to one of tissue engineering.
Whilst many workers have studied the interaction of osteoprogenitor cells on 
numerous potential scaffolds, there remains a scarcity of work investigating the interaction 
of these scaffolds with osteoprogenitors carrying mutations affecting osteogenisis. It was 
therefore important to firstly discover whether osteoprogenitors carrying the FGFR2-C278F
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mutation would be attracted to and attach to bioresorbable scaffolds which might be 
candidates for a bone engineering application.
In the absence of a novel material which had been pledged for study, a commercially 
available co-polymer plate (BioSorbPDX) which was already being widely used for bone 
fixation in the clinical setting was chosen.
Having also observed (Chapter 4) that cells carrying the C278F mutation did not 
attach to culture plastic so readily and detached more easily than the wild type and 
untransfected cells, it was envisaged that it maybe possible to optimise the attachment 
growth and differentiation of these cells on scaffolds by surface modification with the use 
of coating agents. For this purpose, the matrix proteins fibronectin and laminin were 
chosen having previously been studied and shown to affect attachment of several cell 
types to different materials (Cargill et al., 1999; Rezania & Healy, 1999; Yang et al., 2001; 
Stephansson et al., 2002).
In order to combine the attributes of the PLGA co-polymer and bioactive glasses 
which have been shown to be osteoconductive or even osteoinductive (Yuan et al., 2001) 
but which have poor tensile strength and are brittle, a novel composite scaffold made of 
bioactive glass fibres and the biodegradable PLGA co-polymer was also assessed for its 
ability to attach and sustain osteoblasts.
6.2: Results
6.2.1: Early attachm ent to untreated co-polym er plates
Initial attempts to grow the osteoblast cell lines on the BioSorbPDX plate (Figure 6.1) 
revealed that cells were slow to attach compared to tissue culture wells. Whereas MC3T3- 
E1 cells showed no sign of attachment to BioSorbPDX plates (A), cells were well attached 
on culture plastic at 24 hours post plating (B). However, cells eventually attached and at 4 
days post plating, several cells could be seen with pre-confluent morphology on the 
BioSorbPDX surface (C). In contrast cells grown on culture plastic had a typical confluent 
or near-confluent morphology with visibly greater numbers (D).
The poor early attachment of cells to co-polymer plates led to the seeding of cells at 
significantly higher densities for subsequent experiments involving the plates and coating 
agents. This took into consideration the ultimate target of achieving efficient cellular 
expansion upon the scaffolds prior to normal differentiation and in addition allowed for the
-147-
finite availability of the plates and coating agents. There was also recognition of the time 
constraints upon the study. For similar reasons, experiments were subsequently confined 
to the WT and C278F cell lines.
co-polymer plate culture well
Fig 6.1: MC3T3-E1 cells growth on co-polymer plate (BioSorbPDX) and culture well
Non-attached cells on copolymer plate at 24h (A). Cells attached to culture plastic at 24h 
(B). Cells attached to copolymer plate at 4d (C). Near confluent cells on culture plastic at 
4d (D). The parallel line pattern seen in (A) represents the surface profile markings created 
during manufacture of the plates. Arrows represent the edge of the bevelled screw hole. 
Cells seeded at 20,000/cm2 Images obtained by phase contrast microscopy.
Scale bars = 200 pm in (A); 50 pm in (B-D)
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6.2.2: Effect of laminin and fibronectin treatment on cellular attachment
Before attempting to enhance attachment of cells to the BioSorbPDX plates, the 
effect of the two commercially available substrates, laminin and fibronectin on wild type 
and mutated osteoblast growth on tissue culture plastic was quantified. High magnification, 
phase contrast images of mutated cells (Figure 6.2) demonstrated that after two hours 
there is was observable enhancement of cellular attachment, manifest by more highly 
developed filopodia and visible nucleoli in wells coated with fibronectin and laminin (not 
shown).
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Figure 6.2: The effect of fibronectin on early attachment of C278F cells
Cells grown on untreated culture wells two hours after seeding (A), and cells on 
fibronectin coated wells at two hours (B). Cells were seeded at 30,000cells/cm2.
Images obtained by phase contrast microscopy. Scale bars = 25 pm
Wild type and C278F cells were seeded on 12-well plates coated with fibronectin or 
laminin or on untreated wells (-ve control). Wells were imaged at 1, 4 & 24 hours (Fig. 6.3 
and 6.4) and triplicated samples for each condition and time point were released for 
counting at 1, 2, 4 and 48 hours post plating (Fig. 6.5). Approximately half of the WT cells 
appeared to show early signs of attachment one hour after seeding in unprepared culture 
wells (Fig 6.3 A), whereas virtually all cells seeded on wells coated with fibronectin and 
laminin had attached (Fig 6.3 B,C). After 4 hours in culture, most cells in unprepared
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wells demonstrated signs of early attachment (Fig 6.3 D), compared to the visible 
attachment of all viable cells in the fibronectin and laminin coated wells (Fig 6.3 E,F). After 
1 day in culture without coating, all viable cells had attached (Fig 6.3 G). However, cells 
growing on fibronectin (Fig 6.3 H) had undergone considerable proliferative expansion and 
those grown on laminin were near confluent (Fig 6 .3 1). Two days after plating (not shown) 
cells on fibronectin and laminin were fully confluent whereas negative controls were 
approximately 70-80% confluent.
Mutated cells (Fig. 6.4) one hour after seeding in uncoated wells, demonstrated 
minimal signs of attachment (Fig 6.4 A). Approximately half of the cells seeded on wells 
coated with fibronectin (Fig 6.4 B) were attached and nearly all cells on laminin (Fig 6.4 C) 
showed signs of attachment. After 4 hours in culture there were progressive signs of 
attachment with fibronectin and laminin coated wells (Fig 6.4 EyF) showing the more 
typical morphology of well attached osteoblasts. After 1 day in culture without coating, 
most cells had attached and undergone a limited degree of expansion (Fig 6.4 G). Cells 
growing on both fibronectin and laminin were near confluent (Fig 6.4 H,l).
Quantification of cell numbers as described previously, are represented graphically in 
figure 6.5. Attachment of WT cells was significantly enhanced by both laminin and 
fibronectin at all time points although this effect was greatest for early cultures. Laminin 
and fibronectin had an equal effect on cell numbers in cultures of four hours or less. In 
later cultures at 48 hours, laminin had a statistically significant advantage on wild type cells 
compared to fibronectin which also significantly increased cellular attachment Laminin and 
fibronectin significantly increased C278F cell numbers for time points up to 4 hours. There 
was no significant difference between laminin and fibronectin at 1 hour. However laminin 
had a significantly greater effect than fibronectin at 2 and 4 hours. Both substrates 
significantly increased cell numbers at 48 hours, although interestingly, the increase at this 
time point was significantly greater with fibronectin.
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Figure 6.3: Effect of fibronectin & laminin coating on WT adhesion
Wild type cells were imaged at 1 hour (A-C), 4 (D-F) or 24 hours(G-l) after seeding in 
untreated wells(A,D,G), or in wells coated with fibronectin (FN) (B,E,H) or laminin (C,F,I). 
Approximately half the cells were attached at 1 hour on uncoated wells (A) compared to 
almost all cells on coated wells (B,C). After 4 hours, most cells showed early attachment on 
uncoated wells (D), whereas all viable cells were well attached on coated wells (E,F). At one 
day, all viable cells on uncoated wells had attached and appeared to have undergone some 
expansion (G), whereas cells grown on FN had undergone greater expansion (H) and cells 
grown on laminin were confluent (I). Cells were seeded at 30,000cells/cm2. Images obtained 
by phase contrast microscopy. Scale bars = 200 pm
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Figure 6.4: Effect of fibronectin & laminin coating on C278F adhesion
Cells carrying the C278F mutation were imaged at 1 hour (A-C), 4 (D-F) or 24 hours(G-l) 
after seeding in untreated wells (A,D,G), or in wells coated with fibronectin (FN) (B,E,H) or 
laminin (C,F,I). After 1 hour, cells grown on uncoated wells showed minimal attachment (A). 
Approximately half of the cells grown on FN (B) showed attachment and nearly all cells 
seeded on laminin (C) appeared to be attached. After 4 hours in culture cells in FN (E) and 
laminin (F) coated wells appeared well attached compared to non coated wells (D). After 1 
day in the uncoated wells (G), cells were mostly attached, whereas cells grown on FN and 
laminin were near confluent (H,l) Cells were seeded at 30,000cells/cm2. Images obtained by 
phase contrast microscopy. Scale bars = 200 pm
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Figure 6.5: Effect of fibronectin & laminin coating on adhesion and growth of 
WTand C278F cells
Analysis of effect of fibronectin and laminin on wild type (A) and C278F (B) cells.
Cells were seeded as triplicates at 30,000/cm2 in standard medium. Data are expressed as 
the mean + SEM. Statistical difference amongst treatment groups (n=3) were evaluated 
using analysis of variance (ANOVA). Significance was determined by post hoc testing 
using Bonferronis’s method. S=significant (p < 0.05 was taken as significant)
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6.2.3: Effect of laminin and fibronectin treatment on cellular attachment to 
BioSorbPDX plates
Having shown significant attachment enhancement of both wild type and mutated 
cells to tissue culture plastic with laminin and fibronectin, the next step, having also 
observed the poor early attachment of osteoblasts to the BioSorbPDX plate, was to assess 
the potential of these two substrates to optimise the attachment, growth and mineralisation 
on the plates.
Observation of the BioSorbPDX plates within the first 1-6 hours (not shown), after 
seeding with C278F cells, revealed that early attachment had been enhanced by both 
fibronectin and laminin in a similar fashion to that observed when cells were seeded on 
treated culture dishes as shown in figure 6.4. Five days after seeding, cells were fully 
confluent on the fibronectin (Fig. 6.6 C) and laminin (Fig. 6.6 E) coated membranes, while 
some non-confluent areas remained on the untreated plate (Fig. 6.6 A). After 20 days of 
culture, multilayered nodules had developed in all conditions (Fig. 6.6 B,D,F) with nodules 
on the fibronectin coated plates appearing more developed (Fig. 6.6 D).
When compared with non coated plates, both substrates produced a significant 
increase in cell numbers at days 1 and 5 and this effect was significantly greater for 
laminin than fibronectin at both time points (Fig. 6.7). Surprisingly, at day 20, BioSorbPDX 
plates which had not been treated showed significantly greater cell numbers than either of 
the treatment groups. Of the two coating agents, fibronectin appeared to produce the 
greatest increase in cell numbers although this did not reach statistical significance.
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Figure 6.6: C278F cells on BioSorbPDX plate with fibronectin or laminin coatings.
Five days after seeding, cells were fully confluent on the fibronectin (C) and laminin (E) 
coated plates. Non-confluent areas remained on the untreated plate (yellow arrows) (A). 
After 20 days of culture, multilayered nodules had developed in all conditions (B,D,F), 
as indicated by the white arrows. Scale bars = 200 pm
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Figure 6.7: Quantitative effect of substrate coating of BioSorbPDX plates on C278F 
adhesion
Cells were seeded at 75,000/cm2 in normal medium (replaced daily) onto untreated 
BioSorbPDX plates or plates coated with fibronectin or laminin. Cells were harvested and 
counted at days 1, 5 and 20. Data are expressed as the mean + SEM for each group 
(n=3). Statistical differences among treatment groups were evaluated using analysis of 
variance (ANOVA) and the significance of differences was determined by post hoc testing 
using Bonferroni’s method. S = significant (p < 0.05 was considered significant).
6.2.4: Alkaline phosphatase activity of C278F cells on treated BioSorbPDX plates.
Having observed and quantified the ability of cells carrying the C278F activating 
mutation to attach and expand on BioSorbPDX plates in the presence or absence of ECM 
coating, assessment of the cells ability to mineralise on the plates was undertaken.
Observed at day 20, ALP activity was greatest within the multilayered, nodular 
structures and appeared similar in cells growing on untreated membranes (Fig. 6.8 B) and 
those treated with fibronectin (Fig. 6.8 D) and laminin (Fig. 6.8 F). Interestingly, areas of 
cellular detachment were observed most obviously on plates treated with laminin,
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Figure 6.8: Alkaline phosphatase staining of C278F cells on treated BioSorbPDX plates.
Day 20, C278F cells on BioSorbPDX plates in differentiating medium, demonstrated 
multilayered structures in unstained (A,C,E) and stained (B,D,F) wells. Staining for alkaline 
phosphatase was maximal in the nodular regions. White arrows indicate examples of 
multilayer, nodular structures. Areas of cellular detachment are indicated by red arrows. 
Cells were seeded at 75,000 cells/cm2. Images obtained by plain backlit microscopy.
Scale bars = 500 pm
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6.2.5: Copolymer-bioactive glass composite membrane
This composite material consisted of bioactive glass fibres embedded onto an 
amorphous matrix of PLGA copolymer. The surface characteristics and microscopic 
appearance of the copolymer in this composite differed from the BiosorbPDX* studied 
previously in this chapter and did not allow the cells to be distinguished when viewed by 
microscopy (Fig. 6.9 A). Therefore, a vital cell tracker (CMFDA) was incorporated into the 
cells to allow observation under fluorescent microscopy (Fig. 6.9 B).
Initial observations of C278F cells 20 hours after seeding, revealed that attachment 
to both the co-polymer (Fig. 6.9 A, B) and bioactive glass fibre (Fig. 6.9 C) components of 
the composite was poor; they appeared rounded in shape with little evidence of 
development of pseudopodia or the typical elongated morphology of attached cells. 
Clumps of cells did however appear to be attracted towards the bioactive glass fibres (Fig. 
6.9 C). Five days after seeding, cells were arranged longitudinally along the glass fibres 
suggesting that attachment had occurred (Fig. 6.9 D).
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Figure. 6.9: Attachment of C278F cells onto copolymer-bioactive glass composite membrane
At 20 hours after seeding in normal medium, cells were difficult to observe on the copolymer 
component (A). Cells stained with CMFDA were visualised under fluorescent microscopy 
and the image digitally superimposed on the phase contrast image (B). When bioactive 
glass fibres were brought into focus, cells could be seen (arrow) clustering adjacent to the 
fibres (C). After 5 days, cells were attached (arrow) to the bioactive glass fibres (D). Cells 
seeded at 20,000 cells/cm2. Scale bars = 200 pm (A,B) and 100 pm (C,D)
(See Appendix for note on published data)
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6.3: Discussion
6.3.1: Effect of coating agents on cellular attachment
Initial observations revealed that the cell lines did not readily attach to the 
BioSorbPDX plate. This was an expected finding and consistent with the reports, using 
various cell types, of other authors who have demonstrated that polyester materials are 
only weakly hydrophilic and initially attach cells less efficiently than tissue culture plastic 
(Quirk et al., 2001; Moran et al., 2003; Lim et al., 2004). Furthermore, there are no cell 
recognition sites on the surfaces of PLGA scaffolds, leading to less than optimal cell 
affinity. It was therefore attempted to optimise cellular attachment to the BioSorbPDX 
plates as this appeared intuitively, to be a beneficial manipulation to enhance what would 
ultimately be an autograft, tissue engineering application. This study aimed to determine if 
there was a quantifiable benefit in coating potential scaffolds with ECM proteins and if 
there was any relative advantage between the ECM proteins.
Fibronectin and laminin coating of tissue culture plastic significantly enhanced the 
attachment of the cell lines which was demonstrated by the early morphological change in 
appearance of the WT and C278F cells. The visual impact of the enhanced attachment 
was obvious at early time points and appeared to have facilitated enhancement of cell 
numbers and growth at the later time points. This appearance was confirmed by 
quantification of the effect. Interestingly, at time points upto 4 hours, fibronectin and 
laminin similarly enhanced WT cell attachment with laminin having a significantly greater 
effect over fibronectin at 48 hours. However, attachment of cells carrying the mutation was 
enhanced to a greater degree by laminin, although at 48 hours this differential effect had 
been reversed to show fibronectin having the largest effect. The fact that laminin had a 
significantly greater affect on C278F ceils soon after seeding, suggests that the mutation 
conferred on the cell an early selective receptor affinity for the different ECMs.
Whilst the RGD peptide is the single most important binding domain, other domains 
on the fibronectin and laminin molecules may be differentially bound by receptors 
expressed by the different cell lines. Moreover, passive adsorption could induce the 
competitive adsorption of other factors in the system and change the configuration of the 
adsorbed fibronectin or laminin molecules. As a result, its cell-binding activity would be 
influenced. For this reason it would have been informative to have also studied the effect 
of plates coated with the solitary RGD peptide.
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It is more difficult to explain why there should have been switching between an early 
attachment advantage for laminin and a later advantage for fibronectin in the C278F cells. 
This effect is more likely to have been due to a cellular-ECM interaction than due to the 
chemico-physical interaction between the ECM protein and the culture plate surface, as 
laminin had produced increased attachment at 48 hours in the WT cells.
Culture dishes and BioSorbPDX plates were coated at the manufacturers 
recommended concentration and no attempt was made to study the concentration effect of 
laminin and fibronectin. However, it has been shown that attachment, proliferation and 
mineralisation of human osteoblasts is dose dependant for fibronectin or RGD peptide. 
(Yang et al., 2001; Behravesh et al., 2003).
Further studies of the cellular-ECM interaction would have been informative, both 
in quantifying the differential effect of extracellular proteins for enhancing attachment to 
scaffold materials and with respect to the differences in adhesion characteristics between 
the mutated and WT cells. These studies which could have involved such techniques as 
microcantilever (Bowen et al., 1997) micropipette (Athanassiou & Deligiannil 2001) or jet 
impingement (Gilberti et al., 2002) could have been linked with expression assays of 
cytoskeletal structures to facilitate the determination of the fundamental relationships 
between cell adhesion and function within these cells.
6.3.2: Attachment and growth on copolymer (BioSorbPDX) plates
Having demonstrated a clear attachment advantage for both fibronectin and laminin 
coated culture plastic, it was important to demonstrate if this advantage was transferable 
to the BioSorbPDX plates and whether this might influence mineralisation.
Fibronectin and laminin significantly increased C278F cell numbers on the 
BioSorbPDX plate at days 1 and 5. As with the study on tissue culture plastic, laminin had 
the greatest effect at the earlier time points. However at some point between day 5 and 
day 20 this advantage was lost such that day 20 plates which were untreated, surprisingly 
had significantly greater cell numbers attached than those treated with either of the coating 
agents. This may have been due to the influence of the adsorbed proteins on cellular 
proliferation or apoptosis or both, as the cells moved from a proliferative to a differentiative 
phase. However, it is possible that the biomass of attached cells combined with even the 
minimalist agitation of the culture fluid when changing medium, may have caused shearing 
of cells from the plates and indeed voids can be seen on the plates where areas of cells 
have become detached (Figure 6.8). This would be consistent with the fact that polyesters 
lack chemical reactivity due to the absence of functional groups to support covalent
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attachment. There may in fact come a point at which the mechanical attachment of cells to 
irregularities on the plate surface (see parallel grooves in Figure 6.1) is stronger than the 
surface-ECM interface, a concept supported by the findings of Matsuzaka et al., (1999).
The pattern of C278F growth was different on BioSorbPDX plates and culture 
dishes. Cells grown on BioSorbPDX appeared to reach confluence compared to their 
inability to reach full confluence (in the absence of growth factor) on tissue culture plastic. 
This might be explained by the recognition that nuclear shape which in turn may be 
influenced by overall cell shape has been shown to significantly affect cell function and 
regulatory pathways (Folkman & Mosconal 1978; Meyle et al., 1993; Lampin et al., 1997; 
Huang & ingberl, 2000). This is also consistent with the finding that MC3T3-E1 
differentiation and mineralisation is dependant upon the 3D conformation of the FN 
molecule which is itself dependant on the surface characteristics of the material upon 
which it is adsorbed (Stephansson et al., 2002).
A morphological feature which appears to be necessary across the spectrum of 
osteogenerative cells if functional bone is to be produced, is the development of 
mineralised nodules. Cellular growth on all of the plates in this study, supported the ability 
to form multilayered nodules. The nodules appeared to be more highly developed in the 
fibronectin coated plates, although this was not obvious when plates were stained for ALP 
expression. It should be noted however, that cells intended for ALP staining were grown in 
differentiating medium which may have influenced the growth and functionality of the cells.
6.3.3: Cellular alkaline phosphatase activity on BioSorbPDX plates
Successful mineralisation of matrix is one of the ultimate requirements for 
engineered bone tissues. It is recognised that potential materials for bone engineering are 
highly variable in their ability to support mineralisation (Calvert et al., 2005) and even the 
potylactic-polyglycolic (PLGA) co-polymer has been shown to greatly affect the ability of 
osteoblasts to mineralise matrix, depending upon the particular formulation of the material 
(Meredith et al., 2003). It was important therefore to establish whether the formulation 
being used in this study supported mineralisation.
The C278F cells at 20 days, stained for ALP in all conditions. The appearances 
suggested that staining was strongest on the plates not pre-coated. However this may 
have been due simply to more cells per unit area on the uncoated plates rather than an 
ability of these cells to express ALP more readily. There did not appear to be any obvious 
differential expression of ALP between the fibronectin and laminin coated plates.
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The strong expression of ALP in all test conditions was interesting, in light of the 
finding in chapter 4, that C278F cells grown on tissue culture plastic did not express 
significant levels of ALP mRNA until day 30. While direct correlation of ALP mRNA 
expression and ALP protein activity cannot be made, Wang et al., (1999), have shown 
good correlation between mRNA expression and protein transcription for ALP in MC3T3- 
E1 cells. It can therefore be postulated that this apparent enhancement of ALP activity 
might be due to the influence of the co-polymer plate or its acidic breakdown products. 
Indeed this is supported by Ikarashi et al., (2000), who observed that poly-L-lactide (80% 
of the polyester in the BiosorbPDX plates) can stimulate ALP activity in MC3T3-E1 cells.
Attempts to stain for mineralisation using von Kossas’ technique proved 
unsuccessful as the process caused almost total detachment of the cells from the plates.
6.3.4: Copolymer-Bioactive glass composite
A novel composite formulation of PLGA-bioactive glass became available towards 
the end of the project which allowed only limited investigation of the material.
Consistent with the previous findings of cellular growth on the BiosorbPDX plates, 
C278F cells did not attach readily to the amorphous co-polymer component of the material 
or the glass fibres. At 5 days however, cells were aligned longitudinally along the fibres.
Further work within our laboratory has demonstrated the ability of another 
formulation of this PLGA-bioactive glass composite to attract and allow proliferation and 
osteo-differentiation of the C278F line (Santos-Ruiz et al., 2007).
6.3.5: Summary
The findings in this chapter confirm that preosteoblasts carrying the C278F mutation 
attached poorly in the first instance to the co-polymer plates used in this study. It was 
shown that this early attachment can be enhanced by pre-coating with the extra-cellular 
matrix proteins, fibronectin and laminin and those cells carrying the mutation attach 
preferentially to laminin coated tissue culture plastic and co-polymer plates. Whilst early 
attachment is enhanced this seems to confer no later advantage in terms of cellular 
expansion. Indeed, when cells were in the late stages of osteodifferentiation there 
appeared to be a depletion of cell mass compared to untreated plates, which may have 
been due to detachment of cells at the material-ECM interface.
Co-polymer plates supported the formation of multilayered nodules and the 
expression of alkaline phosphatase, and may have demonstrated fod of mineralisation 
had the staining technique chosen not prevented the assay.
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The limited analysis of cellular interaction with a novel composite material 
consisting of bioactive glass and co-polymer revealed that whilst early attachment of cells 
was poor, subsequent cellular attachment provides encouragement to proceed with further 
evaluation of this material.
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Chapter 7: Final discussion
This study aimed to assess the feasibility of the MC3T3-E1 cell line carrying a 
craniosynostotic mutation, as a model for studying osteogenisis in craniosynostosis. It 
further sought to study the potential use of craniosynostotic osteoprogenitors in 
combination with bioresorbable materials and to identify potential modifiers to optimally 
manipulate these interactions.
Although transformed murine cells are inappropriate for therapeutic applications, 
MC3T3-E1 cells stably transfected with the human FGFR-C278F mutation coding for 
craniosynostosis, enabled studies on the growth and differentiation of craniosynostotic 
osteoprogenitor cells. These cells retained several properties of primary osteoblast 
cultures, including the ability to form a mineralised, collagenous, extracellular matrix and 
express gene products consistent with the osteoblast phenotype, thereby allowing the 
study of the functional effects of an FGFR2 mutation.
Cells carrying the FGFR2-C278F mutation appeared morphologically distinct from 
the MC3T3-E1 and WT cells. They required more frequent feeding and demonstrated 
higher levels of cell death suggesting a fundamental difference in phenotype and 
metabolic demands. When attached, they appeared more rounded implying lower levels of 
cellular prestress and possibly greater differentiation. Their attachment and clumping 
behaviour confirmed these differences although increased levels of Cx43 did not reach 
statistical significance. Hence, further studies directed at the mechanisms of cellular 
attachment in craniosynostotic cells, paying particular emphasis to the functional 
interaction between the extracellular matrix and the integrin linked cytoskeleton would be 
warranted.
The temporal expression of mRNA markers of osteodifferentiation did not wholly 
conform to expected findings. High early levels of osteocalcin in all cell lines and 
mineralisation of the C278F cells despite the delayed expression of alkaline phosphatase 
gives support to the findings of others that mineralisation can be dissociated from 
expression of osteocalcin and alkaline phosphatase (Beck et al., 1998; Ratisoontom et al., 
2003). This may also suggest that the well defined temporal relationships reported by the 
early workers with the MC3T3-E1 cell line, may have shifted due to significant clonal drift 
and subpopulation transformation, in keeping with the findings of Wang et al., (1999). In
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this respect, the model studied could be questioned as to its suitability to represent and 
predict the effect of an in vivo mutation on progression of osteoprogenitors through the 
osteoblast lineage.
The study of growth factor manipulation and scaffold modification has been facilitated 
by these cells and should continue to allow the investigation and comparison between 
other mutations involved in pathological osteogenisis. This should allow further studies 
aimed at “reverting” the craniosynostotic phenotype without the need for genetic 
modification. In conclusion, the FGFR2-C278F cell line has been a useful osteoprogenitor 
model throughout this study and central to its findings. This model, compared with primary 
human craniosynostotic cultures for bio-scaffold engineering, has been further investigated 
in subsequent work carried out in our laboratory, (Santos-Ruiz et al., 2007).
The observation that FGF18 was expressed at higher levels in the early proliferative 
phase of C278F cell growth, suggested an important role for this growth factor in 
osteogenisis and in particular proliferative expansion. Therefore, for the first time the effect 
of exogenous FGF18 treatment on cells carrying a mutation for craniosynostosis was 
studied. In the presence of adequate serum concentrations, treatment with FGF18 
enhanced proliferation of the cells in a dose dependant manner and allowed them to reach 
confluence, whereas C278F cells underwent cell death in low serum concentrations. This 
implied that these cells were more dependent on serum factors for cell survival and 
proliferation and as discussed in chapter 4, this may have been linked to levels of 
prestress within the cells and their dependence on adequate ECM attachments. Moreover, 
the levels of endogenous FGF18 produced by the cells were already raised and further 
treatment with exogenous mitogenic factors may have been additively detrimental when 
the cells were poorly attached. These findings suggest that FGF18, under the right 
conditions, may be a useful growth factor for the enhanced expansion of cell numbers.
Since the completion of this study the importance of FGF18 in osteogenisis has been 
further elucidated. Reinhold and Naski (2007), have shown that the transcription factors, 
Runx2 and TCF/Lef which are transducers of Wnt signals and considered essential for 
osteogenisis, converge on the FGF18 promotor and suggest that expansion of an early 
osteoblast population through stimulation of cell proliferation will almost certainly be a key 
attribute of FGF18.
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In further considering the possible clinical translation of FGF18 function, Haque et al., 
(2007), have recently found that chondrocytes within fracture callus of long bones 
undergoing distraction osteogenisis in a rabbit model, express FGF18 at high and 
persisting levels. It may be a significant observation that in children undergoing 
craniofacial distraction osteogenisis, the areas of bone which demonstrates regeneration 
are not those forming in membranous bone, but those at the skull base formed by 
endochondral ossification (Fig. 1.5B).
Taken together, these findings and observations suggest that FGF18 is a worthy 
candidate for further study in future developments of osteogenisis and bone engineering.
There are many different interacting and complex factors which will ultimately affect 
the progress of osteogenesis on bio-composite scaffolds. It has been shown that 
osteoprogenitor cells carrying this particular FGFR2-C278F mutation, attach, grow and 
express an osteoblast like phenotype on PLGA (Biosort) PDX) fixation plates and that the 
ECM molecules, fibronectin and laminin, support early attachment and growth of these 
cells. However, a non-activating FGFR mutation such as those found in Aperts syndrome 
may respond differently to the same proteins. Likewise, the optimum concentration of 
growth factors for any particular culture system on any particular scaffold formulation or 
architecture may be very different. This study has hence demonstrated that these 
complexities overwhelm the conventional “one-sample/one-measurement” approach to the 
evaluation of bioactive systems.
In recognition of these multifactorial and complex interactions, superior bioactive 
systems must be designed by taking into account the synergisms of the most important of 
these factors. To this end, attempts are being made to approach this problem by the 
development of combinatorial libraries using such techniques as micro-array gene 
analysis, chromatographic gradient libraries and high-throughput polymer concentration 
and surface libraries (Chicurel, 2001; Meredith et al., 2003). Ultimately, this approach 
might lead to the customised engineering of bone for any individual patient, dependant 
upon the genotype/phenotype of the autologous osteoprogenitors
Overall, this study has found the transfected MC3T3-E1 cell lines to be a useful 
model for studying the molecular basis of craniosynostoses and the response of mutated 
osteoprogenitors to different materials, extracellular matrix molecules and growth factors. 
Fibronectin and laminin supported cellular attachment and growth to facilitate the early 
expansion of mutated osteoprogenitors on a commercially available bioresorbable
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scaffold. FGF18 expression and its exogenous effects on osteoprogenitor behaviour, 
suggest that this is an important growth factor in osteogenisis. This study provides the 
basis for further investigation aimed at using these molecules to develop bio-composites 
for autologous cell therapy, without the medical and ethical hazards of genetic 
manipulation, in the management of these challenging surgical reconstructions.
Appendix
Publication Note
The contribution of the author to the referenced publication Santos-Ruiz et al., 
(2007), involved reviews and revisions of the original manuscript and contribution of the 
following data:
p202, Figure 1, Osteocalcin expression data
p203, Figure 2 (G,H,I), MC3T3/WT/C278F von Kossa staining at 21 days
p208 Figure 9 (A,B,C), MC3T3 on culture wells, BiosorbPDX with and without alizarin
The copolymer-bioglass membrane which appears in Figure 6.9 of this thesis was 
material which became available towards the end of this study and is an earlier formulation 
than that which appears in the published paper.
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